Cover
Cover - USD ($) | 12 Months Ended | ||
Dec. 31, 2020 | Jan. 31, 2021 | Jun. 30, 2020 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2020 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Transition Report | false | ||
Entity File Number | 1-15525 | ||
Entity Registrant Name | EDWARDS LIFESCIENCES CORPORATION | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 36-4316614 | ||
Entity Address, Address Line One | One Edwards Way | ||
Entity Address, City or Town | Irvine | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 92614 | ||
City Area Code | 949 | ||
Local Phone Number | 250-2500 | ||
Title of 12(b) Security | Common Stock, par value $1.00 per share | ||
Trading Symbol | EW | ||
Security Exchange Name | NYSE | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Entity Public Float | $ 42,640,586,293 | ||
Entity Common Stock, Shares Outstanding | 624,518,873 | ||
Documents Incorporated by Reference | Portions of the registrant's proxy statement for the 2021 Annual Meeting of Stockholders (to be filed within 120 days of December 31, 2020) are incorporated by reference into Part III, as indicated herein. | ||
Entity Central Index Key | 0001099800 | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2020 | ||
Document Fiscal Period Focus | FY |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Current assets | ||
Cash and cash equivalents | $ 1,183.2 | $ 1,179.1 |
Short-term investments (Note 7) | 219.4 | 337.8 |
Accounts receivable, net of allowances of $9.6 and $8.7, respectively | 514.6 | 543.6 |
Other receivables | 88.2 | 55.5 |
Inventories (Note 5) | 802.3 | 640.9 |
Prepaid expenses | 75.1 | 59.1 |
Other current assets | 208.2 | 168 |
Total current assets | 3,091 | 2,984 |
Long-term investments (Note 7) | 801.6 | 585.5 |
Property, plant, and equipment, net (Note 5) | 1,395.2 | 1,060.3 |
Operating lease right-of-use assets (Note 6) | 94.2 | 80.1 |
Goodwill (Note 9) | 1,173.2 | 1,167.7 |
Other intangible assets, net (Note 9) | 331.4 | 336.5 |
Deferred income taxes | 230.9 | 172.2 |
Other assets | 119.6 | 101.8 |
Total assets | 7,237.1 | 6,488.1 |
Current liabilities | ||
Accounts payable | 196.5 | 180.4 |
Accrued and other liabilities (Note 5) | 670.2 | 696.5 |
Operating lease liabilities (Note 6) | 27.2 | 25.5 |
Total current liabilities | 893.9 | 902.4 |
Long-term debt (Note 10) | 595 | 594.4 |
Contingent consideration liabilities (Notes 8 and 11) | 186.1 | 172.5 |
Taxes payable (Note 17) | 215.3 | 236.6 |
Operating lease liabilities (Note 6) | 72.7 | 58.9 |
Uncertain tax positions (Note 17) | 214.4 | 171.7 |
Litigation settlement (Notes 3 and 18) | 233 | 0 |
Other long-term liabilities | 252.4 | 203.3 |
Commitments and contingencies (Notes 6, 10 and 18) | ||
Stockholders' equity (Note 14) | ||
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding | 0 | 0 |
Common stock, $1.00 par value, 1,050.0 shares authorized, 636.4 and 218.1 shares issued, and 624.3 and 209.1 shares outstanding, respectively | 636.4 | 218.1 |
Additional paid-in capital | 1,438.1 | 1,623.3 |
Retained earnings | 4,565 | 3,741.6 |
Accumulated other comprehensive loss | (161.1) | (156) |
Treasury stock, at cost, 12.1 and 9.0 shares, respectively | (1,904.1) | (1,278.7) |
Total stockholders' equity | 4,574.3 | 4,148.3 |
Total liabilities and stockholders' equity | $ 7,237.1 | $ 6,488.1 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Statement of Financial Position [Abstract] | ||
Allowance for doubtful accounts | $ 9.6 | $ 8.7 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, authorized shares (in shares) | 50,000,000 | 50,000,000 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 1 | $ 1 |
Common stock, shares authorized (in shares) | 1,050,000,000 | 1,050,000,000 |
Common stock, shares issued (in shares) | 636,400,000 | 218,100,000 |
Common stock, shares outstanding (in shares) | 624,300,000 | 209,100,000 |
Treasury stock, shares (in shares) | 12,100,000 | 9,000,000 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income Statement [Abstract] | |||
Net sales | $ 4,386.3 | $ 4,348 | $ 3,722.8 |
Cost of sales | 1,080.6 | 1,114.4 | 939.4 |
Gross profit | 3,305.7 | 3,233.6 | 2,783.4 |
Selling, general, and administrative expenses | 1,228.4 | 1,242.2 | 1,088.5 |
Research and development expenses | 760.7 | 752.7 | 622.2 |
Intellectual property litigation expenses, net (Note 3) | 405.4 | 33.4 | 214 |
Change in fair value of contingent consideration liabilities | 13.6 | (6.1) | (5.7) |
Special charges (Note 4) | 0 | 64.6 | 116.2 |
Operating income | 897.6 | 1,146.8 | 748.2 |
Interest expense | 15.8 | 20.7 | 29.9 |
Interest income | (23.4) | (32.2) | (32) |
Special gain (Note 4) | 0 | 0 | (7.1) |
Other income, net (Note 16) | (11.5) | (8.2) | (4) |
Income before provision for income taxes | 916.7 | 1,166.5 | 761.4 |
Provision for income taxes (Note 17) | 93.3 | 119.6 | 39.2 |
Net income | $ 823.4 | $ 1,046.9 | $ 722.2 |
Earnings per share: | |||
Basic (in dollars per share) | $ 1.32 | $ 1.68 | $ 1.15 |
Diluted (in dollars per share) | $ 1.30 | $ 1.64 | $ 1.13 |
Weighted-average number of common shares outstanding: | |||
Basic (in shares) | 622.6 | 624.8 | 627.6 |
Diluted (in shares) | 631.9 | 636.7 | 640.9 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Statement of Comprehensive Income [Abstract] | |||
Net income | $ 823.4 | $ 1,046.9 | $ 722.2 |
Other comprehensive (loss) income, net of tax (Note 15): | |||
Foreign currency translation adjustments | 32.4 | (11.2) | (38.6) |
Unrealized (loss) gain on hedges | (40.2) | (11.1) | 40.4 |
Unrealized pension costs | (4.2) | (1.9) | 0.6 |
Unrealized gain (loss) on available-for-sale investments | 6.6 | 6.3 | (3.3) |
Reclassification of net realized investment loss to earnings | 0.3 | 0.4 | 2.9 |
Other comprehensive (loss) income, net of tax | (5.1) | (17.5) | 2 |
Comprehensive income | $ 818.3 | $ 1,029.4 | $ 724.2 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Cash flows from operating activities | |||
Net income | $ 823.4 | $ 1,046.9 | $ 722.2 |
Adjustments to reconcile net income to cash provided by operating activities: | |||
Depreciation and amortization | 107.2 | 89.3 | 77.4 |
Non-cash operating lease cost | 28.2 | 25.3 | 0 |
Stock-based compensation (Notes 2 and 14) | 92.6 | 81.3 | 71 |
Inventory write off | 0 | 73.1 | 0 |
Impairment charges (Note 4) | 0 | 40.6 | 118.8 |
Change in fair value of contingent consideration liabilities, net (Note 11) | 13.6 | (6.1) | (5.7) |
Deferred income taxes | (49.4) | 12.1 | (27.3) |
Purchased in-process research and development | 0 | 24 | 0 |
Other | (3.5) | (2.8) | 13 |
Changes in operating assets and liabilities: | |||
Accounts and other receivables, net | 41.9 | (88) | (28.7) |
Inventories | (120.6) | (105.4) | (65.7) |
Prepaid expenses and other current assets | (28.5) | (6.8) | 15.6 |
Accounts payable and accrued liabilities | (84.5) | 116.5 | 12.5 |
Litigation settlement accrual | 270.5 | (180) | 180 |
Income taxes | (52.9) | 43.2 | (157.8) |
Other | 16.3 | 19.7 | 1.4 |
Net cash provided by operating activities | 1,054.3 | 1,182.9 | 926.7 |
Cash flows from investing activities | |||
Capital expenditures | (407) | (254.4) | (238.7) |
Purchases of held-to-maturity investments (Note 7) | (162) | (130.2) | (210) |
Proceeds from sales and maturities of held-to-maturity investments (Note 7) | 212.2 | 50 | 578.1 |
Purchases of available-for-sale investments (Note 7) | (689.7) | (437.9) | (249.3) |
Proceeds from sales and maturities of available-for-sale investments (Note 7) | 564.8 | 359.9 | 223.2 |
Acquisition (Notes 8 and 9) | 0 | (100.2) | 0 |
Payment for acquisition option | (10) | (35) | 0 |
Issuances of notes receivable | (27) | (12.9) | (0.6) |
Investments in intangible assets and in-process research and development | (0.3) | (24) | (3) |
Other | (12.1) | (11.1) | (23) |
Net cash (used in) provided by investing activities | (531.1) | (595.8) | 76.7 |
Cash flows from financing activities | |||
Proceeds from issuance of debt | 16.2 | 18.9 | 688 |
Payments on debt and finance lease obligations | (17) | (28.9) | (1,125.3) |
Purchases of treasury stock | (625.4) | (263.3) | (795.5) |
Proceeds from stock plans | 140.5 | 160.5 | 147 |
Payment of contingent consideration | 0 | 0 | (15.1) |
Other | (1.2) | (2.8) | (0.3) |
Net cash used in financing activities | (486.9) | (115.6) | (1,101.2) |
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash | (20.5) | (3) | (6.5) |
Net increase (decrease) in cash, cash equivalents, and restricted cash | 15.8 | 468.5 | (104.3) |
Cash, cash equivalents, and restricted cash at beginning of year | 1,184.4 | 715.9 | 820.2 |
Cash, cash equivalents, and restricted cash at end of year | $ 1,200.2 | $ 1,184.4 | $ 715.9 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Millions, $ in Millions | Total | Common Stock | Treasury Stock | Additional Paid-in Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Impact to retained earnings from adoption of ASU 2016-16 and ASU 2018-02 | Impact to retained earnings from adoption of ASU 2016-16 and ASU 2018-02Retained Earnings | Impact to retained earnings from adoption of ASU 2016-16 and ASU 2018-02Accumulated Other Comprehensive Loss | Cumulative Effect, Period of Adoption, Adjusted Balance | Cumulative Effect, Period of Adoption, Adjusted BalanceCommon Stock | Cumulative Effect, Period of Adoption, Adjusted BalanceTreasury Stock | Cumulative Effect, Period of Adoption, Adjusted BalanceAdditional Paid-in Capital | Cumulative Effect, Period of Adoption, Adjusted BalanceRetained Earnings | Cumulative Effect, Period of Adoption, Adjusted BalanceAccumulated Other Comprehensive Loss |
Beginning balance (in shares) at Dec. 31, 2017 | 212 | 2.3 | 212 | 2.3 | |||||||||||
Beginning balance at Dec. 31, 2017 | $ 2,956.2 | $ 212 | $ (252.1) | $ 1,166.9 | $ 1,962.1 | $ (132.7) | $ 2.6 | $ 10.4 | $ (7.8) | $ 2,958.8 | $ 212 | $ (252.1) | $ 1,166.9 | $ 1,972.5 | $ (140.5) |
Increase (Decrease) in Stockholders' Equity | |||||||||||||||
Net income | 722.2 | 722.2 | |||||||||||||
Other comprehensive income (loss), net of tax | 2 | 2 | |||||||||||||
Common stock issued under equity plans, including tax benefits (in shares) | 3.2 | ||||||||||||||
Common stock issued under equity plans | 147 | $ 3.2 | 143.8 | ||||||||||||
Stock-based compensation expense | 71 | 71 | |||||||||||||
Stock issued in payment for contingent consideration liabilities (in shares) | (0.3) | ||||||||||||||
Shares issued in payment for contingent consideration liabilities | 34.9 | $ 32.2 | 2.7 | ||||||||||||
Purchases of treasury stock (in shares) | 5.5 | ||||||||||||||
Purchases of treasury stock | (795.5) | $ (795.5) | |||||||||||||
Ending balance (in shares) at Dec. 31, 2018 | 215.2 | 7.5 | |||||||||||||
Ending balance at Dec. 31, 2018 | 3,140.4 | $ 215.2 | $ (1,015.4) | 1,384.4 | 2,694.7 | (138.5) | |||||||||
Increase (Decrease) in Stockholders' Equity | |||||||||||||||
Net income | 1,046.9 | 1,046.9 | |||||||||||||
Other comprehensive income (loss), net of tax | (17.5) | (17.5) | |||||||||||||
Common stock issued under equity plans, including tax benefits (in shares) | 2.9 | ||||||||||||||
Common stock issued under equity plans | 160.5 | $ 2.9 | 157.6 | ||||||||||||
Stock-based compensation expense | 81.3 | 81.3 | |||||||||||||
Purchases of treasury stock (in shares) | 1.5 | ||||||||||||||
Purchases of treasury stock | (263.3) | $ (263.3) | |||||||||||||
Ending balance (in shares) at Dec. 31, 2019 | 218.1 | 9 | |||||||||||||
Ending balance at Dec. 31, 2019 | 4,148.3 | $ 218.1 | $ (1,278.7) | 1,623.3 | 3,741.6 | (156) | |||||||||
Increase (Decrease) in Stockholders' Equity | |||||||||||||||
Net income | 823.4 | 823.4 | |||||||||||||
Other comprehensive income (loss), net of tax | (5.1) | (5.1) | |||||||||||||
Common stock issued under equity plans, including tax benefits (in shares) | 4.5 | ||||||||||||||
Common stock issued under equity plans | 140.5 | $ 4.5 | 136 | ||||||||||||
Stock-based compensation expense | 92.6 | 92.6 | |||||||||||||
Purchases of treasury stock (in shares) | 3.1 | ||||||||||||||
Purchases of treasury stock | (625.4) | $ (625.4) | |||||||||||||
Stock issued to effect stock split (in shares) | 413.8 | ||||||||||||||
Stock issued to effect stock split | 0 | $ 413.8 | (413.8) | ||||||||||||
Ending balance (in shares) at Dec. 31, 2020 | 636.4 | 12.1 | |||||||||||||
Ending balance at Dec. 31, 2020 | $ 4,574.3 | $ 636.4 | $ (1,904.1) | $ 1,438.1 | $ 4,565 | $ (161.1) |
DESCRIPTION OF BUSINESS
DESCRIPTION OF BUSINESS | 12 Months Ended |
Dec. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
DESCRIPTION OF BUSINESS | DESCRIPTION OF BUSINESSEdwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") conducts operations worldwide and is managed in the following geographical regions: United States, Europe, Japan, and Rest of World. Edwards Lifesciences is focused on technologies that treat structural heart disease and critically ill patients. The products and technologies provided by Edwards Lifesciences are categorized into the following main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The accompanying consolidated financial statements include the accounts of Edwards Lifesciences and its majority-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company reviews its investments in other entities to determine whether the Company is the primary beneficiary of a variable interest entity ("VIE"). The Company would be the primary beneficiary of the VIE, and would be required to consolidate the VIE, if it has the power to direct the significant activities of the entity and the obligation to absorb losses or receive benefits from the entity that may be significant to the VIE. Based on the Company's analysis, it determined it is not the primary beneficiary of any VIEs; however, future events may require VIEs to be consolidated if the Company becomes the primary beneficiary. Certain reclassifications of previously reported amounts have been made to conform to classifications used in the current year. Stock Split On May 7, 2020, the Company’s Board of Directors declared a three-for-one stock split of its outstanding shares of common stock effected in the form of a stock dividend, distributed on May 29, 2020 to stockholders of record on May 18, 2020. The Company distributed two newly issued shares of common stock to holders of record of each share of common stock to effect the stock split. All applicable share and per-share amounts in the consolidated financial statements and the notes to consolidated financial statements have been retroactively adjusted to reflect this stock split. The consolidated balance sheet as of December 31, 2019 and the consolidated statements of stockholders’ equity for the twelve months ended December 31, 2019 have not been retroactively adjusted to reflect the stock split. Use of Estimates The consolidated financial statements of Edwards Lifesciences have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") which have been applied consistently in all material respects. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates. In particular, the novel Coronavirus ("COVID-19") pandemic has adversely impacted and is likely to further adversely impact nearly all aspects of our business and markets, including our workforce and the operations of our customers, suppliers, and business partners. The full extent to which the pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including sales, expenses, manufacturing, clinical trials, research and development costs, reserves and allowances, fair value measurements, asset impairment charges, contingent consideration obligations, and the effectiveness of the Company's hedging instruments, will depend on future developments that are highly uncertain and difficult to predict. These developments include, but are not limited to, the duration and spread of the outbreak (including new variants of COVID-19), its severity, the actions to contain the virus or address its impact, the timing, distribution, and efficacy of vaccines and other treatments, U.S. and foreign government actions to respond to the reduction in global economic activity, and how quickly and to what extent normal economic and operating conditions can resume. Foreign Currency Translation When the local currency of the Company's foreign entities is the functional currency, all assets and liabilities are translated into United States dollars at the rate of exchange in effect at the balance sheet date. Income and expense items are translated at the weighted-average exchange rate prevailing during the period. The effects of foreign currency translation adjustments for these entities are deferred and reported in stockholders' equity as a component of " Accumulated Other Comprehensive Loss ." The effects of foreign currency transactions denominated in a currency other than an entity's functional currency are included in " Other Income, net. " Revenue Recognition Revenue is recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products or services. The Company generates nearly all of its revenue from direct product sales and sales of products under consignment arrangements. Revenue from direct product sales is recognized at a point in time when the performance obligation is satisfied upon delivery of the product. Revenue from sales of consigned inventory is recognized at a point in time when the performance obligation is satisfied once the product has been implanted or used by the customer. The Company periodically reviews consignment inventories to confirm the accuracy of customer reporting. The Company also generates a small portion of its revenue from service contracts, and recognizes revenue from service contracts ratably over the term of the contracts. Sales taxes and other similar taxes that the Company collects concurrent with revenue-producing activities are excluded from revenue. The Company does not typically have any significant unusual payment terms beyond 90 days in its contracts with customers. In addition, the Company receives royalty payments for the licensing of certain intellectual property and recognizes the royalty when the subsequent sale of product using the intellectual property occurs. The amount of consideration the Company ultimately receives varies depending upon the return terms, sales rebates, discounts, and other incentives that the Company may offer, which are accounted for as variable consideration when estimating the amount of revenue to recognize. The Company includes estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely upon an assessment of historical payment experience, historical relationship to revenues, estimated customer inventory levels, and current contract sales terms with direct and indirect customers. The Company's sales adjustment related to distributor rebates given to the Company's United States distributors represents the difference between the Company's sales price to the distributor and the negotiated price to be paid by the end-customer. This distributor rebate is recorded as a reduction to sales and a reduction to the distributor's accounts receivable at the time of sale to a distributor. The Company periodically monitors current pricing trends and distributor inventory levels to ensure the credit for future distributor rebates is fairly stated. The Company offers volume rebates to certain group purchasing organizations ("GPOs") and customers based upon targeted sales levels. Volume rebates offered to GPOs are recorded as a reduction to sales and an obligation to the GPOs, as the Company expects to pay in cash. Volume rebates offered to customers are recorded as a reduction to sales and either accounts receivable if the Company expects a net payment from the customer, or as an obligation to the customer if the Company expects to pay in cash. The provision for volume rebates is estimated based upon customers' contracted rebate programs, projected sales levels, and historical experience of rebates paid. The Company periodically monitors its customer rebate programs to ensure that the allowance and liability for accrued rebates is fairly stated. Product returns are typically not significant because returns are generally not allowed unless the product is damaged at time of receipt. In limited circumstances, the Company may allow customers to return previously purchased products, such as for next-generation product offerings. For these transactions, the Company defers recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. The Company sells separately priced service contracts, which range from 12 to 36 months, to owners of its hemodynamic monitors. The Company invoices the customer the total amount of consideration at the inception of the contract and recognizes revenue ratably over the term of the contract. As of December 31, 2020 and December 31, 2019, $6.3 million and $8.4 million, respectively, of deferred revenue associated with outstanding service contracts was recorded in “ Accrued and Other Liabilities ” and " Other Long-term Liabilities. " During 2020, the Company recognized as revenue $6.3 million that was included in the balance of deferred revenue as of December 31, 2019, and during 2019, the Company recognized as revenue $5.5 million that was included in the balance of deferred revenue as of December 31, 2018. A limited number of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the transaction price is allocated to each performance obligation based on its relative standalone selling price charged to other customers. The Company applies the optional exemption of not disclosing the amount of the transaction price allocated to unsatisfied performance obligations for contracts with an original expected duration of one year or less. Shipping and Handling Costs Shipping costs, which are costs incurred to physically move product from the Company's premises or third party distribution centers, including storage, to the customer's premises, are included in " Selling, General, and Administrative Expenses ." Handling costs, which are costs incurred to store at the Company's premises, move, and prepare products for shipment, are included in " Cost of Sales ." For the years ended December 31, 2020, 2019, and 2018, shipping costs of $74.0 million, $71.5 million, and $70.6 million, respectively, were included in " Selling, General, and Administrative Expenses ." Cash Equivalents The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. These investments are valued at cost, which approximates fair value. Investments The Company invests its excess cash in debt securities, including time deposits, commercial paper, U.S. government and agency securities, asset-backed securities, corporate debt securities, and municipal debt securities. Investments with maturities of one year or less are classified as short-term, and investments with maturities greater than one year are classified as long-term. Investments that the Company has the ability and intent to hold until maturity are classified as held-to-maturity and carried at amortized cost. Investments in debt securities that are classified as available-for-sale are carried at fair value with unrealized gains and losses included in " Accumulated Other Comprehensive Loss ." The Company determines the appropriate classification of its investments in debt securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company also has long-term equity investments in companies that are in various stages of development. These investments are reported at fair value or under the equity method of accounting, as appropriate. Equity investments that do not have readily determinable fair values are recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The Company accounts for investments in limited partnerships and limited liability corporations, whereby the Company owns a minimum of 5% of the investee's outstanding voting stock, under the equity method of accounting. These investments are recorded at the amount of the Company's investment and adjusted each period for the Company's share of the investee's income or loss, and dividends paid. Realized gains and losses on investments that are sold are determined using the specific identification method, or the first-in, first-out method, depending on the investment type, and recorded to " Other Income, net ." Income relating to investments in debt securities is recorded to " Interest Income. " Equity investments without readily determinable fair value are considered impaired when there is an indication that the fair value of the Company's interest is less than the carrying amount. Equity method investments are considered impaired when there is an indication of an other-than-temporary decline in value below the carrying amount. Impairments of equity investments are recorded in " Other Income, net. " Debt securities in an unrealized loss position are written down to fair value through “ Other Income, net ” if the Company intends to sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security, among other factors. When a credit loss exists, the Company compares the present value of cash flows expected to be collected from the debt security to the amortized cost basis of the security to determine the allowance amount that should be recorded, if any. For available-to-sale debt securities, any additional impairment not recorded through an allowance for credit losses is recognized in “ Accumulated Other Comprehensive Loss. ” Accounts Receivable The majority of the Company’s accounts receivable arise from direct product sales and sales of products under consignment arrangements, and have payment terms that generally require payment within 30 to 90 days. The Company does not adjust its receivables for the effects of a significant financing component at contract exception if collection of the receivable is expected within one year or less from the time of sale. In countries where the Company has experienced a pattern of payments extending beyond the stated terms and collection of the receivable is expected beyond one year from the time of sale, the Company assesses whether the customer has a significant financing component and discounts the receivable and reduces the related revenues over the period of time that the Company estimates those amounts will be paid using the country’s market-based borrowing rate for such period. The Company provides reserves against accounts receivable for estimated losses that may result from a customer’s inability to pay based on customer-specific analysis and general matters such as current assessments of past due balances, economic conditions and forecasts, and historical credit loss activity. Amounts determined to be uncollectible are charged or written-off against the reserve. Inventories Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. Market value for raw materials is based on replacement costs, and for other inventory classifications is based on net realizable value. A write-down for excess or slow moving inventory is recorded for inventory which is obsolete, damaged, nearing its expiration date (generally triggered at six months prior to expiration), or slow moving (generally defined as quantities in excess of a two-year supply). The Company allocates to inventory general and administrative costs that are related to the production process. These costs include insurance, manufacturing accounting personnel, human resources personnel, and information technology. During the years ended December 31, 2020, 2019, and 2018, the Company allocated $63.1 million, $56.6 million, and $45.0 million, respectively, of general and administrative costs to inventory. General and administrative costs included in inventory at December 31, 2020 and 2019 were $30.7 million and $22.8 million, respectively. At December 31, 2020 and 2019, $130.0 million and $117.8 million, respectively, of the Company's finished goods inventories were held on consignment. Property, Plant, and Equipment Property, plant, and equipment are recorded at cost. Depreciation is principally calculated for financial reporting purposes on the straight-line method over the estimated useful lives of the related assets, which range from 10 to 40 years for buildings and improvements, from 3 to 15 years for machinery and equipment, and from 3 to 5 years for software. Leasehold improvements are amortized over the life of the related facility leases or the asset, whichever is shorter. Straight-line and accelerated methods of depreciation are used for income tax purposes. Construction in progress is not depreciated until the asset is ready for its intended use. Depreciation expense for property, plant, and equipment was $101.8 million, $84.7 million, and $74.9 million for the years ended December 31, 2020, 2019, and 2018, respectively. Leases On January 1, 2019, the Company adopted an amendment to the guidance on leases using a modified retrospective transition approach. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. The Company's incremental borrowing rate is determined based on the estimated rate of interest for collateralized borrowing over a similar term as the associated lease. Right-of-use assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received. The Company determines the lease term as the noncancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Certain of the Company’s leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. The Company’s leases do not contain any residual value guarantees. The Company accounts for the lease and non-lease components as a single lease component for all of its leases except vehicle leases, for which the lease and non-lease components are accounted for separately. Operating leases are included in “ Operating Lease Right-of-Use Assets ” and “ Operating Lease Liabilities ” on the Company’s consolidated balance sheets. See Note 6 for further information. Impairment of Goodwill and Long-lived Assets Goodwill is reviewed for impairment annually in the fourth quarter of each fiscal year, or whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Goodwill is tested for impairment at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the reporting unit does not pass the qualitative assessment, then the Company performs a quantitative impairment test. The Company determined, after performing a qualitative review of each reporting unit, that it is more likely than not that the fair value of each of its reporting units substantially exceeds the respective carrying amounts. Accordingly, in 2020, 2019, and 2018, the Company did not record any impairment loss. Indefinite-lived intangible assets relate to in-process research and development acquired in business combinations. The estimated fair values of in-process research and development projects acquired in a business combination which have not reached technological feasibility are capitalized and accounted for as indefinite-lived intangible assets subject to impairment testing until completion or abandonment of the projects. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If the project is abandoned, all remaining capitalized amounts are written off immediately. Indefinite-lived intangible assets are reviewed for impairment annually in the fourth quarter of each fiscal year, or whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. An impairment loss is recognized when the asset's carrying value exceeds its fair value. In-process research and development projects acquired in an asset acquisition are expensed unless the project has an alternative future use. Management reviews the carrying amounts of other finite-lived intangible assets and long-lived tangible assets whenever events or circumstances indicate that the carrying amounts of an asset may not be recoverable. Impairment indicators include, among other conditions, cash flow deficits, historic or anticipated declines in revenue or operating profit, and adverse legal or regulatory developments. If it is determined that such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair market value. Estimated fair market value is determined primarily using the anticipated cash flows discounted at a rate commensurate with the risk involved. For the purposes of identifying and measuring impairment, long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. In 2020, the Company did not record any impairment loss related to its in-process research and development assets. In 2019, the Company recorded a $40.6 million charge related to the impairment of certain in-process research and development assets. In 2018, the Company recorded a $116.2 million charge related to the impairment of certain developed technology and in-process research and development assets. See Note 4 for further information. Income Taxes The Company is subject to income taxes in the United States and numerous foreign jurisdictions. Significant judgment is required in evaluating the Company's uncertain tax positions and determining its provision for income taxes. The Company recognizes the financial statement benefit of a tax position only after determining that a position would more likely than not be sustained based upon its technical merit if challenged by the relevant taxing authority and taken by management to the court of last resort. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company has made an accounting policy election to recognize the U.S. tax effects of global intangible low-taxed income as a component of income tax expense in the period the tax arises. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. The Company evaluates quarterly the realizability of its deferred tax assets by assessing its valuation allowance and adjusting the amount, if necessary. The factors used to assess the likelihood of realization are both historical experience and the Company's forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. Failure to achieve forecasted taxable income in the applicable taxing jurisdictions could affect the ultimate realization of deferred tax assets and could result in an increase in the Company's effective tax rate on future earnings. Research and Development Costs Research and development costs are charged to expense when incurred. Earnings per Share Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during a period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, nonvested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. The table below presents the computation of basic and diluted earnings per share (in millions, except for per share information): Years Ended December 31, 2020 2019 2018 Basic: Net income $ 823.4 $ 1,046.9 $ 722.2 Weighted-average shares outstanding 622.6 624.8 627.6 Basic earnings per share $ 1.32 $ 1.68 $ 1.15 Diluted: Net income $ 823.4 $ 1,046.9 $ 722.2 Weighted-average shares outstanding 622.6 624.8 627.6 Dilutive effect of stock plans 9.3 11.9 13.3 Dilutive weighted-average shares outstanding 631.9 636.7 640.9 Diluted earnings per share $ 1.30 $ 1.64 $ 1.13 Stock options, restricted stock units, and market-based restricted stock units to purchase approximately 2.0 million, 1.5 million, and 3.2 million shares were outstanding for the years ended December 31, 2020, 2019, and 2018, respectively, but were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive. Stock-based Compensation The Company measures and recognizes compensation expense for all stock-based awards based on estimated fair values. Stock-based awards consist of stock options, restricted stock units (service-based, market-based, and performance-based), and employee stock purchase subscriptions. Stock-based compensation expense is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period (vesting period) on a straight-line basis. For performance-based restricted stock units, the Company recognizes stock-based compensation expense if and when the Company concludes that it is probable that the performance condition will be achieved, net of estimated forfeitures. The Company reassesses the probability of vesting at each quarter end and adjusts the stock-based compensation expense based on its probability assessment. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Upon exercise of stock options or vesting of restricted stock units, the Company issues common stock. Total stock-based compensation expense was as follows (in millions): Years Ended December 31, 2020 2019 2018 Cost of sales $ 17.2 $ 14.7 $ 11.4 Selling, general, and administrative expenses 56.6 51.2 46.3 Research and development expenses 18.8 15.4 13.3 Total stock-based compensation expense 92.6 81.3 71.0 Income tax benefit (15.4) (14.8) (13.4) Total stock-based compensation expense, net of tax $ 77.2 $ 66.5 $ 57.6 Upon a participant's retirement, all unvested stock options and performance-based restricted stock units are immediately forfeited. In addition, upon retirement, a participant will immediately vest in 25% of service-based restricted stock units for each full year of employment with the Company measured from the grant date. All remaining unvested service-based restricted stock units are immediately forfeited. For market-based restricted stock units, upon retirement and in certain other specified cases, a participant will receive a pro-rated portion of the shares that would ultimately be issued based on attainment of the performance goals as determined on the vesting date. The pro-rated portion is based on the participant's whole months of service with the Company during the performance period prior to the date of termination. Derivatives The Company uses derivative financial instruments to manage interest rate and foreign currency risks. It is the Company's policy not to enter into derivative financial instruments for speculative purposes. Derivative financial instruments involve credit risk in the event the counterparty should default. It is the Company's policy to execute such instruments with global financial institutions that the Company believes to be creditworthy. The Company diversifies its derivative financial instruments among counterparties to minimize exposure to any one of these entities. The Company also uses International Swap Dealers Association master-netting agreements. The master-netting agreements provide for the net settlement of all contracts through a single payment in a single currency in the event of default, as defined by the agreements. The Company uses foreign currency forward exchange contracts, cross currency swap contracts, and foreign currency denominated debt to manage its exposure to changes in currency exchange rates from (1) future cash flows associated with intercompany transactions and certain local currency expenses expected to occur within the next 13 months (designated as cash flow hedges), (2) its net investment in certain foreign subsidiaries (designated as net investment hedges) and (3) foreign currency denominated assets or liabilities (designated as fair value hedges). The Company also uses foreign currency forward exchange contracts that are not designated as hedging instruments to offset the transaction gains and losses associated with certain assets and liabilities denominated in currencies other than their functional currencies resulting principally from intercompany and local currency transactions. All derivative financial instruments are recognized at fair value in the consolidated balance sheets. For each derivative instrument that is designated as a fair value hedge, the gain or loss on the derivative included in the assessment of hedge effectiveness is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. The Company reports in " Accumulated Other Comprehensive Loss " the gain or loss on derivative financial instruments that are designated, and that qualify, as cash flow hedges. The Company reclassifies these gains and losses into earnings in the same line item and in the same period in which the underlying hedged transactions affect earnings. Changes in the fair value of net investment hedges are reported in " Accumulated Other Comprehensive Loss " as a part of the cumulative translation adjustment and would be reclassified into earnings if the underlying net investment is sold or substantially liquidated. The portion of the change in fair value related to components excluded from the hedge effectiveness assessment are amortized into earnings over the life of the derivative. The gains and losses on derivative financial instruments for which the Company does not elect hedge accounting treatment are recognized in the consolidated statements of operations in each period based upon the change in the fair value of the derivative financial instrument. Cash flows from net investment hedges are reported as investing activities in the consolidated statements of cash flows, and cash flows from all other derivative financial instruments are reported as operating activities. Recently Adopted Accounting Standards In August 2018, the Financial Accounting Standards Board ("FASB") issued an amendment to the accounting guidance on cloud computing service arrangements. The guidance aligns the requirements for capitalizing implementation costs incurred i |
INTELLECTUAL PROPERTY LITIGATIO
INTELLECTUAL PROPERTY LITIGATION EXPENSES, NET | 12 Months Ended |
Dec. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
INTELLECTUAL PROPERTY LITIGATION EXPENSES, NET | INTELLECTUAL PROPERTY LITIGATION EXPENSES, NET The Company incurred intellectual property litigation expenses, including settlements and external legal costs, of $405.4 million, $33.4 million and $214.0 million during 2020, 2019 and 2018, respectively. On July 12, 2020, the Company reached an agreement with Abbott Laboratories and its direct and indirect subsidiaries ("Abbott") to, among other things, settle all outstanding patent disputes between the companies (the “Settlement Agreement”) in cases related to transcatheter mitral and tricuspid repair products. See Note 18 for additional information. The Settlement Agreement resulted in the Company recording an estimated $367.9 million pre-tax charge and related liability in June 2020 related to past damages. In addition, the Company will incur royalty expenses through May 2024 totaling an estimated $100 million. The Company made a one-time $100.0 million payment to Abbott in July 2020, and will make quarterly payments in future years. |
SPECIAL CHARGES (GAIN)
SPECIAL CHARGES (GAIN) | 12 Months Ended |
Dec. 31, 2020 | |
Other Income and Expenses [Abstract] | |
SPECIAL CHARGES (GAIN) | SPECIAL CHARGES (GAIN) Impairment of Long-lived Assets In December 2019, the Company recorded a charge of $40.6 million related to the impairment of certain in-process research and development assets, and in December 2018, the Company recorded a charge of $116.2 million related to the impairment of certain developed technology and in-process research and development assets. These assets were acquired as part of the acquisition of Valtech Cardio Ltd. ("Valtech"). The Company measured the amount of the impairments by calculating the amount by which the carrying values exceeded the estimated fair values, which were based on projected discounted future net cash flows. Based on market and clinical trial developments at the time of the impairments, the Company re-evaluated the clinical development plans for the technologies acquired from Valtech, which resulted in a reduction to the projected near-term discounted future net cash flows related to the acquired mitral technology for the 2018 charge, and related to the acquired mitral and tricuspid technology for the 2019 charge. The impairments were recorded to the Company’s Rest of World segment. Acquisition of Intellectual Property In March 2019, the Company recorded a $24.0 million charge related to the acquisition of early-stage transcatheter intellectual property and associated clinical and regulatory experience. Pension Gain |
OTHER CONSOLIDATED FINANCIAL ST
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS | 12 Months Ended |
Dec. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS | OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS Composition of Certain Financial Statement Captions Components of selected captions in the consolidated balance sheets are as follows: As of December 31, 2020 2019 (in millions) Inventories Raw materials $ 136.7 $ 118.0 Work in process 140.0 121.7 Finished products 525.6 401.2 $ 802.3 $ 640.9 Property, plant, and equipment, net Land $ 97.6 $ 98.0 Buildings and leasehold improvements 881.5 619.8 Machinery and equipment 564.9 466.3 Equipment with customers 42.2 35.6 Software 94.2 87.9 Construction in progress 313.3 265.0 1,993.7 1,572.6 Accumulated depreciation (598.5) (512.3) $ 1,395.2 $ 1,060.3 Accrued and other liabilities Employee compensation and withholdings $ 236.7 $ 295.8 Accrued rebates 67.2 67.1 Property, payroll, and other taxes 49.7 51.4 Research and development accruals 52.3 51.4 Litigation settlement (Notes 3 and 18) 37.5 — Litigation and insurance reserves (Note 18) 23.3 20.0 Taxes payable 18.6 52.9 Fair value of derivatives 39.3 6.4 Accrued marketing expenses 14.3 17.5 Accrued professional services 7.6 10.1 Accrued realignment reserves 14.5 16.7 Accrued relocation related costs 21.0 17.4 Other accrued liabilities 88.2 89.8 $ 670.2 $ 696.5 In 2019, the Company recorded a $73.1 million charge to " Cost of Sales ," primarily comprised of the write off of inventory related to strategic decisions regarding its transcatheter aortic valve portfolio, including the decision to discontinue its CENTERA program. Supplemental Cash Flow Information (in millions) Years Ended December 31, 2020 2019 2018 Cash paid during the year for: Interest $ 19.9 $ 19.9 $ 30.1 Income taxes $ 197.9 $ 61.5 $ 223.7 Amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 29.7 $ 28.6 $ — Non-cash investing and financing transactions: Fair value of shares issued in payment for contingent consideration liabilities $ — $ — $ 34.3 Right-of-use assets obtained in exchange for new lease liabilities $ 39.7 $ 49.6 $ — Capital expenditures accruals $ 80.4 $ 50.8 $ 18.7 Cash, Cash Equivalents, and Restricted Cash (in millions) Years Ended December 31, 2020 2019 2018 Cash and cash equivalents $ 1,183.2 $ 1,179.1 $ 714.1 Restricted cash included in other current assets 16.6 1.6 1.5 Restricted cash included in other assets 0.4 3.7 0.3 Total cash, cash equivalents, and restricted cash $ 1,200.2 $ 1,184.4 $ 715.9 Amounts included in restricted cash primarily represent funds placed in escrow related to litigation and real estate purchases, and funds restricted for construction. |
LEASES
LEASES | 12 Months Ended |
Dec. 31, 2020 | |
Leases [Abstract] | |
LEASES | LEASES The Company leases certain office space, manufacturing facilities, land, apartments, warehouses, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 20 years, some of which include options to extend or terminate the leases. Operating lease costs for the years ended December 31, 2020, 2019, and 2018 were $30.5 million, $27.9 million, and $27.0 million, respectively. Short-term and variable lease costs were not material for the years ended December 31, 2020 and 2019. Supplemental balance sheet information related to operating leases was as follows (in millions, except lease term and discount rate): As of December 31, 2020 2019 Operating lease right-of-use assets $ 94.2 $ 80.1 Operating lease liabilities, current portion $ 27.2 $ 25.5 Operating lease liabilities, long-term portion 72.7 58.9 Total operating lease liabilities $ 99.9 $ 84.4 Maturities of operating lease liabilities at December 31, 2020 were as follows (in millions): 2021 $ 30.0 2022 20.7 2023 14.4 2024 8.8 2025 6.1 Thereafter 28.1 Total lease payments 108.1 Less: imputed interest (8.2) Total lease liabilities $ 99.9 The following table provides information on the lease terms and discount rates: Years Ended December 31, 2020 2019 Weighted-average remaining lease term (in years) 6.6 5.3 Weighted-average discount rate 2.7 % 2.8 % |
INVESTMENTS
INVESTMENTS | 12 Months Ended |
Dec. 31, 2020 | |
Investments, Debt and Equity Securities [Abstract] | |
INVESTMENTS | INVESTMENTS Debt Securities Investments in debt securities at the end of each period were as follows (in millions): December 31, 2020 December 31, 2019 Held-to-maturity Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Bank time deposits $ 50.0 $ — $ — $ 50.0 $ 100.2 $ — $ — $ 100.2 Available-for-sale Bank time deposits $ 24.1 $ — $ — $ 24.1 $ 13.1 $ — $ — $ 13.1 Commercial paper — — — — 34.3 — — 34.3 U.S. government and agency securities 147.0 2.2 — 149.2 113.2 0.6 — 113.8 Foreign government bonds — — — — 1.7 — — 1.7 Asset-backed securities 149.6 1.9 — 151.5 141.2 0.6 (0.1) 141.7 Corporate debt securities 600.8 7.5 — 608.3 487.0 2.3 (0.1) 489.2 Municipal securities 2.8 — — 2.8 — — — — $ 924.3 $ 11.6 $ — $ 935.9 $ 790.5 $ 3.5 $ (0.2) $ 793.8 The cost and fair value of investments in debt securities, by contractual maturity, as of December 31, 2020 were as follows: Held-to-Maturity Available-for-Sale Amortized Cost Fair Value Amortized Cost Fair Value (in millions) Due in 1 year or less $ 50.0 $ 50.0 $ 168.4 $ 169.4 Due after 1 year through 5 years — — 578.2 586.5 Instruments not due at a single maturity date — — 177.7 180.0 $ 50.0 $ 50.0 $ 924.3 $ 935.9 Actual maturities may differ from the contractual maturities due to call or prepayment rights. There were no investments that were in an unrealized loss position as of December 31, 2020. The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2019, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in millions): December 31, 2019 Less than 12 Months 12 Months or Greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Asset-backed securities $ 73.4 $ (0.1) $ — $ — $ 73.4 $ (0.1) Corporate debt securities 81.4 (0.1) — — 81.4 (0.1) $ 154.8 $ (0.2) $ — $ — $ 154.8 $ (0.2) Investments in Unconsolidated Affiliates The Company has a number of equity investments in privately and publicly held companies. Investments in these unconsolidated affiliates are recorded in " Long-term Investments " on the consolidated balance sheets, and are as follows: December 31, 2020 2019 (in millions) Equity method investments Carrying value of equity method investments $ 5.7 $ 6.2 Equity securities Carrying value of non-marketable equity securities 29.4 23.1 Total investments in unconsolidated affiliates $ 35.1 $ 29.3 Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values, and are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The Company recorded an upward adjustment of $1.8 million based on observable price changes and a downward adjustment of $0.7 million due to an impairment during 2020, and an upward adjustment of $0.3 million based on observable price changes during 2019. As of December 31, 2020 and 2019, the Company had recorded accumulated upward adjustments of $3.8 million and $2.0 million, respectively, based on observable price changes, and accumulated downward adjustments of $2.6 million and $1.9 million, respectively, due to impairment and observable price changes. |
ACQUISITIONS
ACQUISITIONS | 12 Months Ended |
Dec. 31, 2020 | |
Business Combinations [Abstract] | |
ACQUISITIONS | ACQUISITIONS CAS Medical Systems, Inc. On February 11, 2019, the Company entered into an agreement and plan of merger to acquire all the outstanding shares of CAS Medical Systems, Inc. ("CASMED") for an aggregate cash purchase price of $2.45 per share of common stock, or an equity value of approximately $100 million. The transaction closed on April 18, 2019, and the cash purchase price was $100.8 million. Acquisition-related costs of $2.0 million were recorded in “ Selling, General, and Administrative Expenses ” during the year ended December 31, 2019. CASMED is a medical technology company dedicated to noninvasive monitoring of tissue oxygenation in the brain. The Company integrated the acquired technology platform into its hemodynamic monitoring platform. The acquisition was accounted for as a business combination. Tangible and intangible assets acquired were recorded based on their estimated fair values at the acquisition date. The excess of the purchase price over the fair value of net assets acquired was recorded to goodwill. The following table summarizes the fair values of the assets acquired and liabilities assumed (in millions): Current assets $ 6.1 Property and equipment, net 1.3 Goodwill 64.4 Developed technology 35.9 Customer relationships 8.8 Deferred tax assets 2.2 Liabilities assumed (17.9) Total purchase price 100.8 Less: cash acquired (0.6) Total purchase price, net of cash acquired $ 100.2 Goodwill includes expected synergies and other benefits the Company believes will result from the acquisition. Goodwill was assigned to the Company’s United States segment and is not deductible for tax purposes. Developed technology assets are being amortized over a weighted-average useful life of 14 years. Customer relationships assets are being amortized over a weighted-average useful life of 10 years. The results of operations for CASMED have been included in the accompanying consolidated financial statements from the date of acquisition. Pro forma results have not been presented as the results of CASMED are not material in relation to the consolidated financial statements of Edwards Lifesciences. Harpoon Medical, Inc. On December 1, 2017, the Company acquired all the outstanding shares of Harpoon Medical, Inc. for an aggregate cash purchase price of $119.5 million, which includes $16.0 million paid previously for a cost method investment and an exclusive option to acquire Harpoon Medical, Inc., and is net of $8.0 million received from the sale of the Company's previous ownership interest. In addition, the Company agreed to pay up to an additional $150.0 million in pre-specified milestone-driven payments over the next 10 years. The Company recognized in " Contingent Consideration Liabilities " a $59.7 million liability for the estimated fair value of the contingent milestone payments. The fair value of the contingent milestone payments are remeasured each quarter, with changes in the fair value recognized within operating expenses on the consolidated statements of operations. For further information on the fair value of the contingent milestone payments, see Note 11. In-process research and development assets acquired as part of this transaction were capitalized at fair value, which was determined using the income approach. This approach determines fair value based on cash flow projections which are discounted to present value using a risk-adjusted rate of return. Completion of successful design developments, bench testing, pre-clinical studies and human clinical studies are required prior to selling any product. The risks and uncertainties associated with completing development within a reasonable period of time include those related to the design, development, and manufacturability of the product, the success of pre-clinical and clinical studies, and the timing of regulatory approvals. The valuation assumed $41.4 million of additional research and development expenditures would be incurred prior to the date of product introduction. In the valuation, net cash inflows were modeled to commence in Europe in 2018, and in the United States and Japan in 2022. The Company does not currently anticipate significant changes to forecasted research and development expenditures, and net cash inflows commenced in Europe in 2020 and are now expected to commence in the United States and Japan in 2023. Upon completion of development, the underlying in-process research and development asset will be amortized over its estimated useful life. Valtech Cardio Ltd. On November 26, 2016, the Company entered into an agreement and plan of merger to acquire Valtech Cardio Ltd. ("Valtech") for approximately $340.0 million, subject to certain adjustments, with the potential for up to an additional $350.0 million in pre-specified milestone-driven payments over the next 10.0 years. The transaction closed on January 23, 2017, and the consideration paid included the issuance of approximately 2.8 million shares of the Company's common stock (fair value of $266.5 million) and cash of $86.2 million. The Company recognized in " Contingent Consideration Liabilities " a $162.9 million liability for the estimated fair value of the contingent milestone payments. For further information on the fair value of the contingent milestone payments, see Note 11. Prior to the close of the transaction, Valtech spun off its early-stage transseptal mitral valve replacement technology program. Concurrent with the closing, the Company entered into an agreement for an exclusive option to acquire that program and its associated intellectual property for approximately $200.0 million, subject to certain adjustments, plus an additional $50.0 million if a certain European regulatory approval is obtained within 10 years of the acquisition closing date. The option expired in January 2020. In-process research and development assets acquired as part of this transaction were capitalized at fair value, which was determined using the income approach. This approach determines fair value based on cash flow projections which are discounted to present value using a risk-adjusted rate of return. The valuation assumed $87.3 million of additional research and development expenditures would be incurred prior to the date of product introduction and that net cash inflows would commence in 2019. In December 2018, the Company recorded a $116.2 million impairment charge related to Valtech's intangible assets, and in December 2019, the Company recorded a $40.6 million impairment charge to write off the remaining in-process research and development assets. For further information, see Note 4. CardiAQ Valve Technologies, Inc. On July 3, 2015, the Company entered into an agreement and plan of merger to acquire CardiAQ Valve Technologies, Inc. ("CardiAQ") for an aggregate cash purchase price of $350.0 million, subject to certain adjustments. The transaction closed on August 26, 2015, and the cash purchase price after the adjustments was $348.0 million. In addition, the Company agreed to pay an additional $50.0 million if a certain European regulatory approval is obtained within 48 months of the acquisition closing date. The Company recognized in " Contingent Consideration Liabilities " a $30.3 million liability for the estimated fair value of this contingent milestone payment. The Company estimated this milestone would not be achieved and reversed the liability in 2018. For further information on the fair value of the contingent milestone payment, see Note 11. In-process research and development assets acquired as part of this acquisition were capitalized at fair value, which was determined using the income approach. This approach determines fair value based on cash flow projections which are discounted to present value using a risk-adjusted rate of return. Completion of successful design developments, bench testing, pre-clinical studies and human clinical studies are required prior to selling any product. The risks and uncertainties associated with completing development within a reasonable period of time include those related to the design, development, and manufacturability of the product, the success of pre-clinical and clinical studies, and the timing of regulatory approvals. The valuation assumed $97.7 million of additional research and development expenditures would be incurred prior to the date of |
GOODWILL AND OTHER INTANGIBLE A
GOODWILL AND OTHER INTANGIBLE ASSETS | 12 Months Ended |
Dec. 31, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and in-process research and development assets resulting from purchase business combinations are not subject to amortization. Other acquired intangible assets with finite lives are amortized over their expected useful lives on a straight-line basis, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be used. The Company expenses costs incurred to renew or extend the term of acquired intangible assets. In April 2019, the Company acquired CASMED. This transaction resulted in an increase to goodwill of $64.4 million and developed technology of $35.9 million. For further information, see Note 8. The changes in the carrying amount of goodwill, by segment, during the years ended December 31, 2020 and 2019 were as follows: United Europe Rest of World Total (in millions) Goodwill at December 31, 2018 $ 709.3 $ 64.2 $ 338.7 $ 1,112.2 Goodwill acquired during the year 64.4 — — 64.4 Currency translation adjustment — (1.4) (7.5) (8.9) Goodwill at December 31, 2019 773.7 62.8 331.2 1,167.7 Currency translation adjustment — 5.5 — 5.5 Goodwill at December 31, 2020 $ 773.7 $ 68.3 $ 331.2 $ 1,173.2 Other intangible assets consist of the following (in millions): December 31, Weighted-Average Useful Life (in years) 2020 2019 Cost Accumulated Net Cost Accumulated Net Finite-lived intangible assets Patents 7.4 $ 186.1 $ (183.6) $ 2.5 $ 185.7 $ (182.1) $ 3.6 Developed technology 13.1 155.2 (51.0) 104.2 153.5 (46.6) 106.9 Other 10.0 12.6 (6.0) 6.6 12.3 (4.4) 7.9 12.6 353.9 (240.6) 113.3 351.5 (233.1) 118.4 Indefinite-lived intangible assets In-process research and development 218.1 — 218.1 218.1 — 218.1 $ 572.0 $ (240.6) $ 331.4 $ 569.6 $ (233.1) $ 336.5 Amortization expense related to other intangible assets for the years ended December 31, 2020, 2019, and 2018 was $5.4 million, $4.6 million, and $2.5 million, respectively. Estimated amortization expense for each of the years ending December 31 is as follows (in millions): 2021 $ 5.2 2022 7.6 2023 10.1 2024 12.2 2025 14.8 |
DEBT AND CREDIT FACILITIES
DEBT AND CREDIT FACILITIES | 12 Months Ended |
Dec. 31, 2020 | |
Debt Disclosure [Abstract] | |
DEBT AND CREDIT FACILITIES | DEBT AND CREDIT FACILITIES In June 2018, the Company issued $600.0 million of fixed-rate unsecured senior notes (the "Notes") due June 15, 2028. Interest is payable semi-annually in arrears, with payments due in June and December of each year. The Company may redeem the Notes, in whole or in part, at any time and from time to time at specified redemption prices. In addition, upon the occurrence of certain change of control triggering events, the Company may be required to repurchase all or a portion of the Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest. The Notes also include covenants that limit the Company's ability to incur secured indebtedness, enter into sale and leaseback transactions, and consolidate, merge, or transfer all or substantially all of its assets. The following is a summary of the Notes as of December 31, 2020 and 2019: December 31, 2020 2019 Amount Effective Amount Effective (in millions) (in millions) Fixed-rate 4.300% 2018 Notes $ 600.0 4.329 % $ 600.0 4.329 % Unamortized discount (1.1) (1.2) Unamortized debt issuance costs (3.9) (4.4) Total carrying amount $ 595.0 $ 594.4 As of December 31, 2020 and 2019, the fair value of the Notes was $711.2 million and $667.6 million, respectively, based on observable market prices in less active markets and categorized as Level 2 (Note 11). The debt issuance costs, as well as the discount, are being amortized to interest expense over the term of the notes. The Company has a Five-Year Credit Agreement ("the Credit Agreement") which matures on April 28, 2023. The Credit Agreement provides up to an aggregate of $750.0 million in borrowings in multiple currencies. The Company may increase the amount available under the Credit Agreement, subject to agreement of the lenders, by up to an additional $250.0 million in the aggregate. Borrowings generally bear interest at the London interbank offered rate ("LIBOR"), or a comparable or successor rate, plus a spread ranging from 0.9% to 1.3%, depending on the leverage ratio, as defined in the Credit Agreement. The Company also pays a facility fee ranging from 0.1% to 0.2%, depending on the leverage ratio, on the entire credit commitment available, whether drawn or not. The facility fee is expensed as incurred. During 2020, the spread over LIBOR was 0.9% and the facility fee was 0.1%. Issuance costs of $2.4 million are being amortized to interest expense over the term of the Credit Agreement. As of December 31, 2020 and 2019, there were no borrowings outstanding under the Credit Agreement. Amounts outstanding under the Credit Agreement, if any from time to time, are classified as long-term obligations in accordance with the terms of the Credit Agreement. The Credit Agreement is unsecured and contains various financial and other covenants, including a maximum leverage ratio, as defined in the Credit Agreement. The Company was in compliance with all covenants at December 31, 2020. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 12 Months Ended |
Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS The consolidated financial statements include financial instruments for which the fair market value of such instruments may differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, accounts and other receivables, investments, accounts payable, certain accrued liabilities, and borrowings under a revolving credit agreement. The carrying value of these financial instruments generally approximates fair value due to their short-term nature. Financial instruments also include notes payable. See Note 10 for further information on the fair value of the notes payable. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Company prioritizes the inputs used to determine fair values in one of the following three categories: Level 1—Quoted market prices in active markets for identical assets or liabilities. Level 2—Inputs, other than quoted prices in active markets, that are observable, either directly or indirectly. Level 3—Unobservable inputs that are not corroborated by market data. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table summarizes the Company's financial instruments which are measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in millions): December 31, 2020 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 16.2 $ — $ — $ 16.2 Available-for-sale investments: Bank time deposits — 24.1 — 24.1 Corporate debt securities — 608.3 — 608.3 Asset-backed securities — 151.5 — 151.5 U.S. government and agency securities 56.9 92.2 — 149.1 Municipal securities — 2.8 — 2.8 Investments held for deferred compensation plans 111.2 — — 111.2 Derivatives — 8.1 — 8.1 $ 184.3 $ 887.0 $ — $ 1,071.3 Liabilities Derivatives $ — $ 39.3 $ — $ 39.3 Deferred compensation plans 111.6 — — 111.6 Contingent consideration liabilities — — 186.1 186.1 $ 111.6 $ 39.3 $ 186.1 $ 337.0 December 31, 2019 Assets Cash equivalents $ 0.7 $ 31.7 $ — $ 32.4 Available-for-sale investments: Bank time deposits — 13.1 — 13.1 Corporate debt securities — 489.2 — 489.2 Asset-backed securities — 141.7 — 141.7 U.S. government and agency securities 76.1 37.7 — 113.8 Foreign government bonds — 1.7 — 1.7 Commercial paper — 34.3 — 34.3 Investments held for deferred compensation plans 88.9 — — 88.9 Derivatives — 30.7 — 30.7 $ 165.7 $ 780.1 $ — $ 945.8 Liabilities Derivatives $ — $ 6.4 $ — $ 6.4 Deferred compensation plans 88.7 — — 88.7 Contingent consideration liabilities — — 172.5 172.5 $ 88.7 $ 6.4 $ 172.5 $ 267.6 The following table summarizes the changes in fair value of the contingent consideration obligation for the years ended December 31, 2020 and 2019 (in millions): December 31, 2020 2019 Fair value, beginning of year $ 172.5 $ 178.6 Changes in fair value 13.6 (6.1) Fair value, end of year $ 186.1 $ 172.5 The changes in 2020 in fair value of the contingent consideration obligation were primarily driven by the accretion of interest due to the passage of time and adjustments to discount rates, partially offset by a $12.7 million reduction to the liability due to changes in the projected probability and timing of milestone achievements, and the projected timing of cash inflows. During 2019, the contingent consideration liability was reduced by $24.1 million due to delays in product development, which reduced the probability of milestone achievement. This reduction was partially offset by changes in the fair value of the liabilities associated primarily with adjustments to discount rates and accretion of interest due to the passage of time. Cash Equivalents and Available-for-sale Investments The Company estimates the fair values of its money market funds based on quoted prices in active markets for identical assets. The Company estimates the fair values of its time deposits, commercial paper, U.S. and foreign government and agency securities, municipal securities, asset-backed securities, and corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades and broker-dealer quotes on the same or similar securities, benchmark yields, credit spreads, prepayment and default projections based on historical data, and other observable inputs. The Company independently reviews and validates the pricing received from the third-party pricing service by comparing the prices to prices reported by a secondary pricing source. The Company’s validation procedures have not resulted in an adjustment to the pricing received from the pricing service. Deferred Compensation Plans The Company holds investments in trading securities related to its deferred compensation plans. The investments are in a variety of stock, bond, and money market mutual funds. The fair values of these investments and the corresponding liabilities are based on quoted market prices. Derivative Instruments The Company uses derivative financial instruments in the form of foreign currency forward exchange contracts and cross currency swap contracts to manage foreign currency exposures. All derivatives contracts are recognized on the balance sheet at their fair value. The fair value of foreign currency derivative financial instruments and the cross currency swap contracts was estimated based on quoted market foreign exchange rates, cross currency swap basis rates, and market discount rates. Judgment was employed in interpreting market data to develop estimates of fair value; accordingly, the estimates presented herein are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The use of different market assumptions or valuation methodologies could have a material effect on the estimated fair value amounts. Contingent Consideration Liabilities Certain of the Company's acquisitions involve contingent consideration arrangements. Payment of additional consideration is contingent upon the acquired company reaching certain performance milestones, such as attaining specified revenue levels or obtaining regulatory approvals. These contingent consideration liabilities are measured at estimated fair value using either a probability weighted discounted cash flow analysis or a Monte Carlo simulation model, both of which consider significant unobservable inputs. These inputs include (1) the discount rate used to present value the projected cash flows |
DERIVATIVE INSTRUMENTS AND HEDG
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES | 12 Months Ended |
Dec. 31, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES | DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES The Company uses derivative financial instruments to manage its currency exchange rate risk and its interest rate risk as summarized below. Notional amounts are stated in United States dollar equivalents at spot exchange rates at the respective dates. The Company does not enter into these arrangements for trading or speculation purposes. Notional Amount December 31, 2020 December 31, 2019 (in millions) Foreign currency forward exchange contracts $ 1,525.5 $ 1,336.5 Cross currency swap contracts 300.0 300.0 The following table presents the location and fair value amounts of derivative instruments reported in the consolidated balance sheets (in millions): Fair Value Balance Sheet Location December 31, 2020 December 31, 2019 Derivatives designated as hedging instruments Assets Foreign currency contracts Other current assets $ 7.3 $ 14.2 Foreign currency contracts Other assets $ — $ 3.2 Cross currency swap contracts Other assets $ 0.8 $ 13.3 Liabilities Foreign currency contracts Accrued and other liabilities $ 39.3 $ 6.4 The following table presents the effect of master-netting agreements and rights of offset on the consolidated balance sheets (in millions): Gross Amounts Not Offset in the Consolidated Balance Sheet Gross Amounts Net Amounts December 31, 2020 Gross Financial Cash Net Derivative Assets Foreign currency contracts $ 7.3 $ — $ 7.3 $ (6.1) $ — $ 1.2 Cross currency swap contracts $ 0.8 $ — $ 0.8 $ — $ — $ 0.8 Derivative Liabilities Foreign currency contracts $ 39.3 $ — $ 39.3 $ (6.1) $ — $ 33.2 December 31, 2019 Derivative Assets Foreign currency contracts $ 17.4 $ — $ 17.4 $ (5.7) $ — $ 11.7 Cross currency swap contracts $ 13.3 $ — $ 13.3 $ — $ — $ 13.3 Derivative Liabilities Foreign currency contracts $ 6.4 $ — $ 6.4 $ (5.7) $ — $ 0.7 The following tables present the effect of derivative and non-derivative hedging instruments on the consolidated statements of operations and consolidated statements of comprehensive income: Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion) Location of Gain or (Loss) Reclassified from Accumulated OCI into Income Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income 2020 2019 2020 2019 (in millions) (in millions) Cash flow hedges Foreign currency contracts $ (33.7) $ 23.5 Cost of sales $ 18.4 $ 40.9 Selling, general, and administrative expenses $ 2.2 $ 1.9 Amount of Gain or (Loss) Location of Gain or (Loss) Reclassified from Accumulated OCI into Income Amount of Gain or (Loss) 2020 2019 2020 2019 (in millions) (in millions) Net investment hedges Cross currency swap contracts $ (12.6) $ 12.5 Interest expense $ 6.4 $ 6.6 The cross currency swaps have an expiration date of June 15, 2028. At maturity of the cross currency swap contracts, the Company will deliver the notional amount of €257.2 million and will receive $300.0 million from the counterparties. The Company will receive semi-annual interest payments from the counterparties based on a fixed interest rate until maturity of the agreements. Amount of Gain or Location of Gain or 2020 2019 2018 (in millions) Fair value hedges Foreign currency contracts Other income, net $ (1.4) $ 1.4 $ 0.5 Amount of Gain or Location of Gain or 2020 2019 2018 (in millions) Derivatives not designated as hedging instruments Foreign currency contracts Other income, net $ (15.1) $ 0.3 $ 9.7 The following table presents the effect of fair value and cash flow hedge accounting on the consolidated statements of operations: Location and Amount of Gain or (Loss) Recognized in Income on Fair Value and Cash Flow Hedging Relationships Twelve Months Ended December 31, 2020 Cost of sales Selling, general, and administrative expenses Other Income, net Total amounts of income and expense line items shown in the consolidated statements of operations in which the effects of fair value or cash flow hedges are recorded $ (1,080.6) $ (1,228.4) $ 11.5 The effects of fair value and cash flow hedging: Gain (loss) on fair value hedging relationships: Foreign currency contracts: Hedged items — — 4.8 Derivatives designated as hedging instruments — — (4.8) Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 3.4 Gain (loss) on cash flow hedging relationships: Foreign currency contracts: Amount of gain (loss) reclassified from accumulated OCI into income 18.4 2.2 — Location and Amount of Gain or (Loss) Recognized in Income on Fair Value and Cash Flow Hedging Relationships Twelve Months Ended December 31, 2019 Cost of sales Selling, general, and administrative expenses Other Income, net Total amounts of income and expense line items shown in the consolidated statements of operations in which the effects of fair value or cash flow hedges are recorded $ (1,114.4) $ (1,242.2) $ 8.2 The effects of fair value and cash flow hedging: Gain (loss) on fair value hedging relationships: Foreign currency contracts: Hedged items — — 2.9 Derivatives designated as hedging instruments — — (2.9) Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 4.3 Gain (loss) on cash flow hedging relationships: Foreign currency contracts: Amount of gain (loss) reclassified from accumulated OCI into income 40.9 1.9 — The Company expects that during 2021 it will reclassify to earnings a $7.0 million loss currently recorded in " Accumulated Other Comprehensive Loss ." For the years ended December 31, 2020, 2019, and 2018, the Company did not record any gains or losses due to hedge ineffectiveness. |
EMPLOYEE BENEFIT PLANS
EMPLOYEE BENEFIT PLANS | 12 Months Ended |
Dec. 31, 2020 | |
Retirement Benefits [Abstract] | |
EMPLOYEE BENEFIT PLANS | EMPLOYEE BENEFIT PLANS Defined Benefit Plans Edwards Lifesciences maintains defined benefit pension plans in Japan and certain European countries. In 2018, the Company curtailed its defined benefit plan in Horw, Switzerland (see Note 4). Years Ended December 31, 2020 2019 (in millions) Change in projected benefit obligation: Beginning of year $ 105.2 $ 97.4 Service cost 6.3 5.2 Interest cost 0.5 0.9 Participant contributions 1.5 1.3 Actuarial loss 2.9 8.2 Benefits paid (0.6) (4.2) Plan amendment — (4.6) Currency exchange rate changes and other 10.4 1.0 End of year $ 126.2 $ 105.2 Change in fair value of plan assets: Beginning of year $ 63.2 $ 60.4 Actual return on plan assets 0.4 2.0 Employer contributions 2.8 2.6 Participant contributions 1.5 1.3 Benefits paid (0.6) (4.2) Currency exchange rate changes and other 6.0 1.1 End of year $ 73.3 $ 63.2 Funded Status Projected benefit obligation $ (126.2) $ (105.2) Plan assets at fair value 73.3 63.2 Underfunded status $ (52.9) $ (42.0) Net amounts recognized on the consolidated balance sheet: Other long-term liabilities $ 52.9 $ 42.0 Accumulated other comprehensive loss, net of tax: Net actuarial loss $ (30.8) $ (26.3) Net prior service cost 6.6 6.7 Deferred income tax benefit 4.6 4.2 Total $ (19.6) $ (15.4) The accumulated benefit obligation ("ABO") for all defined benefit pension plans was $120.9 million and $101.1 million as of December 31, 2020 and 2019, respectively. The projected benefit obligation and ABO were in excess of plan assets for all pension plans as of December 31, 2020 and 2019. The components of net periodic pension benefit cost (credit) are as follows (in millions): Years Ended December 31, 2020 2019 2018 Service cost, net $ 6.3 $ 5.2 $ 6.0 Interest cost 0.5 0.9 0.8 Expected return on plan assets (1.0) (1.4) (1.3) Settlements and curtailment gain — — (7.4) Amortization of actuarial loss 1.6 0.9 0.8 Amortization of prior service credit (0.7) (0.2) (0.1) Net periodic pension benefit cost (credit) $ 6.7 $ 5.4 $ (1.2) Expected long-term returns for each of the plans' strategic asset classes were developed through consultation with investment advisors. Several factors were considered, including a survey of investment managers' expectations, current market data, minimum guaranteed returns in certain insurance contracts, and historical market returns over long periods. Using policy target allocation percentages and the asset class expected returns, a weighted-average expected return was calculated. To select the discount rates for the defined benefit pension plans, the Company uses a modeling process that involves matching the expected duration of its benefit plans to a yield curve constructed from a portfolio of AA-rated fixed-income debt instruments, or their equivalent. For each country, the Company uses the implied yield of this hypothetical portfolio at the appropriate duration as a discount rate benchmark. The weighted-average assumptions used to determine the benefit obligations are as follows: December 31, 2020 2019 Discount rate 0.3 % 0.5 % Rate of compensation increase 2.6 % 2.7 % Cash balance interest crediting rate 2.5 % 2.6 % Social securities increase 1.6 % 1.6 % Pension increase 1.8 % 1.8 % The weighted-average assumptions used to determine the net periodic pension benefit cost are as follows: Years ended December 31, 2020 2019 2018 Discount rate 0.5 % 0.9 % 0.9 % Expected return on plan assets 1.5 % 2.3 % 2.3 % Rate of compensation increase 2.7 % 2.8 % 2.6 % Cash balance interest crediting rate 1.5 % 1.5 % 1.5 % Social securities increase 1.6 % 1.8 % 1.5 % Pension increase 1.8 % 1.8 % 1.8 % Plan Assets The Company's investment strategy for plan assets is to seek a competitive rate of return relative to an appropriate level of risk and to earn performance rates of return in accordance with the benchmarks adopted for each asset class. Risk management practices include diversification across asset classes and investment styles, and periodic rebalancing toward asset allocation targets. The Administrative and Investment Committee decides on the defined benefit plan provider in each location and that provider decides the target allocation for the Company's defined benefit plan at that location. The target asset allocation selected reflects a risk/return profile the Company feels is appropriate relative to the plans' liability structure and return goals. In certain plans, asset allocations may be governed by local requirements. Target weighted-average asset allocations at December 31, 2020, by asset category, are as follows: Equity securities 25.3 % Debt securities 47.5 % Real estate 7.7 % Other 19.5 % Total 100.0 % The fair values of the Company's defined benefit plan assets at December 31, 2020 and 2019, by asset category, are as follows (in millions): December 31, 2020 Level 1 Level 2 Level 3 Total Asset Category Cash $ 3.0 $ — $ — $ 3.0 Equity securities: United States equities 3.3 — — 3.3 International equities 16.1 — — 16.1 Debt securities: United States government bonds 7.4 — — 7.4 International government bonds 26.0 — — 26.0 Real estate — 5.6 — 5.6 Mortgages — 3.1 — 3.1 Insurance contracts — — 1.0 1.0 Total plan assets measured at fair value $ 55.8 $ 8.7 $ 1.0 $ 65.5 Alternative investments measured at net asset value (a) 7.8 Total plan assets $ 73.3 December 31, 2019 Level 1 Level 2 Level 3 Total Asset Category Cash $ 3.8 $ — $ — $ 3.8 Equity securities: United States equities 3.0 — — 3.0 International equities 11.2 — — 11.2 Debt securities: United States government bonds 8.2 — — 8.2 International government bonds 22.3 — — 22.3 Real estate — 4.4 — 4.4 Mortgages — 2.3 — 2.3 Insurance contracts — — 0.9 0.9 Total plan assets $ 48.5 $ 6.7 $ 0.9 $ 56.1 Alternative investments measured at net asset value (a) 7.1 Total plan assets $ 63.2 _______________________________________ (a) Certain investments that were measured at net asset value per share have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the total plan assets. The following table summarizes the changes in fair value of the Company's defined benefit plan assets that have been classified as Level 3 for the years ended December 31, 2020 and 2019 (in millions): Insurance Balance at December 31, 2018 $ 1.0 Purchases, sales and settlements (0.1) Balance at December 31, 2019 0.9 Currency exchange rate impact 0.1 Balance at December 31, 2020 $ 1.0 Equity and debt securities are valued at fair value based on quoted market prices reported on the active markets on which the individual securities are traded. Real estate investments are valued by discounting to present value the cash flows expected to be generated by the specific properties. Investments in mortgages are valued at cost, which is deemed to approximate its fair value. The insurance contracts are valued at the cash surrender value of the contracts, which is deemed to approximate its fair value. Alternative investments include hedge funds, private equity funds and other miscellaneous investments, and are valued using the net asset value provided by the fund administrator as a practical expedient. The net asset value is based on the fair value of the underlying assets owned by the fund divided by the number of shares outstanding. The following benefit payments, which reflect expected future service, as appropriate, at December 31, 2020, are expected to be paid (in millions): 2021 $ 4.6 2022 4.9 2023 6.7 2024 5.6 2025 5.3 2024-2026 36.7 As of December 31, 2020, expected employer contributions for 2021 are $2.5 million. Defined Contribution Plans The Company's employees in the United States and Puerto Rico are eligible to participate in a qualified defined contribution plan. In the United States, participants may contribute up to 25% of their eligible compensation (subject to tax code limitation) to the plan. Edwards Lifesciences matches the first 4% of the participant's annual eligible compensation contributed to the plan on a dollar-for-dollar basis. Edwards Lifesciences matches the next 2% of the participant's annual eligible compensation to the plan on a 50% basis. In Puerto Rico, participants may contribute up to 25% of their annual compensation (subject to tax code limitation) to the plan. Edwards Lifesciences matches the first 4% of participant's annual eligible compensation contributed to the plan on a 50% basis. The Company also provides a 2% profit sharing contribution calculated on eligible earnings for each employee. Matching contributions relating to Edwards Lifesciences employees were $36.6 million, $31.4 million, and $26.6 million in 2020, 2019, and 2018, respectively. The Company also has nonqualified deferred compensation plans for a select group of employees. The plans provide eligible participants the opportunity to defer eligible compensation to future dates specified by the participant with a return based on investment alternatives selected by the participant. The amount accrued under these nonqualified plans was $111.6 million and $88.7 million at December 31, 2020 and 2019, respectively. |
COMMON STOCK
COMMON STOCK | 12 Months Ended |
Dec. 31, 2020 | |
Equity [Abstract] | |
COMMON STOCK | COMMON STOCK Treasury Stock In May 2019, the Board of Directors approved a stock repurchase program authorizing the Company to purchase up to $1.0 billion of the Company's common stock. The repurchase program does not have an expiration date. Stock repurchased under the program may be used to offset obligations under the Company's employee stock-based benefit programs and stock-based business acquisitions, and will reduce the total shares outstanding. During 2020, 2019, and 2018, the Company repurchased 3.1 million, 1.5 million, and 5.5 million shares, respectively, at an aggregate cost of $625.4 million, $263.3 million, and $795.5 million, respectively, including shares purchased under the accelerated share repurchase ("ASR") agreements described below and shares acquired to satisfy tax withholding obligations in connection with the vesting of restricted stock units issued to employees. The timing and size of any future stock repurchases are subject to a variety of factors, including expected dilution from stock plans, cash capacity, and the market price of the Company's common stock. Accelerated Share Repurchase During 2019 and 2018, the Company entered into ASR agreements providing for the repurchase of the Company's common stock based on the volume-weighted average price ("VWAP") of the Company's common stock during the term of the agreements, less a discount. The following table summarizes the terms of the ASR agreements (dollars and shares in millions, except per share data): Initial Delivery Final Settlement Agreement Date Amount Shares Price per Value of Settlement Total Shares Average Price April 2018 $ 400.0 2.5 $ 127.36 80 % July 2018 2.8 $ 142.37 October 2018 $ 250.0 1.4 $ 139.22 80 % November 2018 1.7 $ 150.54 May 2019 $ 150.0 0.7 $ 178.66 80 % May 2019 0.8 $ 178.42 May 2019 $ 100.0 0.5 $ 170.02 80 % June 2019 0.6 $ 178.46 _______________________________________________________________________________ (a) The three-for-one stock split distributed on May 29, 2020 excluded treasury shares. The shares and per share prices in the table are reflected at the pre-split amounts and prices at the time of the transaction. The ASR agreements were accounted for as two separate transactions: (1) the value of the initial delivery of shares was recorded as shares of common stock acquired in a treasury stock transaction on the acquisition date and (2) the remaining amount of the purchase price paid was recorded as a forward contract indexed to the Company's own common stock and was recorded in " Additional Paid-in Capital " on the consolidated balance sheets. The initial delivery of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted-average common shares outstanding for basic and diluted earnings per share. The Company determined that the forward contract indexed to the Company's common stock met all the applicable criteria for equity classification and, therefore, was not accounted for as a derivative instrument. Employee and Director Stock Plans The Edwards Lifesciences Corporation Long-term Stock Incentive Compensation Program (the "Program") provides for the grant of incentive and non-qualified stock options, restricted stock, and restricted stock units for eligible employees of the Company. Under the Program, these grants are awarded at a price equal to the fair market value at the date of grant based upon the closing price on that date. Options to purchase shares of the Company's common stock granted under the Program generally vest over predetermined periods of between three three The Company also maintains the Nonemployee Directors Stock Incentive Compensation Program (the "Nonemployee Directors Program"). Under the Nonemployee Directors Program, annually each nonemployee director may receive up to 120,000 stock options or 48,000 restricted stock units of the Company's common stock, or a combination thereof, provided that in no event may the total value of the combined annual award exceed $0.2 million. These grants generally vest over one year from the date of grant. Under the Nonemployee Directors Program, an aggregate of 8.4 million shares of the Company's common stock has been authorized for issuance. The Company has an employee stock purchase plan for United States employees and a plan for international employees (collectively "ESPP"). Under the ESPP, eligible employees may purchase shares of the Company's common stock at 85% of the lower of the fair market value of Edwards Lifesciences common stock on the effective date of subscription or the date of purchase. Under the ESPP, employees can authorize the Company to withhold up to 12% (15% effective January 1, 2021) of their compensation for common stock purchases, subject to certain limitations. The ESPP is available to all active employees of the Company paid from the United States payroll and to eligible employees of the Company outside the United States, to the extent permitted by local law. The ESPP for United States employees is qualified under Section 423 of the Internal Revenue Code. The number of shares of common stock authorized for issuance under the ESPP was 45.9 million shares. The fair value of each option award and employee stock purchase subscription is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following tables. The risk-free interest rate is estimated using the U.S. Treasury yield curve and is based on the expected term of the award. Expected volatility is estimated based on a blend of the weighted-average of the historical volatility of Edwards Lifesciences' stock and the implied volatility from traded options on Edwards Lifesciences' stock. The expected term of awards granted is estimated from the vesting period of the award, as well as historical exercise behavior, and represents the period of time that awards granted are expected to be outstanding. The Company uses historical data to estimate forfeitures and has estimated an annual forfeiture rate of 6.4%. The Black-Scholes option pricing model was used with the following weighted-average assumptions for options granted during the following periods: Option Awards 2020 2019 2018 Average risk-free interest rate 0.3 % 2.3 % 2.9 % Expected dividend yield None None None Expected volatility 33 % 30 % 29 % Expected life (years) 5.0 5.1 5.0 Fair value, per share $ 21.70 $ 18.17 $ 14.17 The Black-Scholes option pricing model was used with the following weighted-average assumptions for ESPP subscriptions granted during the following periods: ESPP 2020 2019 2018 Average risk-free interest rate 1.3 % 2.4 % 1.7 % Expected dividend yield None None None Expected volatility 33 % 27 % 31 % Expected life (years) 0.6 0.6 0.6 Fair value, per share $ 16.61 $ 16.43 $ 12.18 The fair value of market-based restricted stock units was determined using a Monte Carlo simulation model, which uses multiple input variables to determine the probability of satisfying the market condition requirements. The weighted-average assumptions used to determine the fair value of the market-based restricted stock units during the years ended December 31, 2020, 2019, and 2018 included a risk-free interest rate of 0.2%, 2.2%, and 2.7%, respectively, and an expected volatility rate of 32.7%, 29.4%, and 29.7%, respectively. Stock option activity during the year ended December 31, 2020 under the Program and the Nonemployee Directors Program was as follows (in millions, except years and per-share amounts): Shares Weighted- Weighted- Aggregate Outstanding as of December 31, 2019 17.1 $ 32.19 Options granted 1.8 73.02 Options exercised (4.3) 18.16 Options forfeited (0.3) 49.74 Outstanding as of December 31, 2020 14.3 41.27 3.4 years $ 712.5 Exercisable as of December 31, 2020 9.5 32.32 2.5 years 558.1 Vested and expected to vest as of December 31, 2020 13.6 40.37 3.3 years 690.4 The following table summarizes nonvested restricted stock unit activity during the year ended December 31, 2020 under the Program and the Nonemployee Directors Program (in millions, except per-share amounts): Shares Weighted- Nonvested as of December 31, 2019 2.7 $ 46.89 Granted (a) 0.9 71.31 Vested (0.9) 40.03 Forfeited (0.1) 49.90 Nonvested as of December 31, 2020 2.6 57.59 _______________________________________________________________________________ (a) The shares granted includes 0.1 million shares of market-based restricted stock units granted during 2020, which represents the target number of shares to be issued, and 0.1 million shares related to a previous year's grant of market-based restricted stock units since the payout percentage achieved at the end of the performance period was in excess of target. As described above, the actual number of shares ultimately issued is determined based on the Company's total stockholder return relative to a selected industry peer group. The intrinsic value of stock options exercised and restricted stock units vested during the years ended December 31, 2020, 2019, and 2018 were $323.5 million, $382.1 million, and $281.1 million, respectively. The intrinsic value of stock options is calculated as the amount by which the market price of the Company's common stock exceeds the exercise price of the option. During the years ended December 31, 2020, 2019, and 2018, the Company received cash from exercises of stock options of $79.2 million, $110.4 million, and $103.7 million, respectively, and tax benefits from exercises of stock options and vesting of restricted stock units of $72.1 million, $85.1 million, and $62.5 million, respectively. The total grant-date fair value of stock options vested during the years ended December 31, 2020, 2019, and 2018 were $34.0 million, $31.2 million, and $29.0 million, respectively. As of December 31, 2020, the total remaining unrecognized compensation expense related to nonvested stock options, restricted stock units, and employee stock purchase subscriptions amounted to $140.9 million, which will be amortized over the weighted-average remaining requisite service period of 30 months. |
ACCUMULATED OTHER COMPREHENSIVE
ACCUMULATED OTHER COMPREHENSIVE LOSS | 12 Months Ended |
Dec. 31, 2020 | |
Equity [Abstract] | |
ACCUMULATED OTHER COMPREHENSIVE LOSS | ACCUMULATED OTHER COMPREHENSIVE LOSS Presented below is a summary of activity for each component of " Accumulated Other Comprehensive Loss " for the years ended December 31, 2020, 2019, and 2018. Foreign Unrealized (Loss) Gain on Hedges Unrealized (Loss) Gain on Unrealized Total (in millions) December 31, 2017 $ (100.1) $ (13.9) $ (4.6) $ (14.1) $ (132.7) Impact from adoption of ASU 2016-16 and ASU 2018-02 (4.9) (2.9) — — (7.8) January 1, 2018 (105.0) (16.8) (4.6) (14.1) (140.5) Other comprehensive (loss) income before reclassifications (36.7) 35.1 (3.1) 7.6 2.9 Amounts reclassified from accumulated other comprehensive loss — 19.1 2.9 (6.7) 15.3 Deferred income tax expense (1.9) (13.8) (0.2) (0.3) (16.2) December 31, 2018 (143.6) 23.6 (5.0) (13.5) (138.5) Other comprehensive (loss) income before reclassifications (1.5) 27.9 7.9 (3.2) 31.1 Amounts reclassified from accumulated other comprehensive loss (6.6) (44.2) 0.4 0.7 (49.7) Deferred income tax (expense) benefit (3.1) 5.2 (1.6) 0.6 1.1 December 31, 2019 (154.8) 12.5 1.7 (15.4) (156.0) Other comprehensive income (loss) before reclassifications 35.7 (34.8) 8.0 (5.5) 3.4 Amounts reclassified from accumulated other comprehensive loss (6.4) (19.2) 0.3 0.9 (24.4) Deferred income tax benefit (expense) 3.1 13.8 (1.4) 0.4 15.9 December 31, 2020 $ (122.4) $ (27.7) $ 8.6 $ (19.6) $ (161.1) _______________________________________________________________________________ (a) For the years ended December 31, 2020, 2019, and 2018, the change in unrealized pension costs consisted of the following (in millions): Pre-Tax Tax (Expense) Benefit Net of Tax 2020 Prior service credit arising during period $ 0.6 $ (0.2) $ 0.4 Amortization of prior service credit (0.7) 0.1 (0.6) Net prior service cost arising during period (0.1) (0.1) (0.2) Net actuarial loss arising during period (4.5) 0.5 (4.0) Unrealized pension costs, net $ (4.6) $ 0.4 $ (4.2) 2019 Prior service credit arising during period $ 4.6 $ (0.6) $ 4.0 Amortization of prior service credit (0.2) 0.1 (0.1) Net prior service credit arising during period 4.4 (0.5) 3.9 Net actuarial loss arising during period (6.9) 1.1 (5.8) Unrealized pension costs, net $ (2.5) $ 0.6 $ (1.9) 2018 Prior service credit arising during period $ 3.3 $ (0.9) $ 2.4 Amortization of prior service credit (0.1) — (0.1) Net prior service credit arising during period 3.2 (0.9) 2.3 Net actuarial loss arising during period (2.3) 0.6 (1.7) Unrealized pension credits, net $ 0.9 $ (0.3) $ 0.6 The following table provides information about amounts reclassified from " Accumulated Other Comprehensive Loss " (in millions): Years Ended December 31, Details about Accumulated Other Comprehensive Loss 2020 2019 Affected Line on Consolidated Foreign currency translation adjustments $ 6.4 $ 6.6 Other income, net (1.6) (1.6) Provision for income taxes $ 4.8 $ 5.0 Net of tax (Loss) gain on hedges $ 18.4 $ 40.9 Cost of sales 2.2 1.9 Selling, general, and administrative expenses (1.4) 1.4 Other income, net 19.2 44.2 Total before tax (5.0) (11.0) Provision for income taxes $ 14.2 $ 33.2 Net of tax (Loss) gain on available-for-sale investments $ (0.3) $ (0.4) Other income, net (0.6) (0.3) Provision for income taxes $ (0.9) $ (0.7) Net of tax Amortization of pension adjustments $ (0.9) $ (0.7) Other income, net 0.2 0.1 Provision for income taxes $ (0.7) $ (0.6) Net of tax |
OTHER INCOME, NET
OTHER INCOME, NET | 12 Months Ended |
Dec. 31, 2020 | |
Other Income and Expenses [Abstract] | |
OTHER INCOME, NET | OTHER INCOME, NET Years Ended December 31, 2020 2019 2018 (in millions) Foreign exchange gains, net $ (12.3) $ (5.9) $ (6.7) Gain on investments (0.6) (0.5) 1.7 Non-service cost components of net periodic pension benefit cost (credit) 0.4 0.2 (0.1) Other 1.0 (2.0) 1.1 Total other income, net $ (11.5) $ (8.2) $ (4.0) |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES The Company's income before provision for income taxes was generated from United States and international operations as follows (in millions): Years Ended December 31, 2020 2019 2018 United States $ 151.3 $ 383.4 $ 266.1 International, including Puerto Rico 765.4 783.1 495.3 $ 916.7 $ 1,166.5 $ 761.4 The provision for income taxes consists of the following (in millions): Years Ended December 31, 2020 2019 2018 Current United States: Federal $ 23.4 $ 31.3 $ 10.9 State and local 48.2 48.7 13.6 International, including Puerto Rico 73.9 29.1 35.9 Current income tax expense $ 145.5 $ 109.1 $ 60.4 Deferred United States: Federal $ 11.0 $ 28.3 $ (16.1) State and local (32.9) (18.3) (22.4) International, including Puerto Rico (30.3) 0.5 17.3 Deferred income tax (benefit) expense (52.2) 10.5 (21.2) Total income tax provision $ 93.3 $ 119.6 $ 39.2 The components of deferred tax assets and liabilities are as follows (in millions): December 31, 2020 2019 Deferred tax assets Compensation and benefits $ 88.6 $ 90.1 Benefits from uncertain tax positions 27.0 22.5 Net tax credit carryforwards 125.5 108.4 Net operating loss carryforwards 64.1 57.6 Accrued liabilities 105.0 41.3 Inventories 16.3 12.9 Cash flow and net investment hedges 3.3 — State income taxes 0.5 0.5 Investments 1.8 1.5 Lease liability obligations 7.7 18.4 Other 3.6 3.4 Total deferred tax assets 443.4 356.6 Deferred tax liabilities Property, plant, and equipment (53.4) (22.6) Cash flow and net investment hedges — (6.8) Deferred tax on foreign earnings (29.2) (35.3) Right-of-use assets (7.0) (17.5) Other intangible assets (76.3) (71.0) Other (3.1) (2.2) Total deferred tax liabilities (169.0) (155.4) Valuation allowance (71.6) (65.8) Net deferred tax assets $ 202.8 $ 135.4 During 2020, net deferred tax assets increased $67.4 million, including items that were recorded to stockholders' equity and which did not impact the Company's income tax provision. The valuation allowance of $71.6 million as of December 31, 2020 reduces certain deferred tax assets to amounts that are more likely than not to be realized. This allowance primarily relates to the net operating loss carryforwards of certain non-United States subsidiaries and certain non-United States credit carryforwards. Net operating loss and capital loss carryforwards and the related carryforward periods at December 31, 2020 are summarized as follows (in millions): Carryforward Tax Benefit Valuation Net Tax Carryforward United States federal net operating losses $ 26.6 $ 5.6 $ — $ 5.6 2030-2037 United States federal net operating losses 11.3 2.4 — 2.4 Indefinite United States state net operating losses 33.5 2.1 (2.1) — 2026-2039 United States state net operating losses 1.0 0.1 (0.1) — Indefinite Non-United States net operating losses 18.2 4.7 (3.6) 1.1 2020-2027 Non-United States net operating losses 295.1 49.2 (39.9) 9.3 Indefinite United States capital losses 34.1 0.2 (0.2) — 2024 Total $ 419.8 $ 64.3 $ (45.9) $ 18.4 Certain tax attributes are subject to an annual limitation as a result of the acquisitions of Harpoon Medical, Inc. and CASMED (see Note 8), which constitute a change of ownership as defined under Internal Revenue Code Section 382. The gross tax credit carryforwards and the related carryforward periods at December 31, 2020 are summarized as follows (in millions): Carryforward Valuation Net Tax Carryforward California research expenditure tax credits $ 145.1 $ — $ 145.1 Indefinite Federal research expenditure tax credits 1.5 — 1.5 2026-2039 Puerto Rico purchases credit 23.4 (23.4) — Indefinite Total $ 170.0 $ (23.4) $ 146.6 The Company has $145.1 million of California research expenditure tax credits it expects to use in future periods. The credits may be carried forward indefinitely. Based upon anticipated future taxable income, the Company expects that it is more likely than not that all California research expenditure tax credits will be utilized, although the utilization of the full benefit is expected to occur over a number of years and into the distant future. Accordingly, no valuation allowance has been provided. The Company has $23.4 million of Puerto Rico purchases credit. Throughout its history and into the future, the Puerto Rico operations generate, or are expected to generate, credits each year in excess of its ability to utilize credits in those years. As a result, even though the credits have an indefinite life, the Company continues to record a valuation allowance on the credit carryforwards. On December 22, 2017, Public Law 115-97, commonly referred to as the Tax Cuts and Jobs Act (the "2017 Act"), was signed into law. The 2017 Act a) reduced the U.S. federal corporate tax rate from 35 percent to 21 percent for tax years beginning after December 31, 2017, b) required companies to pay a one-time mandatory deemed repatriation tax on the cumulative earnings of certain foreign subsidiaries that were previously tax deferred, and c) created new taxes on certain foreign earnings in future years. On December 22, 2017, Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of generally accepted accounting principles in the United States of America in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Act. In accordance with SAB 118, as of December 31, 2017, the Company had estimated provisional amounts for a) $3.3 million of tax benefits in connection with the remeasurement of certain tax assets and liabilities, b) $297.4 million of net tax expense in connection with the one-time mandatory deemed repatriation tax on cumulative earnings of certain foreign subsidiaries, and c) $32.3 million of tax benefits associated with a tax reform related restructuring. In accordance with SAB 118, during 2018 the Company adjusted the provisional amounts as described below. As a result of Internal Revenue Service ("IRS") guidance issued subsequent to the 2017 Act, the $32.3 million of tax benefits associated with the tax reform related restructuring mentioned above were reversed in 2018. In addition, during 2018, the Company recorded a $12.8 million reduction in the repatriation tax and an additional benefit of $3.7 million in connection with the remeasurement of deferred tax assets. In accordance with SAB 118, the Company completed its accounting for the 2017 Act during the fourth quarter of 2018. In addition, the Company elected to pay the repatriation tax in installments over eight years. The Company asserts that $1.1 billion of its foreign earnings continue to be indefinitely reinvested and it intends to repatriate $599.8 million of its foreign earnings as of December 31, 2020. The estimated net tax liability on the indefinitely reinvested earnings if repatriated is $21.1 million. The Company has received tax incentives in certain non-U.S. tax jurisdictions, the primary benefit for which will expire in 2029. The tax reductions as compared to the local statutory rates were $189.2 million ($0.30 per diluted share), $157.6 million ($0.25 per diluted share), and $144.9 million ($0.23 per diluted share) for the years ended December 31, 2020, 2019, and 2018, respectively. A reconciliation of the United States federal statutory income tax rate to the Company's effective income tax rate is as follows (in millions): Years Ended December 31, 2020 2019 2018 Income tax expense at U.S. federal statutory rate $ 192.5 $ 245.0 $ 159.9 Foreign income taxed at different rates (80.5) (75.0) (16.2) State and local taxes, net of federal tax benefit 5.0 11.9 6.8 Tax credits, federal and state (43.1) (42.9) (36.7) Build (release) of reserve for prior years' uncertain tax positions 4.2 5.0 (35.5) U.S. tax on foreign earnings, net of credits 1.5 (2.9) (12.2) Tax on global intangible low-taxed income 49.2 32.0 — Foreign-derived intangible income deduction (2.6) (7.2) (6.6) U.S. federal deductible employee share-based compensation (48.3) (57.6) (41.8) Nondeductible employee share-based compensation 4.2 3.2 2.8 Impact related to 2017 U.S. Tax Reform — 2.8 15.8 Other 11.2 5.3 2.9 Income tax provision $ 93.3 $ 119.6 $ 39.2 The Company's effective tax rate for 2020 decreased slightly in comparison to 2019 primarily due to the tax benefit from the Settlement Agreement with Abbott (see Notes 3 and 18), partially offset by the increase in the U.S. tax on global intangible low-taxed income and the decrease in the tax benefit from employee share-based compensation. The Company's effective tax rate for 2019 increased in comparison to 2018 primarily because of the increase in the U.S. tax on global intangible low-taxed income and the tax benefit in 2018 from audit settlements. Uncertain Tax Positions As of December 31, 2020 and 2019, the gross uncertain tax positions were $281.8 million and $203.1 million, respectively. The Company estimates that these liabilities would be reduced by $95.1 million and $50.1 million, respectively, from offsetting tax benefits associated with the correlative effects of potential transfer pricing adjustments, state income taxes, and timing adjustments. The net amounts of $186.7 million and $153.0 million, respectively, if not required, would favorably affect the Company's effective tax rate. A reconciliation of the beginning and ending amount of uncertain tax positions, excluding interest, penalties, and foreign exchange, is as follows (in millions): December 31, 2020 2019 2018 Uncertain gross tax positions, January 1 $ 203.1 $ 150.7 $ 225.6 Current year tax positions 86.4 55.4 37.8 Increase in prior year tax positions 6.0 0.8 13.9 Decrease in prior year tax positions (10.0) (3.8) (78.8) Settlements (3.7) — (46.5) Lapse of statutes of limitations — — (1.3) Uncertain gross tax positions, December 31 $ 281.8 $ 203.1 $ 150.7 The table above summarizes the gross amounts of uncertain tax positions without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such uncertain tax positions were settled. The Company recognizes interest and penalties, if any, related to uncertain tax positions in the provision for income taxes. As of December 31, 2020, the Company had accrued $14.3 million (net of $5.1 million tax benefit) of interest related to uncertain tax positions, and as of December 31, 2019, the Company had accrued $9.3 million (net of $3.5 million tax benefit) of interest related to uncertain tax positions. During 2020, 2019, and 2018, the Company recognized interest expense (benefit), net of tax benefit, of $5.0 million, $4.7 million, and $(2.8) million, respectively, in " Provision for Income Taxes " on the consolidated statements of operations. The Company strives to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While the Company has accrued for matters it believes are more likely than not to require settlement, the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in the consolidated financial statements. Furthermore, the Company may later decide to challenge any assessments, if made, and may exercise its right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations between tax authorities, identification of new issues, and issuance of new legislation, regulations, or case law. Management believes that adequate amounts of tax and related penalty and interest have been provided in income tax expense for any adjustments that may result from these uncertain tax positions. At December 31, 2020, all material state, local, and foreign income tax matters have been concluded for years through 2015. While not material, the Company continues to address matters in Wisconsin and India for years from 2010. During 2018, the Company executed an Advance Pricing Agreement (“APA”) between the United States and Switzerland governments for tax years 2009 through 2020 covering various, but not all, transfer pricing matters. The unagreed transfer pricing matters, namely Surgical Structural Heart and Transcatheter Aortic Valve Replacement intercompany royalty transactions, then reverted to IRS Examination for further consideration as part of the respective years' regular tax audit. In addition, the Company signed agreements during 2018 with the IRS to settle open tax years 2009 through 2014, including all transfer pricing matters for those years and the tax treatment of a portion of a litigation settlement payment received in 2014. The IRS began its examination of the 2015 and 2016 tax years during the fourth quarter of 2018 and later added the 2017 tax year to this audit cycle during the first quarter of 2019. The IRS audit field work for the 2015-2017 tax years was substantially completed during the fourth quarter of 2020, except for transfer pricing matters. As a result, certain intercompany transactions covering tax years 2015 through 2020 that were not resolved under the APA program remain subject to IRS examination, and those transactions and related tax positions remain uncertain as of December 31, 2020. The IRS has signaled that it may be preparing proposed audit adjustments related to these intercompany transactions for the 2015-2017 tax years which, if issued, could be provided to the Company during 2021. The Company has considered this information in its evaluation of its uncertain tax positions. These unresolved transfer pricing matters, net of any correlative repatriation tax adjustment, may be significant to the Company’s consolidated financial statements. Based on the information currently available and numerous possible outcomes, the Company cannot reasonably estimate what, if any, changes to its existing uncertain tax positions may occur in the next 12 months and, therefore, has continued to record the gross uncertain tax positions as a long-term liability. The Company intends to file to renew the APA between the United States and Switzerland for the years 2021 and forward. In addition, the Company executed other APAs as follows: during 2017, an APA between the United States and Japan covering tax years 2015 through 2019; and during 2018, APAs between Japan and Singapore and between Switzerland and Japan covering tax years 2015 through 2019. The Company has filed to renew these APAs related to Japan for the years 2020 and forward. The execution of some or all of these APAs depends on a number of variables outside of the Company's control. |
LEGAL PROCEEDINGS
LEGAL PROCEEDINGS | 12 Months Ended |
Dec. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
LEGAL PROCEEDINGS | LEGAL PROCEEDINGS In January 2019, Abbott filed lawsuits against Edwards Lifesciences and its direct and indirect subsidiaries (“Edwards”) in the Federal District Court in the District of Delaware, in the United Kingdom, Germany, Switzerland and Italy, and, in February 2020, in Ireland, alleging patent infringement involving Edwards’ PASCAL heart valve repair system (collectively, the “ PASCAL litigation”). In February 2019, Edwards filed a lawsuit against Abbott in the Federal District Court in the Central District of California alleging patent infringement involving Abbott's MITRACLIP device (with the PASCAL litigation, the “Abbott Matters”). On July 12, 2020, Edwards entered into the Settlement Agreement with Abbott to, among other things, settle all patent litigation between the parties related to alleged patent infringement involving Edwards’ PASCAL heart valve repair system and Abbott’s MITRACLIP device. Pursuant to the Settlement Agreement, all of the Abbott Matters and related appeals in courts worldwide were dismissed. The Settlement Agreement resulted in the Company recording an estimated $367.9 million pre-tax net charge in June 2020 related to past damages. See Note 3 for additional information. In addition, the Company is or may be a party to, or may otherwise be responsible for, pending or threatened lawsuits including those related to products and services currently or formerly manufactured or performed, as applicable, by the Company, workplace and employment matters, matters involving real estate, Company operations or health care regulations, or governmental investigations (the "Other Lawsuits"). The Other Lawsuits raise difficult and complex factual and legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. Management does not believe that any loss relating to the Other Lawsuits would have a material adverse effect on the Company's overall financial condition, results of operations or cash flows. However, the resolution of one or more of the Other Lawsuits in any reporting period, could have a material adverse impact on the Company's financial results for that period. The Company is not able to estimate the amount or range of any loss for legal contingencies related to the Other Lawsuits for which there is no reserve or additional loss for matters already reserved. The Company is subject to various environmental laws and regulations both within and outside of the United States. The Company's operations, like those of other medical device companies, involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes. While it is difficult to quantify the potential impact of continuing compliance with environmental protection laws, management believes that such compliance will not have a material impact on the Company's financial results. The Company's threshold of disclosing material environmental legal proceedings involving a governmental authority where potential monetary exposure is involved is $1 million. |
SEGMENT INFORMATION
SEGMENT INFORMATION | 12 Months Ended |
Dec. 31, 2020 | |
Segment Reporting [Abstract] | |
SEGMENT INFORMATION | SEGMENT INFORMATION The Company conducts operations worldwide and is managed in the following geographical regions: United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company's geographic segments are reported based on the financial information provided to the Chief Operating Decision Maker (the Chief Executive Officer). The Company evaluates the performance of its geographic segments based on net sales and operating income. The accounting policies of the segments are substantially the same as those described in Note 2. Segment net sales and segment operating income are based on internally derived standard foreign exchange rates, which may differ from year to year, and do not include inter-segment profits. Because of the interdependence of the reportable segments, the operating profit as presented may not be representative of the geographical distribution that would occur if the segments were not interdependent. Net sales by geographic area are based on the location of the customer. Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include net interest expense, global marketing expenses, corporate research and development expenses, manufacturing variances, corporate headquarters costs, special gains and charges, stock-based compensation, foreign currency hedging activities, certain litigation costs, changes in the fair value of contingent consideration liabilities, and most of the Company's amortization expense. Although most of the Company's depreciation expense is included in segment operating income, due to the Company's methodology for cost build-up, it is impractical to determine the amount of depreciation expense included in each segment, and, therefore, a portion is maintained at the corporate level. The Company neither discretely allocates assets to its operating segments, nor evaluates the operating segments using discrete asset information. The table below presents information about Edwards Lifesciences' reportable segments (in millions): Years Ended December 31, 2020 2019 2018 Segment Net Sales United States $ 2,516.8 $ 2,532.7 $ 2,055.2 Europe 945.2 926.1 826.4 Japan 448.6 441.4 398.4 Rest of World 451.5 433.3 396.0 Total segment net sales $ 4,362.1 $ 4,333.5 $ 3,676.0 Segment Operating Income United States $ 1,727.3 $ 1,742.3 $ 1,368.1 Europe 479.3 472.0 394.8 Japan 286.4 272.3 237.0 Rest of World 150.1 127.9 115.6 Total segment operating income $ 2,643.1 $ 2,614.5 $ 2,115.5 The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated income before provision for income taxes ("pre-tax income") (in millions): Years Ended December 31, 2020 2019 2018 Net Sales Reconciliation Segment net sales $ 4,362.1 $ 4,333.5 $ 3,676.0 Foreign currency 24.2 14.5 46.8 Consolidated net sales $ 4,386.3 $ 4,348.0 $ 3,722.8 Pre-tax Income Reconciliation Segment operating income $ 2,643.1 $ 2,614.5 $ 2,115.5 Unallocated amounts: Corporate items (1,358.0) (1,439.7) (1,058.1) Special charges — (64.6) (116.2) Intellectual property litigation expenses, net (405.4) (33.4) (214.0) Change in fair value of contingent consideration liabilities, net (13.6) 6.1 5.7 Foreign currency 31.5 63.9 15.3 Consolidated operating income 897.6 1,146.8 748.2 Non-operating income 19.1 19.7 13.2 Consolidated pre-tax income $ 916.7 $ 1,166.5 $ 761.4 Enterprise-Wide Information Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated financial statements. As of or for the Years Ended December 31, 2020 2019 2018 (in millions) Net Sales by Geographic Area United States $ 2,516.8 $ 2,532.7 $ 2,055.3 Europe 973.6 941.2 885.1 Japan 460.1 444.7 396.8 Rest of World 435.8 429.4 385.6 $ 4,386.3 $ 4,348.0 $ 3,722.8 Net Sales by Major Product Area Transcatheter Aortic Valve Replacement $ 2,857.3 $ 2,737.9 $ 2,283.8 Transcatheter Mitral and Tricuspid Therapies 41.8 28.2 2.9 Surgical Structural Heart 761.8 841.7 761.6 Critical Care 725.4 740.2 674.5 $ 4,386.3 $ 4,348.0 $ 3,722.8 Long-lived Tangible Assets by Geographic Area United States $ 1,084.3 $ 849.1 $ 642.1 Europe 192.7 101.5 36.6 Japan 20.4 21.7 6.7 Rest of World 311.0 269.4 214.4 $ 1,608.4 $ 1,241.7 $ 899.8 |
QUARTERLY FINANCIAL RESULTS AND
QUARTERLY FINANCIAL RESULTS AND MARKET FOR THE COMPANY'S STOCK (UNAUDITED) | 12 Months Ended |
Dec. 31, 2020 | |
Quarterly Financial Information Disclosure [Abstract] | |
QUARTERLY FINANCIAL RESULTS AND MARKET FOR THE COMPANY'S STOCK (UNAUDITED) | QUARTERLY FINANCIAL RESULTS AND MARKET FOR THE COMPANY'S STOCK (UNAUDITED) Years Ended December 31, First Second Third Fourth Total (in millions, except per share data) 2020 Net sales $ 1,128.7 $ 925.0 $ 1,140.9 $ 1,191.7 $ 4,386.3 Gross profit 863.6 686.8 859.9 895.4 3,305.7 Net income (loss) (a) 310.6 (121.9) 325.2 309.5 823.4 Earnings (loss) per common share (a): Basic 0.50 (0.20) 0.52 0.50 1.32 Diluted 0.49 (0.20) 0.52 0.49 1.30 Market price: High $ 81.90 $ 78.43 $ 87.79 $ 92.08 $ 92.08 Low 51.51 56.44 66.87 70.92 51.51 2019 Net sales $ 993.0 $ 1,086.9 $ 1,094.0 $ 1,174.1 $ 4,348.0 Gross profit 761.2 782.9 801.6 887.9 3,233.6 Net income (b) 249.7 242.3 274.7 280.2 1,046.9 Earnings per common share (b): Basic 0.40 0.39 0.44 0.45 1.68 Diluted 0.39 0.38 0.43 0.44 1.64 Market price: High $ 65.95 $ 65.00 $ 76.06 $ 82.55 $ 82.55 Low 46.95 55.23 61.00 71.08 46.95 _______________________________________________________________________________ (a) The second quarter of 2020 includes a $367.9 million charge related to a litigation settlement. (b) The first quarter of 2019 includes a $24.0 million charge related to the acquisition of early-stage transcatheter intellectual property and associated clinical and regulatory experience. The second and third quarters of 2019 include a $46.2 million and $26.9 million charge, respectively, related to the write off of inventory. The fourth quarter of 2019 includes a $40.6 million charge related to the impairment of certain in-process research and development assets. |
VALUATION AND QUALIFYING ACCOUN
VALUATION AND QUALIFYING ACCOUNTS | 12 Months Ended |
Dec. 31, 2020 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] | |
VALUATION AND QUALIFYING ACCOUNTS | VALUATION AND QUALIFYING ACCOUNTS Additions Balance at Charged to Charged to Deductions Balance at (in millions) Year ended December 31, 2020 Allowance for doubtful accounts (a) $ 14.7 $ 3.1 $ — $ (1.4) $ 16.4 Tax valuation allowance (b) 64.0 6.3 0.6 (1.1) 69.8 Year ended December 31, 2019 Allowance for doubtful accounts (a) $ 13.6 $ 4.7 $ 0.2 $ (3.8) $ 14.7 Tax valuation allowance (b) 44.9 18.9 0.2 — 64.0 Year ended December 31, 2018 Allowance for doubtful accounts (a) $ 13.7 $ 2.2 $ 1.0 $ (3.3) $ 13.6 Tax valuation allowance (b) 41.6 7.1 (1.8) (2.0) 44.9 _______________________________________________________________________________ (a) The deductions related to allowances for doubtful accounts represent accounts receivable which are written off. (b) The tax valuation allowances are provided for other-than-temporary impairments and unrealized losses related to certain investments that may not be recognized due to the uncertainty of the ready marketability of certain impaired investments, and net operating loss and credit carryforwards that may not be recognized due to insufficient taxable income. |
SUBSEQUENT EVENT
SUBSEQUENT EVENT | 12 Months Ended |
Dec. 31, 2020 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENT | SUBSEQUENT EVENTIn February 2021, Edwards entered into an ASR agreement to repurchase $250.0 million of the Company's common stock based on the volume-weighted average price ("VWAP") of the Company's common stock during the term of the agreements, less a discount. Upon entering into the agreement, Edwards received an initial delivery of 2.4 million shares, representing approximately 80% of the shares to be repurchased. At the termination of the ASR, Edwards may receive additional shares or may be required to pay additional cash or shares (at the Company's election). The final settlement is based on the VWAP over the term of the agreement, less a discount. The ASR agreement has a scheduled termination date of March 18, 2021. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Principles of Consolidation | Principles of Consolidation The accompanying consolidated financial statements include the accounts of Edwards Lifesciences and its majority-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company reviews its investments in other entities to determine whether the Company is the primary beneficiary of a variable interest entity ("VIE"). The Company would be the primary beneficiary of the VIE, and would be required to consolidate the VIE, if it has the power to direct the significant activities of the entity and the obligation to absorb losses or receive benefits from the entity that may be significant to the VIE. Based on the Company's analysis, it determined it is not the primary beneficiary of any VIEs; however, future events may require VIEs to be consolidated if the Company becomes the primary beneficiary. Certain reclassifications of previously reported amounts have been made to conform to classifications used in the current year. |
Use of Estimates | Use of Estimates The consolidated financial statements of Edwards Lifesciences have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") which have been applied consistently in all material respects. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates. In particular, the novel Coronavirus ("COVID-19") pandemic has adversely impacted and is likely to further adversely impact nearly all aspects of our business and markets, including our workforce and the operations of our customers, suppliers, and business partners. The full extent to which the pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including sales, expenses, manufacturing, clinical trials, research and development costs, reserves and allowances, fair value measurements, asset impairment charges, contingent consideration obligations, and the effectiveness of the Company's hedging instruments, will depend on future developments that are highly uncertain and difficult to predict. These developments include, but are not limited to, the duration and spread of the outbreak (including new variants of COVID-19), its severity, the actions to contain the virus or address its impact, the timing, distribution, and efficacy of vaccines and other treatments, U.S. and foreign government actions to respond to the reduction in global economic activity, and how quickly and to what extent normal economic and operating conditions can resume. |
Foreign Currency Translation | Foreign Currency Translation When the local currency of the Company's foreign entities is the functional currency, all assets and liabilities are translated into United States dollars at the rate of exchange in effect at the balance sheet date. Income and expense items are translated at the weighted-average exchange rate prevailing during the period. The effects of foreign currency translation adjustments for these entities are deferred and reported in stockholders' equity as a component of " Accumulated Other Comprehensive Loss ." The effects of foreign currency transactions denominated in a currency other than an entity's functional currency are included in " Other Income, net. " |
Revenue Recognition | Revenue Recognition Revenue is recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products or services. The Company generates nearly all of its revenue from direct product sales and sales of products under consignment arrangements. Revenue from direct product sales is recognized at a point in time when the performance obligation is satisfied upon delivery of the product. Revenue from sales of consigned inventory is recognized at a point in time when the performance obligation is satisfied once the product has been implanted or used by the customer. The Company periodically reviews consignment inventories to confirm the accuracy of customer reporting. The Company also generates a small portion of its revenue from service contracts, and recognizes revenue from service contracts ratably over the term of the contracts. Sales taxes and other similar taxes that the Company collects concurrent with revenue-producing activities are excluded from revenue. The Company does not typically have any significant unusual payment terms beyond 90 days in its contracts with customers. In addition, the Company receives royalty payments for the licensing of certain intellectual property and recognizes the royalty when the subsequent sale of product using the intellectual property occurs. The amount of consideration the Company ultimately receives varies depending upon the return terms, sales rebates, discounts, and other incentives that the Company may offer, which are accounted for as variable consideration when estimating the amount of revenue to recognize. The Company includes estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely upon an assessment of historical payment experience, historical relationship to revenues, estimated customer inventory levels, and current contract sales terms with direct and indirect customers. The Company's sales adjustment related to distributor rebates given to the Company's United States distributors represents the difference between the Company's sales price to the distributor and the negotiated price to be paid by the end-customer. This distributor rebate is recorded as a reduction to sales and a reduction to the distributor's accounts receivable at the time of sale to a distributor. The Company periodically monitors current pricing trends and distributor inventory levels to ensure the credit for future distributor rebates is fairly stated. The Company offers volume rebates to certain group purchasing organizations ("GPOs") and customers based upon targeted sales levels. Volume rebates offered to GPOs are recorded as a reduction to sales and an obligation to the GPOs, as the Company expects to pay in cash. Volume rebates offered to customers are recorded as a reduction to sales and either accounts receivable if the Company expects a net payment from the customer, or as an obligation to the customer if the Company expects to pay in cash. The provision for volume rebates is estimated based upon customers' contracted rebate programs, projected sales levels, and historical experience of rebates paid. The Company periodically monitors its customer rebate programs to ensure that the allowance and liability for accrued rebates is fairly stated. Product returns are typically not significant because returns are generally not allowed unless the product is damaged at time of receipt. In limited circumstances, the Company may allow customers to return previously purchased products, such as for next-generation product offerings. For these transactions, the Company defers recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. The Company sells separately priced service contracts, which range from 12 to 36 months, to owners of its hemodynamic monitors. The Company invoices the customer the total amount of consideration at the inception of the contract and recognizes revenue ratably over the term of the contract. As of December 31, 2020 and December 31, 2019, $6.3 million and $8.4 million, respectively, of deferred revenue associated with outstanding service contracts was recorded in “ Accrued and Other Liabilities ” and " Other Long-term Liabilities. " During 2020, the Company recognized as revenue $6.3 million that was included in the balance of deferred revenue as of December 31, 2019, and during 2019, the Company recognized as revenue $5.5 million that was included in the balance of deferred revenue as of December 31, 2018. A limited number of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the transaction price is allocated to each performance obligation based on its relative standalone selling price charged to other customers. The Company applies the optional exemption of not disclosing the amount of the transaction price allocated to unsatisfied performance obligations for contracts with an original expected duration of one year or less. Shipping and Handling Costs Shipping costs, which are costs incurred to physically move product from the Company's premises or third party distribution centers, including storage, to the customer's premises, are included in " Selling, General, and Administrative Expenses ." Handling costs, which are costs incurred to store at the Company's premises, move, and prepare products for shipment, are included in " Cost of Sales |
Cash Equivalents | Cash Equivalents The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. These investments are valued at cost, which approximates fair value. |
Investments | Investments The Company invests its excess cash in debt securities, including time deposits, commercial paper, U.S. government and agency securities, asset-backed securities, corporate debt securities, and municipal debt securities. Investments with maturities of one year or less are classified as short-term, and investments with maturities greater than one year are classified as long-term. Investments that the Company has the ability and intent to hold until maturity are classified as held-to-maturity and carried at amortized cost. Investments in debt securities that are classified as available-for-sale are carried at fair value with unrealized gains and losses included in " Accumulated Other Comprehensive Loss ." The Company determines the appropriate classification of its investments in debt securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company also has long-term equity investments in companies that are in various stages of development. These investments are reported at fair value or under the equity method of accounting, as appropriate. Equity investments that do not have readily determinable fair values are recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The Company accounts for investments in limited partnerships and limited liability corporations, whereby the Company owns a minimum of 5% of the investee's outstanding voting stock, under the equity method of accounting. These investments are recorded at the amount of the Company's investment and adjusted each period for the Company's share of the investee's income or loss, and dividends paid. Realized gains and losses on investments that are sold are determined using the specific identification method, or the first-in, first-out method, depending on the investment type, and recorded to " Other Income, net ." Income relating to investments in debt securities is recorded to " Interest Income. " Equity investments without readily determinable fair value are considered impaired when there is an indication that the fair value of the Company's interest is less than the carrying amount. Equity method investments are considered impaired when there is an indication of an other-than-temporary decline in value below the carrying amount. Impairments of equity investments are recorded in " Other Income, net. " Debt securities in an unrealized loss position are written down to fair value through “ Other Income, net ” if the Company intends to sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security, among other factors. When a credit loss exists, the Company compares the present value of cash flows expected to be collected from the debt security to the amortized cost basis of the security to determine the allowance amount that should be recorded, if any. For available-to-sale debt securities, any additional impairment not recorded through an allowance for credit losses is recognized in “ Accumulated Other Comprehensive Loss. ” |
Accounts Receivable | Accounts Receivable The majority of the Company’s accounts receivable arise from direct product sales and sales of products under consignment arrangements, and have payment terms that generally require payment within 30 to 90 days. The Company does not adjust its receivables for the effects of a significant financing component at contract exception if collection of the receivable is expected within one year or less from the time of sale. In countries where the Company has experienced a pattern of payments extending beyond the stated terms and collection of the receivable is expected beyond one year from the time of sale, the Company assesses whether the customer has a significant financing component and discounts the receivable and reduces the related revenues over the period of time that the Company estimates those amounts will be paid using the country’s market-based borrowing rate for such period. The Company provides reserves against accounts receivable for estimated losses that may result from a customer’s inability to pay based on customer-specific analysis and general matters such as current assessments of past due balances, economic conditions and forecasts, and historical credit loss activity. Amounts determined to be uncollectible are charged or written-off against the reserve. |
Inventories | Inventories Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. Market value for raw materials is based on replacement costs, and for other inventory classifications is based on net realizable value. A write-down for excess or slow moving inventory is recorded for inventory which is obsolete, damaged, nearing its expiration date (generally triggered at six months prior to expiration), or slow moving (generally defined as quantities in excess of a two-year supply). |
Property, Plant and Equipment | Property, Plant, and Equipment Property, plant, and equipment are recorded at cost. Depreciation is principally calculated for financial reporting purposes on the straight-line method over the estimated useful lives of the related assets, which range from 10 to 40 years for buildings and improvements, from 3 to 15 years for machinery and equipment, and from 3 to 5 years for software. Leasehold improvements are amortized over the life of the related facility leases or the asset, whichever is shorter. Straight-line and accelerated methods of depreciation are used for income tax purposes. Construction in progress is not depreciated until the asset is ready for its intended use. |
Leases | Leases On January 1, 2019, the Company adopted an amendment to the guidance on leases using a modified retrospective transition approach. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. The Company's incremental borrowing rate is determined based on the estimated rate of interest for collateralized borrowing over a similar term as the associated lease. Right-of-use assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received. The Company determines the lease term as the noncancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Certain of the Company’s leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. The Company’s leases do not contain any residual value guarantees. The Company accounts for the lease and non-lease components as a single lease component for all of its leases except vehicle leases, for which the lease and non-lease components are accounted for separately. Operating leases are included in “ Operating Lease Right-of-Use Assets ” and “ Operating Lease Liabilities ” on the Company’s consolidated balance sheets. See Note 6 for further information. |
Impairment of Goodwill and Long-lived Assets | Impairment of Goodwill and Long-lived Assets Goodwill is reviewed for impairment annually in the fourth quarter of each fiscal year, or whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Goodwill is tested for impairment at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the reporting unit does not pass the qualitative assessment, then the Company performs a quantitative impairment test. The Company determined, after performing a qualitative review of each reporting unit, that it is more likely than not that the fair value of each of its reporting units substantially exceeds the respective carrying amounts. Accordingly, in 2020, 2019, and 2018, the Company did not record any impairment loss. Indefinite-lived intangible assets relate to in-process research and development acquired in business combinations. The estimated fair values of in-process research and development projects acquired in a business combination which have not reached technological feasibility are capitalized and accounted for as indefinite-lived intangible assets subject to impairment testing until completion or abandonment of the projects. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If the project is abandoned, all remaining capitalized amounts are written off immediately. Indefinite-lived intangible assets are reviewed for impairment annually in the fourth quarter of each fiscal year, or whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. An impairment loss is recognized when the asset's carrying value exceeds its fair value. In-process research and development projects acquired in an asset acquisition are expensed unless the project has an alternative future use. Management reviews the carrying amounts of other finite-lived intangible assets and long-lived tangible assets whenever events or circumstances indicate that the carrying amounts of an asset may not be recoverable. Impairment indicators include, among other conditions, cash flow deficits, historic or anticipated declines in revenue or operating profit, and adverse legal or regulatory developments. If it is determined that such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair market value. Estimated fair market value is determined primarily using the anticipated cash flows discounted at a rate commensurate with the risk involved. For the purposes of identifying and measuring impairment, long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. |
Income Taxes | Income Taxes The Company is subject to income taxes in the United States and numerous foreign jurisdictions. Significant judgment is required in evaluating the Company's uncertain tax positions and determining its provision for income taxes. The Company recognizes the financial statement benefit of a tax position only after determining that a position would more likely than not be sustained based upon its technical merit if challenged by the relevant taxing authority and taken by management to the court of last resort. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company has made an accounting policy election to recognize the U.S. tax effects of global intangible low-taxed income as a component of income tax expense in the period the tax arises. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. The Company evaluates quarterly the realizability of its deferred tax assets by assessing its valuation allowance and adjusting the amount, if necessary. The factors used to assess the likelihood of realization are both historical experience and the Company's forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. Failure to achieve forecasted taxable income in the applicable taxing jurisdictions could affect the ultimate realization of deferred tax assets and could result in an increase in the Company's effective tax rate on future earnings. |
Research and Development Costs | Research and Development Costs Research and development costs are charged to expense when incurred. |
Earnings per Share | Earnings per Share Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during a period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, nonvested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. |
Stock-based Compensation | Stock-based Compensation The Company measures and recognizes compensation expense for all stock-based awards based on estimated fair values. Stock-based awards consist of stock options, restricted stock units (service-based, market-based, and performance-based), and employee stock purchase subscriptions. Stock-based compensation expense is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period (vesting period) on a straight-line basis. For performance-based restricted stock units, the Company recognizes stock-based compensation expense if and when the Company concludes that it is probable that the performance condition will be achieved, net of estimated forfeitures. The Company reassesses the probability of vesting at each quarter end and adjusts the stock-based compensation expense based on its probability assessment. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Upon exercise of stock options or vesting of restricted stock units, the Company issues common stock. Total stock-based compensation expense was as follows (in millions): Years Ended December 31, 2020 2019 2018 Cost of sales $ 17.2 $ 14.7 $ 11.4 Selling, general, and administrative expenses 56.6 51.2 46.3 Research and development expenses 18.8 15.4 13.3 Total stock-based compensation expense 92.6 81.3 71.0 Income tax benefit (15.4) (14.8) (13.4) Total stock-based compensation expense, net of tax $ 77.2 $ 66.5 $ 57.6 Upon a participant's retirement, all unvested stock options and performance-based restricted stock units are immediately forfeited. In addition, upon retirement, a participant will immediately vest in 25% of service-based restricted stock units for each full year of employment with the Company measured from the grant date. All remaining unvested service-based restricted stock units are immediately forfeited. For market-based restricted stock units, upon retirement and in certain other specified cases, a participant will receive a pro-rated portion of the shares that would ultimately be issued based on attainment of the |
Derivatives | Derivatives The Company uses derivative financial instruments to manage interest rate and foreign currency risks. It is the Company's policy not to enter into derivative financial instruments for speculative purposes. Derivative financial instruments involve credit risk in the event the counterparty should default. It is the Company's policy to execute such instruments with global financial institutions that the Company believes to be creditworthy. The Company diversifies its derivative financial instruments among counterparties to minimize exposure to any one of these entities. The Company also uses International Swap Dealers Association master-netting agreements. The master-netting agreements provide for the net settlement of all contracts through a single payment in a single currency in the event of default, as defined by the agreements. The Company uses foreign currency forward exchange contracts, cross currency swap contracts, and foreign currency denominated debt to manage its exposure to changes in currency exchange rates from (1) future cash flows associated with intercompany transactions and certain local currency expenses expected to occur within the next 13 months (designated as cash flow hedges), (2) its net investment in certain foreign subsidiaries (designated as net investment hedges) and (3) foreign currency denominated assets or liabilities (designated as fair value hedges). The Company also uses foreign currency forward exchange contracts that are not designated as hedging instruments to offset the transaction gains and losses associated with certain assets and liabilities denominated in currencies other than their functional currencies resulting principally from intercompany and local currency transactions. All derivative financial instruments are recognized at fair value in the consolidated balance sheets. For each derivative instrument that is designated as a fair value hedge, the gain or loss on the derivative included in the assessment of hedge effectiveness is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. The Company reports in " Accumulated Other Comprehensive Loss " the gain or loss on derivative financial instruments that are designated, and that qualify, as cash flow hedges. The Company reclassifies these gains and losses into earnings in the same line item and in the same period in which the underlying hedged transactions affect earnings. Changes in the fair value of net investment hedges are reported in " Accumulated Other Comprehensive Loss " as a part of the cumulative translation adjustment and would be reclassified into earnings if the underlying net investment is sold or substantially liquidated. The portion of the change in fair value related to components excluded from the hedge effectiveness assessment are amortized into earnings over the life of the derivative. The gains and losses on derivative financial instruments for which the Company does not elect hedge accounting treatment are recognized in the consolidated statements of operations in each period based upon the change in the fair value of the derivative financial instrument. Cash flows from net investment hedges are reported as investing activities in the consolidated statements of cash flows, and cash flows from all other derivative financial instruments are reported as operating activities. |
Recently Adopted Accounting Standards | Recently Adopted Accounting Standards In August 2018, the Financial Accounting Standards Board ("FASB") issued an amendment to the accounting guidance on cloud computing service arrangements. The guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance also requires an entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. The guidance was effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The adoption of this guidance on January 1, 2020 did not have a material impact on the Company's consolidated financial statements. In August 2018, the FASB issued an amendment to the accounting guidance on fair value measurements. The guidance modifies the disclosure requirements on fair value measurements, including the removal of disclosures of the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels, and the valuation processes for Level 3 fair value measurements. The guidance also adds certain disclosure requirements related to Level 3 fair value measurements. The guidance was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The adoption of this guidance on January 1, 2020 did not have a material impact on the Company's consolidated financial statements. In June 2016, the FASB issued an amendment to the guidance on the measurement of credit losses on financial instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The guidance was effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The adoption of this guidance on January 1, 2020 did not have a material impact on the Company's consolidated financial statements. |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Schedule of Computation of Basic and Diluted Earnings Per Share | The table below presents the computation of basic and diluted earnings per share (in millions, except for per share information): Years Ended December 31, 2020 2019 2018 Basic: Net income $ 823.4 $ 1,046.9 $ 722.2 Weighted-average shares outstanding 622.6 624.8 627.6 Basic earnings per share $ 1.32 $ 1.68 $ 1.15 Diluted: Net income $ 823.4 $ 1,046.9 $ 722.2 Weighted-average shares outstanding 622.6 624.8 627.6 Dilutive effect of stock plans 9.3 11.9 13.3 Dilutive weighted-average shares outstanding 631.9 636.7 640.9 Diluted earnings per share $ 1.30 $ 1.64 $ 1.13 |
Schedule of Stock-Based Compensation Expense | Total stock-based compensation expense was as follows (in millions): Years Ended December 31, 2020 2019 2018 Cost of sales $ 17.2 $ 14.7 $ 11.4 Selling, general, and administrative expenses 56.6 51.2 46.3 Research and development expenses 18.8 15.4 13.3 Total stock-based compensation expense 92.6 81.3 71.0 Income tax benefit (15.4) (14.8) (13.4) Total stock-based compensation expense, net of tax $ 77.2 $ 66.5 $ 57.6 |
OTHER CONSOLIDATED FINANCIAL _2
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of Components of Selected Captions in the Consolidated Balance Sheets | Components of selected captions in the consolidated balance sheets are as follows: As of December 31, 2020 2019 (in millions) Inventories Raw materials $ 136.7 $ 118.0 Work in process 140.0 121.7 Finished products 525.6 401.2 $ 802.3 $ 640.9 Property, plant, and equipment, net Land $ 97.6 $ 98.0 Buildings and leasehold improvements 881.5 619.8 Machinery and equipment 564.9 466.3 Equipment with customers 42.2 35.6 Software 94.2 87.9 Construction in progress 313.3 265.0 1,993.7 1,572.6 Accumulated depreciation (598.5) (512.3) $ 1,395.2 $ 1,060.3 Accrued and other liabilities Employee compensation and withholdings $ 236.7 $ 295.8 Accrued rebates 67.2 67.1 Property, payroll, and other taxes 49.7 51.4 Research and development accruals 52.3 51.4 Litigation settlement (Notes 3 and 18) 37.5 — Litigation and insurance reserves (Note 18) 23.3 20.0 Taxes payable 18.6 52.9 Fair value of derivatives 39.3 6.4 Accrued marketing expenses 14.3 17.5 Accrued professional services 7.6 10.1 Accrued realignment reserves 14.5 16.7 Accrued relocation related costs 21.0 17.4 Other accrued liabilities 88.2 89.8 $ 670.2 $ 696.5 |
Supplemental Cash Flow Information | Supplemental Cash Flow Information (in millions) Years Ended December 31, 2020 2019 2018 Cash paid during the year for: Interest $ 19.9 $ 19.9 $ 30.1 Income taxes $ 197.9 $ 61.5 $ 223.7 Amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 29.7 $ 28.6 $ — Non-cash investing and financing transactions: Fair value of shares issued in payment for contingent consideration liabilities $ — $ — $ 34.3 Right-of-use assets obtained in exchange for new lease liabilities $ 39.7 $ 49.6 $ — Capital expenditures accruals $ 80.4 $ 50.8 $ 18.7 |
Schedule of Cash and Cash Equivalents | Cash, Cash Equivalents, and Restricted Cash (in millions) Years Ended December 31, 2020 2019 2018 Cash and cash equivalents $ 1,183.2 $ 1,179.1 $ 714.1 Restricted cash included in other current assets 16.6 1.6 1.5 Restricted cash included in other assets 0.4 3.7 0.3 Total cash, cash equivalents, and restricted cash $ 1,200.2 $ 1,184.4 $ 715.9 |
Schedule of Restricted Cash | Cash, Cash Equivalents, and Restricted Cash (in millions) Years Ended December 31, 2020 2019 2018 Cash and cash equivalents $ 1,183.2 $ 1,179.1 $ 714.1 Restricted cash included in other current assets 16.6 1.6 1.5 Restricted cash included in other assets 0.4 3.7 0.3 Total cash, cash equivalents, and restricted cash $ 1,200.2 $ 1,184.4 $ 715.9 |
LEASES (Tables)
LEASES (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Leases [Abstract] | |
Assets And Liabilities Of Lessee | Supplemental balance sheet information related to operating leases was as follows (in millions, except lease term and discount rate): As of December 31, 2020 2019 Operating lease right-of-use assets $ 94.2 $ 80.1 Operating lease liabilities, current portion $ 27.2 $ 25.5 Operating lease liabilities, long-term portion 72.7 58.9 Total operating lease liabilities $ 99.9 $ 84.4 |
Lessee, Operating Lease, Liability, Maturity | Maturities of operating lease liabilities at December 31, 2020 were as follows (in millions): 2021 $ 30.0 2022 20.7 2023 14.4 2024 8.8 2025 6.1 Thereafter 28.1 Total lease payments 108.1 Less: imputed interest (8.2) Total lease liabilities $ 99.9 The following table provides information on the lease terms and discount rates: Years Ended December 31, 2020 2019 Weighted-average remaining lease term (in years) 6.6 5.3 Weighted-average discount rate 2.7 % 2.8 % |
INVESTMENTS (Tables)
INVESTMENTS (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Investments, Debt and Equity Securities [Abstract] | |
Schedule of Investments in Debt Securities | Investments in debt securities at the end of each period were as follows (in millions): December 31, 2020 December 31, 2019 Held-to-maturity Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Bank time deposits $ 50.0 $ — $ — $ 50.0 $ 100.2 $ — $ — $ 100.2 Available-for-sale Bank time deposits $ 24.1 $ — $ — $ 24.1 $ 13.1 $ — $ — $ 13.1 Commercial paper — — — — 34.3 — — 34.3 U.S. government and agency securities 147.0 2.2 — 149.2 113.2 0.6 — 113.8 Foreign government bonds — — — — 1.7 — — 1.7 Asset-backed securities 149.6 1.9 — 151.5 141.2 0.6 (0.1) 141.7 Corporate debt securities 600.8 7.5 — 608.3 487.0 2.3 (0.1) 489.2 Municipal securities 2.8 — — 2.8 — — — — $ 924.3 $ 11.6 $ — $ 935.9 $ 790.5 $ 3.5 $ (0.2) $ 793.8 |
Schedule of Cost and Fair Value of Investments in Debt Securities, by Contractual Maturity | The cost and fair value of investments in debt securities, by contractual maturity, as of December 31, 2020 were as follows: Held-to-Maturity Available-for-Sale Amortized Cost Fair Value Amortized Cost Fair Value (in millions) Due in 1 year or less $ 50.0 $ 50.0 $ 168.4 $ 169.4 Due after 1 year through 5 years — — 578.2 586.5 Instruments not due at a single maturity date — — 177.7 180.0 $ 50.0 $ 50.0 $ 924.3 $ 935.9 |
Gross Unrealized Losses and Fair Values for Investments in Unrealized Loss Position | The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2019, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in millions): December 31, 2019 Less than 12 Months 12 Months or Greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Asset-backed securities $ 73.4 $ (0.1) $ — $ — $ 73.4 $ (0.1) Corporate debt securities 81.4 (0.1) — — 81.4 (0.1) $ 154.8 $ (0.2) $ — $ — $ 154.8 $ (0.2) |
Schedule of Investments in Unconsolidated Affiliates | Investments in these unconsolidated affiliates are recorded in " Long-term Investments " on the consolidated balance sheets, and are as follows: December 31, 2020 2019 (in millions) Equity method investments Carrying value of equity method investments $ 5.7 $ 6.2 Equity securities Carrying value of non-marketable equity securities 29.4 23.1 Total investments in unconsolidated affiliates $ 35.1 $ 29.3 |
ACQUISITIONS (Tables)
ACQUISITIONS (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Business Combinations [Abstract] | |
Summary of Fair Values of Assets Acquired and Liabilities Assumed | The following table summarizes the fair values of the assets acquired and liabilities assumed (in millions): Current assets $ 6.1 Property and equipment, net 1.3 Goodwill 64.4 Developed technology 35.9 Customer relationships 8.8 Deferred tax assets 2.2 Liabilities assumed (17.9) Total purchase price 100.8 Less: cash acquired (0.6) Total purchase price, net of cash acquired $ 100.2 |
GOODWILL AND OTHER INTANGIBLE_2
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Changes in the Carrying Amount of Goodwill, by Segment | The changes in the carrying amount of goodwill, by segment, during the years ended December 31, 2020 and 2019 were as follows: United Europe Rest of World Total (in millions) Goodwill at December 31, 2018 $ 709.3 $ 64.2 $ 338.7 $ 1,112.2 Goodwill acquired during the year 64.4 — — 64.4 Currency translation adjustment — (1.4) (7.5) (8.9) Goodwill at December 31, 2019 773.7 62.8 331.2 1,167.7 Currency translation adjustment — 5.5 — 5.5 Goodwill at December 31, 2020 $ 773.7 $ 68.3 $ 331.2 $ 1,173.2 |
Schedule of Finite-Lived Other Intangible Assets | Other intangible assets consist of the following (in millions): December 31, Weighted-Average Useful Life (in years) 2020 2019 Cost Accumulated Net Cost Accumulated Net Finite-lived intangible assets Patents 7.4 $ 186.1 $ (183.6) $ 2.5 $ 185.7 $ (182.1) $ 3.6 Developed technology 13.1 155.2 (51.0) 104.2 153.5 (46.6) 106.9 Other 10.0 12.6 (6.0) 6.6 12.3 (4.4) 7.9 12.6 353.9 (240.6) 113.3 351.5 (233.1) 118.4 Indefinite-lived intangible assets In-process research and development 218.1 — 218.1 218.1 — 218.1 $ 572.0 $ (240.6) $ 331.4 $ 569.6 $ (233.1) $ 336.5 |
Schedule of Indefinite-Lived Other Intangible Assets | Other intangible assets consist of the following (in millions): December 31, Weighted-Average Useful Life (in years) 2020 2019 Cost Accumulated Net Cost Accumulated Net Finite-lived intangible assets Patents 7.4 $ 186.1 $ (183.6) $ 2.5 $ 185.7 $ (182.1) $ 3.6 Developed technology 13.1 155.2 (51.0) 104.2 153.5 (46.6) 106.9 Other 10.0 12.6 (6.0) 6.6 12.3 (4.4) 7.9 12.6 353.9 (240.6) 113.3 351.5 (233.1) 118.4 Indefinite-lived intangible assets In-process research and development 218.1 — 218.1 218.1 — 218.1 $ 572.0 $ (240.6) $ 331.4 $ 569.6 $ (233.1) $ 336.5 |
Schedule of Estimated Amortization Expense | Estimated amortization expense for each of the years ending December 31 is as follows (in millions): 2021 $ 5.2 2022 7.6 2023 10.1 2024 12.2 2025 14.8 |
DEBT AND CREDIT FACILITIES (Tab
DEBT AND CREDIT FACILITIES (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Debt Disclosure [Abstract] | |
Summary of the Notes | The following is a summary of the Notes as of December 31, 2020 and 2019: December 31, 2020 2019 Amount Effective Amount Effective (in millions) (in millions) Fixed-rate 4.300% 2018 Notes $ 600.0 4.329 % $ 600.0 4.329 % Unamortized discount (1.1) (1.2) Unamortized debt issuance costs (3.9) (4.4) Total carrying amount $ 595.0 $ 594.4 |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Summary of Financial Instruments Measured at Fair Value on a Recurring Basis | The following table summarizes the Company's financial instruments which are measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in millions): December 31, 2020 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 16.2 $ — $ — $ 16.2 Available-for-sale investments: Bank time deposits — 24.1 — 24.1 Corporate debt securities — 608.3 — 608.3 Asset-backed securities — 151.5 — 151.5 U.S. government and agency securities 56.9 92.2 — 149.1 Municipal securities — 2.8 — 2.8 Investments held for deferred compensation plans 111.2 — — 111.2 Derivatives — 8.1 — 8.1 $ 184.3 $ 887.0 $ — $ 1,071.3 Liabilities Derivatives $ — $ 39.3 $ — $ 39.3 Deferred compensation plans 111.6 — — 111.6 Contingent consideration liabilities — — 186.1 186.1 $ 111.6 $ 39.3 $ 186.1 $ 337.0 December 31, 2019 Assets Cash equivalents $ 0.7 $ 31.7 $ — $ 32.4 Available-for-sale investments: Bank time deposits — 13.1 — 13.1 Corporate debt securities — 489.2 — 489.2 Asset-backed securities — 141.7 — 141.7 U.S. government and agency securities 76.1 37.7 — 113.8 Foreign government bonds — 1.7 — 1.7 Commercial paper — 34.3 — 34.3 Investments held for deferred compensation plans 88.9 — — 88.9 Derivatives — 30.7 — 30.7 $ 165.7 $ 780.1 $ — $ 945.8 Liabilities Derivatives $ — $ 6.4 $ — $ 6.4 Deferred compensation plans 88.7 — — 88.7 Contingent consideration liabilities — — 172.5 172.5 $ 88.7 $ 6.4 $ 172.5 $ 267.6 |
Summary of Changes in Fair Value of Contingent Consideration Obligation | The following table summarizes the changes in fair value of the contingent consideration obligation for the years ended December 31, 2020 and 2019 (in millions): December 31, 2020 2019 Fair value, beginning of year $ 172.5 $ 178.6 Changes in fair value 13.6 (6.1) Fair value, end of year $ 186.1 $ 172.5 |
DERIVATIVE INSTRUMENTS AND HE_2
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Summary of Derivative Financial Instruments Used to Manage Currency Exchange and Interest Rate Risk | The Company uses derivative financial instruments to manage its currency exchange rate risk and its interest rate risk as summarized below. Notional amounts are stated in United States dollar equivalents at spot exchange rates at the respective dates. The Company does not enter into these arrangements for trading or speculation purposes. Notional Amount December 31, 2020 December 31, 2019 (in millions) Foreign currency forward exchange contracts $ 1,525.5 $ 1,336.5 Cross currency swap contracts 300.0 300.0 |
Schedule of Location and Fair Value Amounts of Derivative Instruments | The following table presents the location and fair value amounts of derivative instruments reported in the consolidated balance sheets (in millions): Fair Value Balance Sheet Location December 31, 2020 December 31, 2019 Derivatives designated as hedging instruments Assets Foreign currency contracts Other current assets $ 7.3 $ 14.2 Foreign currency contracts Other assets $ — $ 3.2 Cross currency swap contracts Other assets $ 0.8 $ 13.3 Liabilities Foreign currency contracts Accrued and other liabilities $ 39.3 $ 6.4 |
Schedule of Effect of Master-Netting Agreements and Rights of Offset, Assets | The following table presents the effect of master-netting agreements and rights of offset on the consolidated balance sheets (in millions): Gross Amounts Not Offset in the Consolidated Balance Sheet Gross Amounts Net Amounts December 31, 2020 Gross Financial Cash Net Derivative Assets Foreign currency contracts $ 7.3 $ — $ 7.3 $ (6.1) $ — $ 1.2 Cross currency swap contracts $ 0.8 $ — $ 0.8 $ — $ — $ 0.8 Derivative Liabilities Foreign currency contracts $ 39.3 $ — $ 39.3 $ (6.1) $ — $ 33.2 December 31, 2019 Derivative Assets Foreign currency contracts $ 17.4 $ — $ 17.4 $ (5.7) $ — $ 11.7 Cross currency swap contracts $ 13.3 $ — $ 13.3 $ — $ — $ 13.3 Derivative Liabilities Foreign currency contracts $ 6.4 $ — $ 6.4 $ (5.7) $ — $ 0.7 |
Schedule of Effect of Master-Netting Agreements and Rights of Offset, Liabilities | The following table presents the effect of master-netting agreements and rights of offset on the consolidated balance sheets (in millions): Gross Amounts Not Offset in the Consolidated Balance Sheet Gross Amounts Net Amounts December 31, 2020 Gross Financial Cash Net Derivative Assets Foreign currency contracts $ 7.3 $ — $ 7.3 $ (6.1) $ — $ 1.2 Cross currency swap contracts $ 0.8 $ — $ 0.8 $ — $ — $ 0.8 Derivative Liabilities Foreign currency contracts $ 39.3 $ — $ 39.3 $ (6.1) $ — $ 33.2 December 31, 2019 Derivative Assets Foreign currency contracts $ 17.4 $ — $ 17.4 $ (5.7) $ — $ 11.7 Cross currency swap contracts $ 13.3 $ — $ 13.3 $ — $ — $ 13.3 Derivative Liabilities Foreign currency contracts $ 6.4 $ — $ 6.4 $ (5.7) $ — $ 0.7 |
Schedule of Effect of Derivative Instruments | The following tables present the effect of derivative and non-derivative hedging instruments on the consolidated statements of operations and consolidated statements of comprehensive income: Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion) Location of Gain or (Loss) Reclassified from Accumulated OCI into Income Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income 2020 2019 2020 2019 (in millions) (in millions) Cash flow hedges Foreign currency contracts $ (33.7) $ 23.5 Cost of sales $ 18.4 $ 40.9 Selling, general, and administrative expenses $ 2.2 $ 1.9 Amount of Gain or (Loss) Location of Gain or (Loss) Reclassified from Accumulated OCI into Income Amount of Gain or (Loss) 2020 2019 2020 2019 (in millions) (in millions) Net investment hedges Cross currency swap contracts $ (12.6) $ 12.5 Interest expense $ 6.4 $ 6.6 The cross currency swaps have an expiration date of June 15, 2028. At maturity of the cross currency swap contracts, the Company will deliver the notional amount of €257.2 million and will receive $300.0 million from the counterparties. The Company will receive semi-annual interest payments from the counterparties based on a fixed interest rate until maturity of the agreements. Amount of Gain or Location of Gain or 2020 2019 2018 (in millions) Fair value hedges Foreign currency contracts Other income, net $ (1.4) $ 1.4 $ 0.5 Amount of Gain or Location of Gain or 2020 2019 2018 (in millions) Derivatives not designated as hedging instruments Foreign currency contracts Other income, net $ (15.1) $ 0.3 $ 9.7 |
Schedule of the Effect of Fair Value and Cash Flow Hedge | The following table presents the effect of fair value and cash flow hedge accounting on the consolidated statements of operations: Location and Amount of Gain or (Loss) Recognized in Income on Fair Value and Cash Flow Hedging Relationships Twelve Months Ended December 31, 2020 Cost of sales Selling, general, and administrative expenses Other Income, net Total amounts of income and expense line items shown in the consolidated statements of operations in which the effects of fair value or cash flow hedges are recorded $ (1,080.6) $ (1,228.4) $ 11.5 The effects of fair value and cash flow hedging: Gain (loss) on fair value hedging relationships: Foreign currency contracts: Hedged items — — 4.8 Derivatives designated as hedging instruments — — (4.8) Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 3.4 Gain (loss) on cash flow hedging relationships: Foreign currency contracts: Amount of gain (loss) reclassified from accumulated OCI into income 18.4 2.2 — Location and Amount of Gain or (Loss) Recognized in Income on Fair Value and Cash Flow Hedging Relationships Twelve Months Ended December 31, 2019 Cost of sales Selling, general, and administrative expenses Other Income, net Total amounts of income and expense line items shown in the consolidated statements of operations in which the effects of fair value or cash flow hedges are recorded $ (1,114.4) $ (1,242.2) $ 8.2 The effects of fair value and cash flow hedging: Gain (loss) on fair value hedging relationships: Foreign currency contracts: Hedged items — — 2.9 Derivatives designated as hedging instruments — — (2.9) Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 4.3 Gain (loss) on cash flow hedging relationships: Foreign currency contracts: Amount of gain (loss) reclassified from accumulated OCI into income 40.9 1.9 — |
EMPLOYEE BENEFIT PLANS (Tables)
EMPLOYEE BENEFIT PLANS (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Retirement Benefits [Abstract] | |
Schedule of Information Regarding Defined Benefit Pension Plans | Years Ended December 31, 2020 2019 (in millions) Change in projected benefit obligation: Beginning of year $ 105.2 $ 97.4 Service cost 6.3 5.2 Interest cost 0.5 0.9 Participant contributions 1.5 1.3 Actuarial loss 2.9 8.2 Benefits paid (0.6) (4.2) Plan amendment — (4.6) Currency exchange rate changes and other 10.4 1.0 End of year $ 126.2 $ 105.2 Change in fair value of plan assets: Beginning of year $ 63.2 $ 60.4 Actual return on plan assets 0.4 2.0 Employer contributions 2.8 2.6 Participant contributions 1.5 1.3 Benefits paid (0.6) (4.2) Currency exchange rate changes and other 6.0 1.1 End of year $ 73.3 $ 63.2 Funded Status Projected benefit obligation $ (126.2) $ (105.2) Plan assets at fair value 73.3 63.2 Underfunded status $ (52.9) $ (42.0) Net amounts recognized on the consolidated balance sheet: Other long-term liabilities $ 52.9 $ 42.0 Accumulated other comprehensive loss, net of tax: Net actuarial loss $ (30.8) $ (26.3) Net prior service cost 6.6 6.7 Deferred income tax benefit 4.6 4.2 Total $ (19.6) $ (15.4) |
Components of Net Periodic Benefit Cost | The components of net periodic pension benefit cost (credit) are as follows (in millions): Years Ended December 31, 2020 2019 2018 Service cost, net $ 6.3 $ 5.2 $ 6.0 Interest cost 0.5 0.9 0.8 Expected return on plan assets (1.0) (1.4) (1.3) Settlements and curtailment gain — — (7.4) Amortization of actuarial loss 1.6 0.9 0.8 Amortization of prior service credit (0.7) (0.2) (0.1) Net periodic pension benefit cost (credit) $ 6.7 $ 5.4 $ (1.2) |
Schedule of Weighted-Average Assumptions Used to Determine Benefit Obligations | The weighted-average assumptions used to determine the benefit obligations are as follows: December 31, 2020 2019 Discount rate 0.3 % 0.5 % Rate of compensation increase 2.6 % 2.7 % Cash balance interest crediting rate 2.5 % 2.6 % Social securities increase 1.6 % 1.6 % Pension increase 1.8 % 1.8 % The weighted-average assumptions used to determine the net periodic pension benefit cost are as follows: Years ended December 31, 2020 2019 2018 Discount rate 0.5 % 0.9 % 0.9 % Expected return on plan assets 1.5 % 2.3 % 2.3 % Rate of compensation increase 2.7 % 2.8 % 2.6 % Cash balance interest crediting rate 1.5 % 1.5 % 1.5 % Social securities increase 1.6 % 1.8 % 1.5 % Pension increase 1.8 % 1.8 % 1.8 % |
Schedule of Target Weighted-Average Asset Allocations and Fair Value | Target weighted-average asset allocations at December 31, 2020, by asset category, are as follows: Equity securities 25.3 % Debt securities 47.5 % Real estate 7.7 % Other 19.5 % Total 100.0 % The fair values of the Company's defined benefit plan assets at December 31, 2020 and 2019, by asset category, are as follows (in millions): December 31, 2020 Level 1 Level 2 Level 3 Total Asset Category Cash $ 3.0 $ — $ — $ 3.0 Equity securities: United States equities 3.3 — — 3.3 International equities 16.1 — — 16.1 Debt securities: United States government bonds 7.4 — — 7.4 International government bonds 26.0 — — 26.0 Real estate — 5.6 — 5.6 Mortgages — 3.1 — 3.1 Insurance contracts — — 1.0 1.0 Total plan assets measured at fair value $ 55.8 $ 8.7 $ 1.0 $ 65.5 Alternative investments measured at net asset value (a) 7.8 Total plan assets $ 73.3 December 31, 2019 Level 1 Level 2 Level 3 Total Asset Category Cash $ 3.8 $ — $ — $ 3.8 Equity securities: United States equities 3.0 — — 3.0 International equities 11.2 — — 11.2 Debt securities: United States government bonds 8.2 — — 8.2 International government bonds 22.3 — — 22.3 Real estate — 4.4 — 4.4 Mortgages — 2.3 — 2.3 Insurance contracts — — 0.9 0.9 Total plan assets $ 48.5 $ 6.7 $ 0.9 $ 56.1 Alternative investments measured at net asset value (a) 7.1 Total plan assets $ 63.2 _______________________________________ (a) Certain investments that were measured at net asset value per share have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the total plan assets. |
Summary of Changes in Fair Value of Defined Benefit Plan Assets Classified as Level 3 | The following table summarizes the changes in fair value of the Company's defined benefit plan assets that have been classified as Level 3 for the years ended December 31, 2020 and 2019 (in millions): Insurance Balance at December 31, 2018 $ 1.0 Purchases, sales and settlements (0.1) Balance at December 31, 2019 0.9 Currency exchange rate impact 0.1 Balance at December 31, 2020 $ 1.0 |
Schedule of Benefit Payments Which Reflect Expected Future Service | The following benefit payments, which reflect expected future service, as appropriate, at December 31, 2020, are expected to be paid (in millions): 2021 $ 4.6 2022 4.9 2023 6.7 2024 5.6 2025 5.3 2024-2026 36.7 |
COMMON STOCK (Tables)
COMMON STOCK (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Equity [Abstract] | |
Accelerated Share Repurchases | The following table summarizes the terms of the ASR agreements (dollars and shares in millions, except per share data): Initial Delivery Final Settlement Agreement Date Amount Shares Price per Value of Settlement Total Shares Average Price April 2018 $ 400.0 2.5 $ 127.36 80 % July 2018 2.8 $ 142.37 October 2018 $ 250.0 1.4 $ 139.22 80 % November 2018 1.7 $ 150.54 May 2019 $ 150.0 0.7 $ 178.66 80 % May 2019 0.8 $ 178.42 May 2019 $ 100.0 0.5 $ 170.02 80 % June 2019 0.6 $ 178.46 _______________________________________________________________________________ (a) The three-for-one stock split distributed on May 29, 2020 excluded treasury shares. The shares and per share prices in the table are reflected at the pre-split amounts and prices at the time of the transaction. |
Schedule of Weighted-Average Assumptions for Options Granted | The Black-Scholes option pricing model was used with the following weighted-average assumptions for options granted during the following periods: Option Awards 2020 2019 2018 Average risk-free interest rate 0.3 % 2.3 % 2.9 % Expected dividend yield None None None Expected volatility 33 % 30 % 29 % Expected life (years) 5.0 5.1 5.0 Fair value, per share $ 21.70 $ 18.17 $ 14.17 |
Schedule of Weighted-Average Assumptions for ESPP Subscriptions | The Black-Scholes option pricing model was used with the following weighted-average assumptions for ESPP subscriptions granted during the following periods: ESPP 2020 2019 2018 Average risk-free interest rate 1.3 % 2.4 % 1.7 % Expected dividend yield None None None Expected volatility 33 % 27 % 31 % Expected life (years) 0.6 0.6 0.6 Fair value, per share $ 16.61 $ 16.43 $ 12.18 |
Schedule of Stock Option Activity | Stock option activity during the year ended December 31, 2020 under the Program and the Nonemployee Directors Program was as follows (in millions, except years and per-share amounts): Shares Weighted- Weighted- Aggregate Outstanding as of December 31, 2019 17.1 $ 32.19 Options granted 1.8 73.02 Options exercised (4.3) 18.16 Options forfeited (0.3) 49.74 Outstanding as of December 31, 2020 14.3 41.27 3.4 years $ 712.5 Exercisable as of December 31, 2020 9.5 32.32 2.5 years 558.1 Vested and expected to vest as of December 31, 2020 13.6 40.37 3.3 years 690.4 |
Schedule of Restricted Stock Unit Activity | The following table summarizes nonvested restricted stock unit activity during the year ended December 31, 2020 under the Program and the Nonemployee Directors Program (in millions, except per-share amounts): Shares Weighted- Nonvested as of December 31, 2019 2.7 $ 46.89 Granted (a) 0.9 71.31 Vested (0.9) 40.03 Forfeited (0.1) 49.90 Nonvested as of December 31, 2020 2.6 57.59 _______________________________________________________________________________ |
ACCUMULATED OTHER COMPREHENSI_2
ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Equity [Abstract] | |
Summary of Activity for Each Component of Accumulated Other Comprehensive Loss | Presented below is a summary of activity for each component of " Accumulated Other Comprehensive Loss " for the years ended December 31, 2020, 2019, and 2018. Foreign Unrealized (Loss) Gain on Hedges Unrealized (Loss) Gain on Unrealized Total (in millions) December 31, 2017 $ (100.1) $ (13.9) $ (4.6) $ (14.1) $ (132.7) Impact from adoption of ASU 2016-16 and ASU 2018-02 (4.9) (2.9) — — (7.8) January 1, 2018 (105.0) (16.8) (4.6) (14.1) (140.5) Other comprehensive (loss) income before reclassifications (36.7) 35.1 (3.1) 7.6 2.9 Amounts reclassified from accumulated other comprehensive loss — 19.1 2.9 (6.7) 15.3 Deferred income tax expense (1.9) (13.8) (0.2) (0.3) (16.2) December 31, 2018 (143.6) 23.6 (5.0) (13.5) (138.5) Other comprehensive (loss) income before reclassifications (1.5) 27.9 7.9 (3.2) 31.1 Amounts reclassified from accumulated other comprehensive loss (6.6) (44.2) 0.4 0.7 (49.7) Deferred income tax (expense) benefit (3.1) 5.2 (1.6) 0.6 1.1 December 31, 2019 (154.8) 12.5 1.7 (15.4) (156.0) Other comprehensive income (loss) before reclassifications 35.7 (34.8) 8.0 (5.5) 3.4 Amounts reclassified from accumulated other comprehensive loss (6.4) (19.2) 0.3 0.9 (24.4) Deferred income tax benefit (expense) 3.1 13.8 (1.4) 0.4 15.9 December 31, 2020 $ (122.4) $ (27.7) $ 8.6 $ (19.6) $ (161.1) _______________________________________________________________________________ |
Change in Unrealized Pension Costs | For the years ended December 31, 2020, 2019, and 2018, the change in unrealized pension costs consisted of the following (in millions): Pre-Tax Tax (Expense) Benefit Net of Tax 2020 Prior service credit arising during period $ 0.6 $ (0.2) $ 0.4 Amortization of prior service credit (0.7) 0.1 (0.6) Net prior service cost arising during period (0.1) (0.1) (0.2) Net actuarial loss arising during period (4.5) 0.5 (4.0) Unrealized pension costs, net $ (4.6) $ 0.4 $ (4.2) 2019 Prior service credit arising during period $ 4.6 $ (0.6) $ 4.0 Amortization of prior service credit (0.2) 0.1 (0.1) Net prior service credit arising during period 4.4 (0.5) 3.9 Net actuarial loss arising during period (6.9) 1.1 (5.8) Unrealized pension costs, net $ (2.5) $ 0.6 $ (1.9) 2018 Prior service credit arising during period $ 3.3 $ (0.9) $ 2.4 Amortization of prior service credit (0.1) — (0.1) Net prior service credit arising during period 3.2 (0.9) 2.3 Net actuarial loss arising during period (2.3) 0.6 (1.7) Unrealized pension credits, net $ 0.9 $ (0.3) $ 0.6 |
Schedule of Information About Amounts Reclassified from Accumulated Other Comprehensive Loss | The following table provides information about amounts reclassified from " Accumulated Other Comprehensive Loss " (in millions): Years Ended December 31, Details about Accumulated Other Comprehensive Loss 2020 2019 Affected Line on Consolidated Foreign currency translation adjustments $ 6.4 $ 6.6 Other income, net (1.6) (1.6) Provision for income taxes $ 4.8 $ 5.0 Net of tax (Loss) gain on hedges $ 18.4 $ 40.9 Cost of sales 2.2 1.9 Selling, general, and administrative expenses (1.4) 1.4 Other income, net 19.2 44.2 Total before tax (5.0) (11.0) Provision for income taxes $ 14.2 $ 33.2 Net of tax (Loss) gain on available-for-sale investments $ (0.3) $ (0.4) Other income, net (0.6) (0.3) Provision for income taxes $ (0.9) $ (0.7) Net of tax Amortization of pension adjustments $ (0.9) $ (0.7) Other income, net 0.2 0.1 Provision for income taxes $ (0.7) $ (0.6) Net of tax |
OTHER INCOME, NET (Tables)
OTHER INCOME, NET (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Other Income and Expenses [Abstract] | |
Schedule of Other Expense, Net | Years Ended December 31, 2020 2019 2018 (in millions) Foreign exchange gains, net $ (12.3) $ (5.9) $ (6.7) Gain on investments (0.6) (0.5) 1.7 Non-service cost components of net periodic pension benefit cost (credit) 0.4 0.2 (0.1) Other 1.0 (2.0) 1.1 Total other income, net $ (11.5) $ (8.2) $ (4.0) |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income Before Provisions for Income Taxes | The Company's income before provision for income taxes was generated from United States and international operations as follows (in millions): Years Ended December 31, 2020 2019 2018 United States $ 151.3 $ 383.4 $ 266.1 International, including Puerto Rico 765.4 783.1 495.3 $ 916.7 $ 1,166.5 $ 761.4 |
Schedule of Provision for Income Taxes | The provision for income taxes consists of the following (in millions): Years Ended December 31, 2020 2019 2018 Current United States: Federal $ 23.4 $ 31.3 $ 10.9 State and local 48.2 48.7 13.6 International, including Puerto Rico 73.9 29.1 35.9 Current income tax expense $ 145.5 $ 109.1 $ 60.4 Deferred United States: Federal $ 11.0 $ 28.3 $ (16.1) State and local (32.9) (18.3) (22.4) International, including Puerto Rico (30.3) 0.5 17.3 Deferred income tax (benefit) expense (52.2) 10.5 (21.2) Total income tax provision $ 93.3 $ 119.6 $ 39.2 |
Components of Deferred Tax Assets and Liabilities | The components of deferred tax assets and liabilities are as follows (in millions): December 31, 2020 2019 Deferred tax assets Compensation and benefits $ 88.6 $ 90.1 Benefits from uncertain tax positions 27.0 22.5 Net tax credit carryforwards 125.5 108.4 Net operating loss carryforwards 64.1 57.6 Accrued liabilities 105.0 41.3 Inventories 16.3 12.9 Cash flow and net investment hedges 3.3 — State income taxes 0.5 0.5 Investments 1.8 1.5 Lease liability obligations 7.7 18.4 Other 3.6 3.4 Total deferred tax assets 443.4 356.6 Deferred tax liabilities Property, plant, and equipment (53.4) (22.6) Cash flow and net investment hedges — (6.8) Deferred tax on foreign earnings (29.2) (35.3) Right-of-use assets (7.0) (17.5) Other intangible assets (76.3) (71.0) Other (3.1) (2.2) Total deferred tax liabilities (169.0) (155.4) Valuation allowance (71.6) (65.8) Net deferred tax assets $ 202.8 $ 135.4 |
Summary of Net Operating Loss Carryforwards | Net operating loss and capital loss carryforwards and the related carryforward periods at December 31, 2020 are summarized as follows (in millions): Carryforward Tax Benefit Valuation Net Tax Carryforward United States federal net operating losses $ 26.6 $ 5.6 $ — $ 5.6 2030-2037 United States federal net operating losses 11.3 2.4 — 2.4 Indefinite United States state net operating losses 33.5 2.1 (2.1) — 2026-2039 United States state net operating losses 1.0 0.1 (0.1) — Indefinite Non-United States net operating losses 18.2 4.7 (3.6) 1.1 2020-2027 Non-United States net operating losses 295.1 49.2 (39.9) 9.3 Indefinite United States capital losses 34.1 0.2 (0.2) — 2024 Total $ 419.8 $ 64.3 $ (45.9) $ 18.4 |
Summary of Tax Credit Carryforwards | The gross tax credit carryforwards and the related carryforward periods at December 31, 2020 are summarized as follows (in millions): Carryforward Valuation Net Tax Carryforward California research expenditure tax credits $ 145.1 $ — $ 145.1 Indefinite Federal research expenditure tax credits 1.5 — 1.5 2026-2039 Puerto Rico purchases credit 23.4 (23.4) — Indefinite Total $ 170.0 $ (23.4) $ 146.6 |
Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate | A reconciliation of the United States federal statutory income tax rate to the Company's effective income tax rate is as follows (in millions): Years Ended December 31, 2020 2019 2018 Income tax expense at U.S. federal statutory rate $ 192.5 $ 245.0 $ 159.9 Foreign income taxed at different rates (80.5) (75.0) (16.2) State and local taxes, net of federal tax benefit 5.0 11.9 6.8 Tax credits, federal and state (43.1) (42.9) (36.7) Build (release) of reserve for prior years' uncertain tax positions 4.2 5.0 (35.5) U.S. tax on foreign earnings, net of credits 1.5 (2.9) (12.2) Tax on global intangible low-taxed income 49.2 32.0 — Foreign-derived intangible income deduction (2.6) (7.2) (6.6) U.S. federal deductible employee share-based compensation (48.3) (57.6) (41.8) Nondeductible employee share-based compensation 4.2 3.2 2.8 Impact related to 2017 U.S. Tax Reform — 2.8 15.8 Other 11.2 5.3 2.9 Income tax provision $ 93.3 $ 119.6 $ 39.2 |
Reconciliation of Beginning and Ending Amount of Uncertain Tax Positions | A reconciliation of the beginning and ending amount of uncertain tax positions, excluding interest, penalties, and foreign exchange, is as follows (in millions): December 31, 2020 2019 2018 Uncertain gross tax positions, January 1 $ 203.1 $ 150.7 $ 225.6 Current year tax positions 86.4 55.4 37.8 Increase in prior year tax positions 6.0 0.8 13.9 Decrease in prior year tax positions (10.0) (3.8) (78.8) Settlements (3.7) — (46.5) Lapse of statutes of limitations — — (1.3) Uncertain gross tax positions, December 31 $ 281.8 $ 203.1 $ 150.7 |
SEGMENT INFORMATION (Tables)
SEGMENT INFORMATION (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Segment Reporting [Abstract] | |
Schedule of Information About Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income | The table below presents information about Edwards Lifesciences' reportable segments (in millions): Years Ended December 31, 2020 2019 2018 Segment Net Sales United States $ 2,516.8 $ 2,532.7 $ 2,055.2 Europe 945.2 926.1 826.4 Japan 448.6 441.4 398.4 Rest of World 451.5 433.3 396.0 Total segment net sales $ 4,362.1 $ 4,333.5 $ 3,676.0 Segment Operating Income United States $ 1,727.3 $ 1,742.3 $ 1,368.1 Europe 479.3 472.0 394.8 Japan 286.4 272.3 237.0 Rest of World 150.1 127.9 115.6 Total segment operating income $ 2,643.1 $ 2,614.5 $ 2,115.5 The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated income before provision for income taxes ("pre-tax income") (in millions): Years Ended December 31, 2020 2019 2018 Net Sales Reconciliation Segment net sales $ 4,362.1 $ 4,333.5 $ 3,676.0 Foreign currency 24.2 14.5 46.8 Consolidated net sales $ 4,386.3 $ 4,348.0 $ 3,722.8 Pre-tax Income Reconciliation Segment operating income $ 2,643.1 $ 2,614.5 $ 2,115.5 Unallocated amounts: Corporate items (1,358.0) (1,439.7) (1,058.1) Special charges — (64.6) (116.2) Intellectual property litigation expenses, net (405.4) (33.4) (214.0) Change in fair value of contingent consideration liabilities, net (13.6) 6.1 5.7 Foreign currency 31.5 63.9 15.3 Consolidated operating income 897.6 1,146.8 748.2 Non-operating income 19.1 19.7 13.2 Consolidated pre-tax income $ 916.7 $ 1,166.5 $ 761.4 |
Schedule of Enterprise-Wide Information | Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated financial statements. As of or for the Years Ended December 31, 2020 2019 2018 (in millions) Net Sales by Geographic Area United States $ 2,516.8 $ 2,532.7 $ 2,055.3 Europe 973.6 941.2 885.1 Japan 460.1 444.7 396.8 Rest of World 435.8 429.4 385.6 $ 4,386.3 $ 4,348.0 $ 3,722.8 Net Sales by Major Product Area Transcatheter Aortic Valve Replacement $ 2,857.3 $ 2,737.9 $ 2,283.8 Transcatheter Mitral and Tricuspid Therapies 41.8 28.2 2.9 Surgical Structural Heart 761.8 841.7 761.6 Critical Care 725.4 740.2 674.5 $ 4,386.3 $ 4,348.0 $ 3,722.8 Long-lived Tangible Assets by Geographic Area United States $ 1,084.3 $ 849.1 $ 642.1 Europe 192.7 101.5 36.6 Japan 20.4 21.7 6.7 Rest of World 311.0 269.4 214.4 $ 1,608.4 $ 1,241.7 $ 899.8 |
QUARTERLY FINANCIAL RESULTS A_2
QUARTERLY FINANCIAL RESULTS AND MARKET FOR THE COMPANY'S STOCK (UNAUDITED) (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Quarterly Financial Information Disclosure [Abstract] | |
Schedule of Quarterly Financial Results and Market for the Company's Stock | Years Ended December 31, First Second Third Fourth Total (in millions, except per share data) 2020 Net sales $ 1,128.7 $ 925.0 $ 1,140.9 $ 1,191.7 $ 4,386.3 Gross profit 863.6 686.8 859.9 895.4 3,305.7 Net income (loss) (a) 310.6 (121.9) 325.2 309.5 823.4 Earnings (loss) per common share (a): Basic 0.50 (0.20) 0.52 0.50 1.32 Diluted 0.49 (0.20) 0.52 0.49 1.30 Market price: High $ 81.90 $ 78.43 $ 87.79 $ 92.08 $ 92.08 Low 51.51 56.44 66.87 70.92 51.51 2019 Net sales $ 993.0 $ 1,086.9 $ 1,094.0 $ 1,174.1 $ 4,348.0 Gross profit 761.2 782.9 801.6 887.9 3,233.6 Net income (b) 249.7 242.3 274.7 280.2 1,046.9 Earnings per common share (b): Basic 0.40 0.39 0.44 0.45 1.68 Diluted 0.39 0.38 0.43 0.44 1.64 Market price: High $ 65.95 $ 65.00 $ 76.06 $ 82.55 $ 82.55 Low 46.95 55.23 61.00 71.08 46.95 _______________________________________________________________________________ (a) The second quarter of 2020 includes a $367.9 million charge related to a litigation settlement. (b) The first quarter of 2019 includes a $24.0 million charge related to the acquisition of early-stage transcatheter intellectual property and associated clinical and regulatory experience. The second and third quarters of 2019 include a $46.2 million and $26.9 million charge, respectively, related to the write off of inventory. The fourth quarter of 2019 includes a $40.6 million charge related to the impairment of certain in-process research and development assets. |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue (Narrative) (Details) - USD ($) $ in Millions | May 29, 2020 | May 07, 2020 | Dec. 31, 2020 | Dec. 31, 2019 |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||||
Stock split, conversion ratio | 300.00% | 300.00% | ||
Deferred revenue | $ 6.3 | $ 8.4 | ||
Revenue recognized that was previously deferred | $ 6.3 | $ 5.5 | ||
Hemodynamic Monitors | ||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||||
Contract length | The Company sells separately priced service contracts, which range from 12 to 36 months, to owners of its hemodynamic monitors. |
SUMMARY OF SIGNIFICANT ACCOUN_5
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Shipping and Handling Costs (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Product Information [Line Items] | |||
Cost of sales | $ 1,080.6 | $ 1,114.4 | $ 939.4 |
Shipping and Handling | |||
Product Information [Line Items] | |||
Cost of sales | $ 74 | $ 71.5 | $ 70.6 |
SUMMARY OF SIGNIFICANT ACCOUN_6
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Investments (Narrative) (Details) | Dec. 31, 2020 |
Minimum | |
Schedule of Equity Method Investments [Line Items] | |
Equity method investment, ownership percentage | 5.00% |
SUMMARY OF SIGNIFICANT ACCOUN_7
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details) | 12 Months Ended |
Dec. 31, 2020 | |
Minimum | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | |
Accounts receivable, required payment terms | 30 days |
Maximum | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | |
Accounts receivable, required payment terms | 90 days |
SUMMARY OF SIGNIFICANT ACCOUN_8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventories (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Accounting Policies [Abstract] | |||
Period prior to expiration date which triggers write-down of inventory | 6 months | ||
Period used to evaluate slow-moving inventory levels | 2 years | ||
General and administrative costs allocated to inventory | $ 63.1 | $ 56.6 | $ 45 |
General and administrative costs included in inventory | 30.7 | 22.8 | |
Finished goods inventories held on consignment | $ 130 | $ 117.8 |
SUMMARY OF SIGNIFICANT ACCOUN_9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant, and Equipment (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Property, Plant and Equipment [Line Items] | |||
Depreciation expense for property, plant and equipment | $ 101.8 | $ 84.7 | $ 74.9 |
Buildings and improvements | Minimum | |||
Property, Plant and Equipment [Line Items] | |||
Estimated useful life | 10 years | ||
Buildings and improvements | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Estimated useful life | 40 years | ||
Machinery and equipment | Minimum | |||
Property, Plant and Equipment [Line Items] | |||
Estimated useful life | 3 years | ||
Machinery and equipment | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Estimated useful life | 15 years | ||
Software | Minimum | |||
Property, Plant and Equipment [Line Items] | |||
Estimated useful life | 3 years | ||
Software | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Estimated useful life | 5 years |
SUMMARY OF SIGNIFICANT ACCOU_10
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Narrative) (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
In-process research and development | ||||
Indefinite-lived Intangible Assets [Line Items] | ||||
Impairment of intangible assets | $ 0 | $ 40.6 | ||
Developed Technology and In-process Research and Development | Valtech | ||||
Indefinite-lived Intangible Assets [Line Items] | ||||
Impairment of intangible assets | $ 116.2 | $ 116.2 |
SUMMARY OF SIGNIFICANT ACCOU_11
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Basic: | |||||||||||
Net income | $ 309.5 | $ 325.2 | $ (121.9) | $ 310.6 | $ 280.2 | $ 274.7 | $ 242.3 | $ 249.7 | $ 823.4 | $ 1,046.9 | $ 722.2 |
Weighted-average shares outstanding (in shares) | 622.6 | 624.8 | 627.6 | ||||||||
Basic earnings per share (in dollars per share) | $ 0.50 | $ 0.52 | $ (0.20) | $ 0.50 | $ 0.45 | $ 0.44 | $ 0.39 | $ 0.40 | $ 1.32 | $ 1.68 | $ 1.15 |
Diluted: | |||||||||||
Net income | $ 309.5 | $ 325.2 | $ (121.9) | $ 310.6 | $ 280.2 | $ 274.7 | $ 242.3 | $ 249.7 | $ 823.4 | $ 1,046.9 | $ 722.2 |
Weighted-average shares outstanding (in shares) | 622.6 | 624.8 | 627.6 | ||||||||
Dilutive effect of stock plans (in shares) | 9.3 | 11.9 | 13.3 | ||||||||
Dilutive weighted-average shares outstanding (in shares) | 631.9 | 636.7 | 640.9 | ||||||||
Diluted earnings per share (in dollars per share) | $ 0.49 | $ 0.52 | $ (0.20) | $ 0.49 | $ 0.44 | $ 0.43 | $ 0.38 | $ 0.39 | $ 1.30 | $ 1.64 | $ 1.13 |
SUMMARY OF SIGNIFICANT ACCOU_12
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings per Share (Narrative) (Details) - shares shares in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Stock compensation plan | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Anti-dilutive securities excluded from the computation of earnings per share (in shares) | 2 | 1.5 | 3.2 |
SUMMARY OF SIGNIFICANT ACCOU_13
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Allocation of stock-based compensation expense | |||
Total stock-based compensation expense | $ 92.6 | $ 81.3 | $ 71 |
Income tax benefit | (15.4) | (14.8) | (13.4) |
Total stock-based compensation expense, net of tax | 77.2 | 66.5 | 57.6 |
Cost of sales | |||
Allocation of stock-based compensation expense | |||
Total stock-based compensation expense | 17.2 | 14.7 | 11.4 |
Selling, general, and administrative expenses | |||
Allocation of stock-based compensation expense | |||
Total stock-based compensation expense | 56.6 | 51.2 | 46.3 |
Research and development expenses | |||
Allocation of stock-based compensation expense | |||
Total stock-based compensation expense | $ 18.8 | $ 15.4 | $ 13.3 |
SUMMARY OF SIGNIFICANT ACCOU_14
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Stock-based Compensation (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2020 | |
Restricted stock units | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Percentage vesting upon retirement for each full year of employment subsequent to the grant date | 25.00% |
SUMMARY OF SIGNIFICANT ACCOU_15
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Derivatives (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Period when cash flows associated with future transactions and certain local currency expenses are expected to occur | 13 months |
INTELLECTUAL PROPERTY LITIGAT_2
INTELLECTUAL PROPERTY LITIGATION EXPENSES, NET (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | 41 Months Ended | |||
Jul. 31, 2020 | Jun. 30, 2020 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | May 31, 2024 | |
Loss Contingencies [Line Items] | |||||||
Intellectual property litigation expenses | $ 405.4 | $ 33.4 | $ 214 | ||||
Gain (loss) on litigation settlement | $ 367.9 | ||||||
Abbott Laboratories | |||||||
Loss Contingencies [Line Items] | |||||||
Intellectual property litigation expenses | $ 367.9 | ||||||
Payments for Legal Settlements | $ 100 | ||||||
Abbott Laboratories | Forecast | Subsequent Event | |||||||
Loss Contingencies [Line Items] | |||||||
Royalty Expense | $ 100 | ||||||
Transcatheter Mitral Valve Replacement | |||||||
Loss Contingencies [Line Items] | |||||||
Gain (loss) on litigation settlement | $ (180) |
SPECIAL CHARGES (GAIN) - Impair
SPECIAL CHARGES (GAIN) - Impairment of Long-lived Assets (Details) - Valtech - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2020 | Dec. 31, 2018 | |
Developed technology | ||||
Indefinite-lived Intangible Assets [Line Items] | ||||
Impairment of intangible assets | $ 40.6 | |||
Developed Technology and In-process Research and Development | ||||
Indefinite-lived Intangible Assets [Line Items] | ||||
Impairment of intangible assets | $ 116.2 | $ 116.2 | ||
Rest of World | Developed technology | ||||
Indefinite-lived Intangible Assets [Line Items] | ||||
Impairment of intangible assets | $ 40.6 | |||
Rest of World | Developed Technology and In-process Research and Development | ||||
Indefinite-lived Intangible Assets [Line Items] | ||||
Impairment of intangible assets | $ 116.2 |
SPECIAL CHARGES (GAIN) - Acquis
SPECIAL CHARGES (GAIN) - Acquisition of Intellectual Property (Details) $ in Millions | Mar. 31, 2019USD ($) |
Early-stage Transcatheter Intellectual Property | |
Business Acquisition [Line Items] | |
Acquisition transaction costs | $ 24 |
SPECIAL CHARGES (GAIN) - Realig
SPECIAL CHARGES (GAIN) - Realignment Expenses (Details) $ in Millions | 1 Months Ended |
Mar. 31, 2018USD ($) | |
Defined benefit pension plans | |
Restructuring Cost and Reserve [Line Items] | |
Gain due to curtailment | $ 7.1 |
OTHER CONSOLIDATED FINANCIAL _3
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Components of Selected Captions (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Inventories | ||
Raw materials | $ 136.7 | $ 118 |
Work in process | 140 | 121.7 |
Finished products | 525.6 | 401.2 |
Total inventories | 802.3 | 640.9 |
Property, plant, and equipment, net | ||
Land | 97.6 | 98 |
Buildings and leasehold improvements | 881.5 | 619.8 |
Machinery and equipment | 564.9 | 466.3 |
Equipment with customers | 42.2 | 35.6 |
Software | 94.2 | 87.9 |
Construction in progress | 313.3 | 265 |
Total property, plant and equipment, gross | 1,993.7 | 1,572.6 |
Accumulated depreciation | (598.5) | (512.3) |
Total property, plant and equipment, net | 1,395.2 | 1,060.3 |
Accrued and other liabilities | ||
Employee compensation and withholdings | 236.7 | 295.8 |
Accrued rebates | 67.2 | 67.1 |
Property, payroll, and other taxes | 49.7 | 51.4 |
Research and development accruals | 52.3 | 51.4 |
Litigation settlement (Notes 3 and 18) | 37.5 | 0 |
Litigation and insurance reserves (Note 18) | 23.3 | 20 |
Taxes payable | 18.6 | 52.9 |
Fair value of derivatives | 39.3 | 6.4 |
Accrued marketing expenses | 14.3 | 17.5 |
Accrued professional services | 7.6 | 10.1 |
Accrued realignment reserves | 14.5 | 16.7 |
Accrued relocation related costs | 21 | 17.4 |
Other accrued liabilities | 88.2 | 89.8 |
Total accrued and other liabilities | $ 670.2 | $ 696.5 |
OTHER CONSOLIDATED FINANCIAL _4
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||
Sep. 30, 2019 | Jun. 30, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Statement of Financial Position [Abstract] | |||||
Inventory write off | $ 26.9 | $ 46.2 | $ 0 | $ 73.1 | $ 0 |
OTHER CONSOLIDATED FINANCIAL _5
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Supplemental Cash Flow Information (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Cash paid during the year for: | |||
Interest | $ 19.9 | $ 19.9 | $ 30.1 |
Income taxes | 197.9 | 61.5 | 223.7 |
Amounts included in the measurement of lease liabilities: | |||
Operating cash flows from operating leases | 29.7 | 28.6 | 0 |
Non-cash investing and financing transactions: | |||
Fair value of shares issued in payment for contingent consideration liabilities | 0 | 0 | 34.3 |
Right-of-use assets obtained in exchange for new lease liabilities | 39.7 | 49.6 | 0 |
Capital expenditures accruals | $ 80.4 | $ 50.8 | $ 18.7 |
OTHER CONSOLIDATED FINANCIAL _6
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Inventory Disclosure [Abstract] | ||||
Cash and cash equivalents | $ 1,183.2 | $ 1,179.1 | $ 714.1 | |
Restricted cash included in other current assets | 16.6 | 1.6 | 1.5 | |
Restricted cash included in other assets | 0.4 | 3.7 | 0.3 | |
Total cash, cash equivalents, and restricted cash | $ 1,200.2 | $ 1,184.4 | $ 715.9 | $ 820.2 |
LEASES - Narrative (Details)
LEASES - Narrative (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Lessee, Lease, Description [Line Items] | |||
Operating lease cost | $ 30.5 | $ 27.9 | $ 27 |
Lease commitments for leases not yet commenced | $ 0 | ||
Minimum | |||
Lessee, Lease, Description [Line Items] | |||
Lease term | 1 year | ||
Maximum | |||
Lessee, Lease, Description [Line Items] | |||
Lease term | 20 years |
LEASES - Assets and Liabilities
LEASES - Assets and Liabilities of Operating Leases (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Leases [Abstract] | ||
Operating lease right-of-use assets | $ 94.2 | $ 80.1 |
Operating lease liabilities, current portion | 27.2 | 25.5 |
Operating lease liabilities, long-term portion | 72.7 | 58.9 |
Total operating lease liabilities | $ 99.9 | $ 84.4 |
LEASES - Maturities Of Operatin
LEASES - Maturities Of Operating Lease Liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Leases [Abstract] | ||
2021 | $ 30 | |
2022 | 20.7 | |
2023 | 14.4 | |
2024 | 8.8 | |
2025 | 6.1 | |
Thereafter | 28.1 | |
Total lease payments | 108.1 | |
Less: imputed interest | (8.2) | |
Total lease liabilities | $ 99.9 | $ 84.4 |
Weighted-average remaining lease term (in years) | 6 years 7 months 6 days | 5 years 3 months 18 days |
Weighted-average discount rate | 2.70% | 2.80% |
INVESTMENTS - Schedule of Inves
INVESTMENTS - Schedule of Investments in Debt Securities (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Available-for-sale | ||
Amortized Cost | $ 924.3 | $ 790.5 |
Gross Unrealized Gains | 11.6 | 3.5 |
Gross Unrealized Losses | 0 | (0.2) |
Fair Value | 935.9 | 793.8 |
Held-to-maturity | ||
Amortized Cost | 50 | |
Fair Value | 50 | |
Bank time deposits | ||
Available-for-sale | ||
Amortized Cost | 24.1 | 13.1 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 24.1 | 13.1 |
Held-to-maturity | ||
Amortized Cost | 50 | 100.2 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 50 | 100.2 |
Commercial paper | ||
Available-for-sale | ||
Amortized Cost | 0 | 34.3 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 0 | 34.3 |
U.S. government and agency securities | ||
Available-for-sale | ||
Amortized Cost | 147 | 113.2 |
Gross Unrealized Gains | 2.2 | 0.6 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 149.2 | 113.8 |
Foreign government bonds | ||
Available-for-sale | ||
Amortized Cost | 0 | 1.7 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 0 | 1.7 |
Asset-backed securities | ||
Available-for-sale | ||
Amortized Cost | 149.6 | 141.2 |
Gross Unrealized Gains | 1.9 | 0.6 |
Gross Unrealized Losses | 0 | (0.1) |
Fair Value | 151.5 | 141.7 |
Corporate debt securities | ||
Available-for-sale | ||
Amortized Cost | 600.8 | 487 |
Gross Unrealized Gains | 7.5 | 2.3 |
Gross Unrealized Losses | 0 | (0.1) |
Fair Value | 608.3 | 489.2 |
Municipal securities | ||
Available-for-sale | ||
Amortized Cost | 2.8 | 0 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | $ 2.8 | $ 0 |
INVESTMENTS - Schedule of Cost
INVESTMENTS - Schedule of Cost and Fair Value of Investments in Debt Securities, by Contractual Maturity (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Amortized Cost | ||
Due in 1 year or less | $ 50 | |
Due after 1 year through 5 years | 0 | |
Instruments not due at a single maturity date | 0 | |
Amortized Cost | 50 | |
Fair Value | ||
Due in 1 year or less | 50 | |
Due after 1 year through 5 years | 0 | |
Instruments not due at a single maturity date | 0 | |
Total | 50 | |
Amortized Cost | ||
Due in 1 year or less | 168.4 | |
Due after 1 year through 5 years | 578.2 | |
Instruments not due at a single maturity date | 177.7 | |
Amortized Cost | 924.3 | $ 790.5 |
Fair Value | ||
Due in 1 year or less | 169.4 | |
Due after 1 year through 5 years | 586.5 | |
Instruments not due at a single maturity date | 180 | |
Total | $ 935.9 | $ 793.8 |
INVESTMENTS - Narrative (Detail
INVESTMENTS - Narrative (Details) $ in Millions | 12 Months Ended | |
Dec. 31, 2020USD ($)investment | Dec. 31, 2019USD ($) | |
Debt and Equity Securities, FV-NI [Line Items] | ||
Number of Investments | investment | 0 | |
Upward price adjustments | $ 1.8 | $ 0.3 |
Impairment of equity securities | 0.7 | |
Other income, net | ||
Debt and Equity Securities, FV-NI [Line Items] | ||
Increase in non-marketable equity securities due to observable price changes | 3.8 | 2 |
Decrease in non-marketable equity securities due to observable price changes | $ 2.6 | $ 1.9 |
INVESTMENTS - Schedule of Unrea
INVESTMENTS - Schedule of Unrealized Losses on Debt Securities (Details) $ in Millions | Dec. 31, 2019USD ($) |
Debt Securities, Available-for-sale [Line Items] | |
Fair value, less than 12 months | $ 154.8 |
Gross unrealized losses, less than 12 months | (0.2) |
Fair value, 12 months or greater | 0 |
Gross unrealized losses, 12 months or greater | 0 |
Total fair value | 154.8 |
Total gross unrealized losses | (0.2) |
Asset-backed securities | |
Debt Securities, Available-for-sale [Line Items] | |
Fair value, less than 12 months | 73.4 |
Gross unrealized losses, less than 12 months | (0.1) |
Fair value, 12 months or greater | 0 |
Gross unrealized losses, 12 months or greater | 0 |
Total fair value | 73.4 |
Total gross unrealized losses | (0.1) |
Corporate debt securities | |
Debt Securities, Available-for-sale [Line Items] | |
Fair value, less than 12 months | 81.4 |
Gross unrealized losses, less than 12 months | (0.1) |
Fair value, 12 months or greater | 0 |
Gross unrealized losses, 12 months or greater | 0 |
Total fair value | 81.4 |
Total gross unrealized losses | $ (0.1) |
INVESTMENTS - Schedule of Inv_2
INVESTMENTS - Schedule of Investments in Unconsolidated Affiliates (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Equity method investments | ||
Carrying value of equity method investments | $ 5.7 | $ 6.2 |
Equity securities | ||
Carrying value of non-marketable equity securities | 29.4 | 23.1 |
Total investments in unconsolidated affiliates | $ 35.1 | $ 29.3 |
ACQUISITIONS - CAS Medical Syst
ACQUISITIONS - CAS Medical Systems, Inc. (Narrative) (Details) - CAS Medical Systems, Inc. - USD ($) $ / shares in Units, $ in Millions | Apr. 18, 2019 | Feb. 11, 2019 | Dec. 31, 2019 |
Business Acquisition [Line Items] | |||
Consideration per share to be transferred (in dollars per share) | $ 2.45 | ||
Acquisition price, subject uncertain adjustments | $ 100 | ||
Cash purchase price | $ 100.8 | ||
Acquisition-related costs | $ 2 | ||
Developed technology | |||
Business Acquisition [Line Items] | |||
Weighted average useful life | 14 years | ||
Customer Relationships | |||
Business Acquisition [Line Items] | |||
Weighted average useful life | 10 years |
ACQUISITIONS - Summary of Fair
ACQUISITIONS - Summary of Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions | Apr. 18, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Business Acquisition [Line Items] | ||||
Goodwill | $ 1,173.2 | $ 1,167.7 | $ 1,112.2 | |
CAS Medical Systems, Inc. | ||||
Business Acquisition [Line Items] | ||||
Current assets | $ 6.1 | |||
Property and equipment, net | 1.3 | |||
Goodwill | 64.4 | |||
Deferred tax assets | 2.2 | |||
Liabilities assumed | (17.9) | |||
Total purchase price | 100.8 | |||
Less: cash acquired | (0.6) | |||
Total purchase price, net of cash acquired | 100.2 | |||
Developed technology | CAS Medical Systems, Inc. | ||||
Business Acquisition [Line Items] | ||||
Finite lived intangible assets | 35.9 | |||
Customer Relationships | CAS Medical Systems, Inc. | ||||
Business Acquisition [Line Items] | ||||
Finite lived intangible assets | $ 8.8 |
ACQUISITIONS - Harpoon Medical,
ACQUISITIONS - Harpoon Medical, Inc. (Narrative) (Details) - Harpoon Medical - USD ($) $ in Millions | Dec. 01, 2017 | Nov. 30, 2017 |
Business Acquisition [Line Items] | ||
Purchase price subject to certain adjustments | $ 119.5 | |
Cash previously paid for cost method investment | $ 16 | |
Net proceeds from sale of previous ownership | $ 8 | |
Potential milestone-driven payments | $ 150 | |
Period to make additional pre-specified milestone-driven payments | 10 years | |
Liability for estimated fair value of contingent milestone payment | $ 59.7 | |
Additional research and development expenditures to be incurred prior to product introduction | $ 41.4 |
ACQUISITIONS - Valtech Cardio,
ACQUISITIONS - Valtech Cardio, Ltd. (Narrative) (Details) - USD ($) shares in Millions, $ in Millions | Jan. 23, 2017 | Nov. 26, 2016 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Business Acquisition [Line Items] | ||||||||
Cash paid to acquire business | $ 0 | $ 100.2 | $ 0 | |||||
Valtech | ||||||||
Business Acquisition [Line Items] | ||||||||
Purchase price subject to certain adjustments | $ 340 | |||||||
Potential milestone-driven payments | $ 350 | |||||||
Period to make additional pre-specified milestone-driven payments | 10 years | |||||||
Issuance of shares of common stock (in shares) | 2.8 | |||||||
Fair value of shares issued in connection with business combinations (Note 8) | $ 266.5 | |||||||
Cash paid to acquire business | 86.2 | |||||||
Liability for estimated fair value of contingent milestone payment | 162.9 | |||||||
Additional research and development expenditures to be incurred prior to product introduction | 87.3 | |||||||
Valtech spin off | ||||||||
Business Acquisition [Line Items] | ||||||||
Future option to acquire business, amount | 200 | |||||||
Future option to acquire business, additional amount subject to regulatory approval | $ 50 | |||||||
Future option to acquire business, period to obtain regulatory approval | 10 years | |||||||
Developed Technology and In-process Research and Development | Valtech | ||||||||
Business Acquisition [Line Items] | ||||||||
Impairment of intangible assets | $ 116.2 | $ 116.2 | ||||||
Developed technology | Valtech | ||||||||
Business Acquisition [Line Items] | ||||||||
Impairment of intangible assets | $ 40.6 | |||||||
Rest of World | Developed Technology and In-process Research and Development | Valtech | ||||||||
Business Acquisition [Line Items] | ||||||||
Impairment of intangible assets | $ 116.2 | |||||||
Rest of World | Developed technology | Valtech | ||||||||
Business Acquisition [Line Items] | ||||||||
Impairment of intangible assets | $ 40.6 |
ACQUISITIONS - CardiAQ Valve Te
ACQUISITIONS - CardiAQ Valve Technologies, Inc. (Narrative) (Details) - USD ($) $ in Millions | Aug. 26, 2015 | Jul. 03, 2015 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Business Acquisition [Line Items] | |||||
Cash purchase price subject to certain adjustments | $ 0 | $ 100.2 | $ 0 | ||
CardiAQ | |||||
Business Acquisition [Line Items] | |||||
Cash purchase price subject to certain adjustments | $ 350 | ||||
Purchase price subject to certain adjustments | $ 348 | ||||
Additional payments if certain European regulatory approval is obtained | $ 50 | ||||
Period to obtain certain European regulatory approval | 48 months | ||||
Liability for estimated fair value of contingent milestone payment | $ 30.3 | ||||
Additional research and development expenditures to be incurred prior to product introduction | $ 97.7 |
GOODWILL AND OTHER INTANGIBLE_3
GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended | ||
Apr. 30, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Finite-Lived Intangible Assets [Line Items] | ||||
Increase to goodwill | $ 64.4 | |||
Amortization expense related to other intangible assets | $ 5.4 | $ 4.6 | $ 2.5 | |
Casmed | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Increase to goodwill | $ 64.4 | |||
Increase to intangible assets | $ 35.9 |
GOODWILL AND OTHER INTANGIBLE_4
GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in the Carrying Amount of Goodwill, by Segment (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Goodwill | ||
Beginning balance | $ 1,167.7 | $ 1,112.2 |
Goodwill acquired during the year | 64.4 | |
Currency translation adjustment | 5.5 | (8.9) |
Ending balance | 1,173.2 | 1,167.7 |
United States | ||
Goodwill | ||
Beginning balance | 773.7 | 709.3 |
Goodwill acquired during the year | 64.4 | |
Currency translation adjustment | 0 | 0 |
Ending balance | 773.7 | 773.7 |
Europe | ||
Goodwill | ||
Beginning balance | 62.8 | 64.2 |
Goodwill acquired during the year | 0 | |
Currency translation adjustment | 5.5 | (1.4) |
Ending balance | 68.3 | 62.8 |
Rest of World | ||
Goodwill | ||
Beginning balance | 331.2 | 338.7 |
Goodwill acquired during the year | 0 | |
Currency translation adjustment | 0 | (7.5) |
Ending balance | $ 331.2 | $ 331.2 |
GOODWILL AND OTHER INTANGIBLE_5
GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Other Intangible Assets (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Finite-lived intangible assets | ||
Weighted-Average Useful Life (in years) | 12 years 7 months 6 days | |
Cost | $ 353.9 | $ 351.5 |
Accumulated Amortization | (240.6) | (233.1) |
Net Carrying Value | 113.3 | 118.4 |
Indefinite-lived intangible assets | ||
Cost | 572 | 569.6 |
Net Carrying Value | 331.4 | 336.5 |
In-process research and development | ||
Indefinite-lived intangible assets | ||
In-process research and development | $ 218.1 | 218.1 |
Patents | ||
Finite-lived intangible assets | ||
Weighted-Average Useful Life (in years) | 7 years 4 months 24 days | |
Cost | $ 186.1 | 185.7 |
Accumulated Amortization | (183.6) | (182.1) |
Net Carrying Value | $ 2.5 | 3.6 |
Developed technology | ||
Finite-lived intangible assets | ||
Weighted-Average Useful Life (in years) | 13 years 1 month 6 days | |
Cost | $ 155.2 | 153.5 |
Accumulated Amortization | (51) | (46.6) |
Net Carrying Value | $ 104.2 | 106.9 |
Other | ||
Finite-lived intangible assets | ||
Weighted-Average Useful Life (in years) | 10 years | |
Cost | $ 12.6 | 12.3 |
Accumulated Amortization | (6) | (4.4) |
Net Carrying Value | $ 6.6 | $ 7.9 |
GOODWILL AND OTHER INTANGIBLE_6
GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Estimated Amortization Expense (Details) $ in Millions | Dec. 31, 2020USD ($) |
Goodwill and Intangible Assets Disclosure [Abstract] | |
2021 | $ 5.2 |
2022 | 7.6 |
2023 | 10.1 |
2024 | 12.2 |
2025 | $ 14.8 |
DEBT AND CREDIT FACILITIES - Na
DEBT AND CREDIT FACILITIES - Narrative (Details) - USD ($) | 1 Months Ended | 12 Months Ended | ||
Jun. 30, 2018 | Apr. 30, 2018 | Dec. 31, 2020 | Dec. 31, 2019 | |
Debt Instrument [Line Items] | ||||
Weighted-average interest rate under all debt obligations (as a percent) | 3.50% | 3.40% | ||
Senior Notes | Fixed-rate 4.300% 2018 Notes | ||||
Debt Instrument [Line Items] | ||||
Fixed-rate unsecured senior notes | $ 600,000,000 | |||
2013 Notes | ||||
Debt Instrument [Line Items] | ||||
Price equal to principal amount, plus accrued and unpaid interest (as a percent) | 101.00% | |||
2013 Notes | Level 2 | ||||
Debt Instrument [Line Items] | ||||
Fair value of the notes, based on Level 2 inputs | $ 711,200,000 | $ 667,600,000 | ||
Credit agreement, maturity July 2019 | Credit Facility | ||||
Debt Instrument [Line Items] | ||||
Term of the credit agreement | 5 years | |||
Credit Agreement Maturity April 2023 | Credit Facility | ||||
Debt Instrument [Line Items] | ||||
Aggregate borrowings in multiple currencies | $ 750,000,000 | |||
Facility fee (as a percent) | 0.10% | |||
Issuance costs | $ 2,400,000 | |||
Borrowings outstanding | $ 0 | $ 0 | ||
Credit Agreement Maturity April 2023 | Credit Facility | LIBOR | ||||
Debt Instrument [Line Items] | ||||
Basis spread on variable rate (as a percent) | 0.90% | |||
Credit Agreement Maturity April 2023 | Credit Facility | Low | ||||
Debt Instrument [Line Items] | ||||
Facility fee (as a percent) | 0.10% | |||
Credit Agreement Maturity April 2023 | Credit Facility | Low | LIBOR | ||||
Debt Instrument [Line Items] | ||||
Basis spread on variable rate (as a percent) | 0.90% | |||
Credit Agreement Maturity April 2023 | Credit Facility | High | ||||
Debt Instrument [Line Items] | ||||
Additional amount available, subject to lender approval | $ 250,000,000 | |||
Facility fee (as a percent) | 0.20% | |||
Credit Agreement Maturity April 2023 | Credit Facility | High | LIBOR | ||||
Debt Instrument [Line Items] | ||||
Basis spread on variable rate (as a percent) | 1.30% |
DEBT AND CREDIT FACILITIES - Su
DEBT AND CREDIT FACILITIES - Summary of the Notes (Details) - Senior Notes - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Debt Instrument [Line Items] | ||
Unamortized discount | $ (1.1) | $ (1.2) |
Unamortized debt issuance costs | (3.9) | (4.4) |
Total carrying amount | $ 595 | 594.4 |
Fixed-rate 4.300% 2018 Notes | ||
Debt Instrument [Line Items] | ||
Fixed interest rate | 4.30% | |
Amount | $ 600 | $ 600 |
Effective Interest Rate | 4.329% | 4.329% |
FAIR VALUE MEASUREMENTS - Summa
FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Assets | ||
Available-for-sale investments | $ 935.9 | $ 793.8 |
Fair Value on a Recurring Basis | Estimate of Fair Value Measurement | ||
Assets | ||
Cash equivalents | 16.2 | 32.4 |
Investments held for deferred compensation plans | 111.2 | 88.9 |
Derivatives | 8.1 | 30.7 |
Total assets | 1,071.3 | 945.8 |
Liabilities | ||
Derivatives | 39.3 | 6.4 |
Deferred compensation plans | 111.6 | 88.7 |
Contingent consideration liabilities | 186.1 | 172.5 |
Total liabilities | 337 | 267.6 |
Fair Value on a Recurring Basis | Level 1 | Estimate of Fair Value Measurement | ||
Assets | ||
Cash equivalents | 16.2 | 0.7 |
Investments held for deferred compensation plans | 111.2 | 88.9 |
Derivatives | 0 | 0 |
Total assets | 184.3 | 165.7 |
Liabilities | ||
Derivatives | 0 | 0 |
Deferred compensation plans | 111.6 | 88.7 |
Contingent consideration liabilities | 0 | 0 |
Total liabilities | 111.6 | 88.7 |
Fair Value on a Recurring Basis | Level 2 | Estimate of Fair Value Measurement | ||
Assets | ||
Cash equivalents | 0 | 31.7 |
Investments held for deferred compensation plans | 0 | 0 |
Derivatives | 8.1 | 30.7 |
Total assets | 887 | 780.1 |
Liabilities | ||
Derivatives | 39.3 | 6.4 |
Deferred compensation plans | 0 | 0 |
Contingent consideration liabilities | 0 | 0 |
Total liabilities | 39.3 | 6.4 |
Fair Value on a Recurring Basis | Level 3 | Estimate of Fair Value Measurement | ||
Assets | ||
Cash equivalents | 0 | 0 |
Investments held for deferred compensation plans | 0 | 0 |
Derivatives | 0 | 0 |
Total assets | 0 | 0 |
Liabilities | ||
Derivatives | 0 | 0 |
Deferred compensation plans | 0 | 0 |
Contingent consideration liabilities | 186.1 | 172.5 |
Total liabilities | 186.1 | 172.5 |
Bank time deposits | ||
Assets | ||
Available-for-sale investments | 24.1 | 13.1 |
Bank time deposits | Fair Value on a Recurring Basis | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 24.1 | 13.1 |
Bank time deposits | Fair Value on a Recurring Basis | Level 1 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Bank time deposits | Fair Value on a Recurring Basis | Level 2 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 24.1 | 13.1 |
Bank time deposits | Fair Value on a Recurring Basis | Level 3 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Corporate debt securities | ||
Assets | ||
Available-for-sale investments | 608.3 | 489.2 |
Corporate debt securities | Fair Value on a Recurring Basis | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 608.3 | 489.2 |
Corporate debt securities | Fair Value on a Recurring Basis | Level 1 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Corporate debt securities | Fair Value on a Recurring Basis | Level 2 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 608.3 | 489.2 |
Corporate debt securities | Fair Value on a Recurring Basis | Level 3 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Asset-backed securities | ||
Assets | ||
Available-for-sale investments | 151.5 | 141.7 |
Asset-backed securities | Fair Value on a Recurring Basis | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 151.5 | 141.7 |
Asset-backed securities | Fair Value on a Recurring Basis | Level 1 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Asset-backed securities | Fair Value on a Recurring Basis | Level 2 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 151.5 | 141.7 |
Asset-backed securities | Fair Value on a Recurring Basis | Level 3 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
U.S. government and agency securities | ||
Assets | ||
Available-for-sale investments | 149.2 | 113.8 |
U.S. government and agency securities | Fair Value on a Recurring Basis | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 149.1 | 113.8 |
U.S. government and agency securities | Fair Value on a Recurring Basis | Level 1 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 56.9 | 76.1 |
U.S. government and agency securities | Fair Value on a Recurring Basis | Level 2 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 92.2 | 37.7 |
U.S. government and agency securities | Fair Value on a Recurring Basis | Level 3 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Municipal securities | ||
Assets | ||
Available-for-sale investments | 2.8 | 0 |
Municipal securities | Fair Value on a Recurring Basis | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 2.8 | |
Municipal securities | Fair Value on a Recurring Basis | Level 1 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 0 | |
Municipal securities | Fair Value on a Recurring Basis | Level 2 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 2.8 | |
Municipal securities | Fair Value on a Recurring Basis | Level 3 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 0 | |
Foreign government bonds | ||
Assets | ||
Available-for-sale investments | 0 | 1.7 |
Foreign government bonds | Fair Value on a Recurring Basis | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 1.7 | |
Foreign government bonds | Fair Value on a Recurring Basis | Level 1 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 0 | |
Foreign government bonds | Fair Value on a Recurring Basis | Level 2 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 1.7 | |
Foreign government bonds | Fair Value on a Recurring Basis | Level 3 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 0 | |
Commercial paper | ||
Assets | ||
Available-for-sale investments | $ 0 | 34.3 |
Commercial paper | Fair Value on a Recurring Basis | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 34.3 | |
Commercial paper | Fair Value on a Recurring Basis | Level 1 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 0 | |
Commercial paper | Fair Value on a Recurring Basis | Level 2 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | 34.3 | |
Commercial paper | Fair Value on a Recurring Basis | Level 3 | Estimate of Fair Value Measurement | ||
Assets | ||
Available-for-sale investments | $ 0 |
FAIR VALUE MEASUREMENTS - Sum_2
FAIR VALUE MEASUREMENTS - Summary of Changes in Fair Value of Contingent Consideration Obligation (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation | ||
Fair value, beginning of year | $ 172.5 | $ 178.6 |
Changes in fair value | 13.6 | (6.1) |
Fair value, end of year | $ 186.1 | $ 172.5 |
FAIR VALUE MEASUREMENTS - Narra
FAIR VALUE MEASUREMENTS - Narrative (Details) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Dec. 31, 2018USD ($) | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Change in fair value of contingent consideration liabilities, net | $ (13.6) | $ 6.1 | $ 5.7 |
Measurement Input, Discount Rate | Minimum | Level 3 | Obligations | |||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Contingent consideration liability measurement input | 0.0008 | ||
Measurement Input, Discount Rate | Maximum | Level 3 | Obligations | |||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Contingent consideration liability measurement input | 0.0853 | ||
Measurement Input, Discount Rate | Weighted Average | Level 3 | Obligations | |||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Contingent consideration liability measurement input | 0.031 | ||
Measurement Input, Probability of Milestone Achievement | Minimum | Level 3 | Obligations | |||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Contingent consideration liability measurement input | 0.004 | ||
Measurement Input, Probability of Milestone Achievement | Maximum | Level 3 | Obligations | |||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Contingent consideration liability measurement input | 0.997 | ||
Measurement Input, Probability of Milestone Achievement | Weighted Average | Level 3 | Obligations | |||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Contingent consideration liability measurement input | 0.707 | ||
Measurement Input, Volatility of Future Revenue | Minimum | Level 3 | Obligations | |||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Contingent consideration liability measurement input | 0.370 | ||
Measurement Input, Volatility of Future Revenue | Maximum | Level 3 | Obligations | |||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Contingent consideration liability measurement input | 0.400 | ||
Measurement Input, Volatility of Future Revenue | Weighted Average | Level 3 | Obligations | |||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Contingent consideration liability measurement input | 0.388 | ||
Two Previous Acquisitions | |||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Change in fair value of contingent consideration liabilities, net | $ 12.7 | $ 24.1 |
DERIVATIVE INSTRUMENTS AND HE_3
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Derivative Financial Instruments Used to Manage Currency Exchange and Interest Rate Risk (Details) - Derivatives designated as hedging instruments - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Foreign currency forward exchange contracts | ||
Derivative [Line Items] | ||
Notional Amount | $ 1,525.5 | $ 1,336.5 |
Cross currency swap contracts | ||
Derivative [Line Items] | ||
Notional Amount | $ 300 | $ 300 |
DERIVATIVE INSTRUMENTS AND HE_4
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Location and Fair Value Amounts of Derivative Instruments (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Foreign currency contracts | ||
Assets | ||
Fair Value | $ 7.3 | $ 17.4 |
Liabilities | ||
Fair Value | 39.3 | 6.4 |
Cross currency swap contracts | ||
Assets | ||
Fair Value | 0.8 | 13.3 |
Derivatives designated as hedging instruments | Foreign currency contracts | Other current assets | ||
Assets | ||
Fair Value | 7.3 | 14.2 |
Derivatives designated as hedging instruments | Foreign currency contracts | Other assets | ||
Assets | ||
Fair Value | 0 | 3.2 |
Derivatives designated as hedging instruments | Foreign currency contracts | Accrued and other liabilities | ||
Liabilities | ||
Fair Value | 39.3 | 6.4 |
Derivatives designated as hedging instruments | Cross currency swap contracts | Other assets | ||
Assets | ||
Fair Value | $ 0.8 | $ 13.3 |
DERIVATIVE INSTRUMENTS AND HE_5
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Effect of Master-Netting Agreements and Rights of Offset (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Foreign currency contracts | ||
Derivative Assets | ||
Gross Amounts | $ 7.3 | $ 17.4 |
Gross Amounts Offset in the Consolidated Balance Sheet | 0 | 0 |
Net Amounts Presented in the Consolidated Balance Sheet | 7.3 | 17.4 |
Gross Amounts Not Offset in the Consolidated Balance Sheet | ||
Financial Instruments | (6.1) | (5.7) |
Cash Collateral Received | 0 | 0 |
Net Amount | 1.2 | 11.7 |
Derivative Liabilities | ||
Gross Amounts | 39.3 | 6.4 |
Gross Amounts Offset in the Consolidated Balance Sheet | 0 | 0 |
Net Amounts Presented in the Consolidated Balance Sheet | 39.3 | 6.4 |
Gross Amounts Not Offset in the Consolidated Balance Sheet | ||
Financial Instruments | (6.1) | (5.7) |
Cash Collateral Received | 0 | 0 |
Net Amount | 33.2 | 0.7 |
Cross currency swap contracts | ||
Derivative Assets | ||
Gross Amounts | 0.8 | 13.3 |
Gross Amounts Offset in the Consolidated Balance Sheet | 0 | 0 |
Net Amounts Presented in the Consolidated Balance Sheet | 0.8 | 13.3 |
Gross Amounts Not Offset in the Consolidated Balance Sheet | ||
Financial Instruments | 0 | 0 |
Cash Collateral Received | 0 | 0 |
Net Amount | $ 0.8 | $ 13.3 |
DERIVATIVE INSTRUMENTS AND HE_6
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Effect of Derivative Instruments (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Foreign currency contracts | Other income, net | Derivatives not designated as hedging instruments | |||
Derivative Instruments, Gain (Loss) | |||
Amount of Gain or (Loss) Recognized in Income on Derivative | $ (15.1) | $ 0.3 | $ 9.7 |
Cash flow hedges | Foreign currency contracts | Derivatives designated as hedging instruments | |||
Derivative Instruments, Gain (Loss) | |||
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion) | (33.7) | 23.5 | |
Cash flow hedges | Foreign currency contracts | Cost of sales | Derivatives designated as hedging instruments | |||
Derivative Instruments, Gain (Loss) | |||
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income | 18.4 | 40.9 | |
Cash flow hedges | Foreign currency contracts | Selling, general, and administrative expenses | Derivatives designated as hedging instruments | |||
Derivative Instruments, Gain (Loss) | |||
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income | 2.2 | 1.9 | |
Net investment hedges | Cross currency swap contracts | Derivatives designated as hedging instruments | |||
Derivative Instruments, Gain (Loss) | |||
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion) | (12.6) | 12.5 | |
Net investment hedges | Cross currency swap contracts | Interest expense | Derivatives designated as hedging instruments | |||
Derivative Instruments, Gain (Loss) | |||
Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) | 6.4 | 6.6 | |
Fair value hedges | Foreign currency contracts | Other income, net | Derivatives designated as hedging instruments | |||
Derivative Instruments, Gain (Loss) | |||
Amount of Gain or (Loss) Recognized in Income on Derivative | $ (1.4) | $ 1.4 | $ 0.5 |
DERIVATIVE INSTRUMENTS AND HE_7
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Location of Gain or Loss on Derivative Instruments (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Derivative Instruments, Gain (Loss) | |||
Cost of sales | $ (1,080.6) | $ (1,114.4) | $ (939.4) |
Selling, general, and administrative expenses | (1,228.4) | (1,242.2) | (1,088.5) |
Other income, net | 11.5 | 8.2 | $ 4 |
Foreign currency contracts | Cost of sales | |||
Gain (loss) on fair value hedging relationships: | |||
Hedged items | 0 | 0 | |
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach | 0 | 0 | |
Gain (loss) on cash flow hedging relationships: | |||
Amount of gain (loss) reclassified from accumulated OCI into income | 18.4 | 40.9 | |
Foreign currency contracts | Cost of sales | Derivatives designated as hedging instruments | |||
Gain (loss) on fair value hedging relationships: | |||
Derivatives designated as hedging instruments | 0 | 0 | |
Foreign currency contracts | Selling, general, and administrative expenses | |||
Gain (loss) on fair value hedging relationships: | |||
Hedged items | 0 | 0 | |
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach | 0 | 0 | |
Gain (loss) on cash flow hedging relationships: | |||
Amount of gain (loss) reclassified from accumulated OCI into income | 2.2 | 1.9 | |
Foreign currency contracts | Selling, general, and administrative expenses | Derivatives designated as hedging instruments | |||
Gain (loss) on fair value hedging relationships: | |||
Derivatives designated as hedging instruments | 0 | 0 | |
Foreign currency contracts | Other income, net | |||
Gain (loss) on fair value hedging relationships: | |||
Hedged items | 4.8 | 2.9 | |
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach | 3.4 | 4.3 | |
Gain (loss) on cash flow hedging relationships: | |||
Amount of gain (loss) reclassified from accumulated OCI into income | 0 | 0 | |
Foreign currency contracts | Other income, net | Derivatives designated as hedging instruments | |||
Gain (loss) on fair value hedging relationships: | |||
Derivatives designated as hedging instruments | $ (4.8) | $ (2.9) |
DERIVATIVE INSTRUMENTS AND HE_8
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) € in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2020USD ($) | Dec. 31, 2020EUR (€) | Dec. 31, 2019USD ($) | |
Derivative Instruments, Gain (Loss) | |||
Cash flow hedge loss to be reclassified | $ 7 | ||
Cross currency swap contracts | Derivatives designated as hedging instruments | |||
Derivative Instruments, Gain (Loss) | |||
Notional Amount | 300 | $ 300 | |
Cross currency swap contracts | Net investment hedges | Derivatives designated as hedging instruments | |||
Derivative Instruments, Gain (Loss) | |||
Notional Amount | $ 300 | € 257.2 |
EMPLOYEE BENEFIT PLANS - Schedu
EMPLOYEE BENEFIT PLANS - Schedule of Information Regarding Defined Benefit Pension Plans (Details) - Defined benefit pension plans - USD ($) $ in Millions | 12 Months Ended | ||||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2020 | Dec. 31, 2019 | |
Change in projected benefit obligation: | |||||
Beginning of year | $ 105.2 | $ 97.4 | |||
Service cost | 6.3 | 5.2 | $ 6 | ||
Interest cost | 0.5 | 0.9 | 0.8 | ||
Participant contributions | 1.5 | 1.3 | |||
Actuarial loss | 2.9 | 8.2 | |||
Benefits paid | (0.6) | (4.2) | |||
Plan amendment | 0 | (4.6) | |||
Currency exchange rate changes and other | 10.4 | 1 | |||
End of year | 126.2 | 105.2 | 97.4 | ||
Change in fair value of plan assets: | |||||
Beginning of year | 63.2 | 60.4 | |||
Actual return on plan assets | 0.4 | 2 | |||
Employer contributions | 2.8 | 2.6 | |||
Participant contributions | 1.5 | 1.3 | |||
Benefits paid | (0.6) | (4.2) | |||
Currency exchange rate changes and other | 6 | 1.1 | |||
End of year | 73.3 | 63.2 | 60.4 | ||
Funded Status | |||||
Projected benefit obligation | (126.2) | (97.4) | (97.4) | $ (126.2) | $ (105.2) |
Plan assets at fair value | $ 73.3 | $ 60.4 | $ 60.4 | 73.3 | 63.2 |
Underfunded status | (52.9) | (42) | |||
Accumulated other comprehensive loss, net of tax: | |||||
Net actuarial loss | (30.8) | (26.3) | |||
Net prior service cost | 6.6 | 6.7 | |||
Deferred income tax benefit | 4.6 | 4.2 | |||
Total | (19.6) | (15.4) | |||
Other long-term liabilities | |||||
Net amounts recognized on the consolidated balance sheet: | |||||
Other long-term liabilities | $ 52.9 | $ 42 |
EMPLOYEE BENEFIT PLANS - Narrat
EMPLOYEE BENEFIT PLANS - Narrative (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Defined Contribution Plans | |||
Expected employer contributions | $ 2.5 | ||
Matching contributions relating to entity's employees | 36.6 | $ 31.4 | $ 26.6 |
Defined benefit pension plans | |||
Defined Contribution Plans | |||
Accumulated benefit obligation | 120.9 | 101.1 | |
Nonqualified deferred compensation plans | |||
Defined Contribution Plans | |||
Amount accrued under nonqualified plans | $ 111.6 | $ 88.7 | |
United States | |||
Defined Contribution Plans | |||
Maximum contributions of a participant's eligible compensation (as a percent) | 25.00% | ||
Dollar-for-dollar match of employee's annual eligible compensation (as a percent) | 4.00% | ||
Company match of eligible compensation after dollar-for-dollar basis (as a percent) | 2.00% | ||
Company match, second level (as a percent) | 50.00% | ||
Puerto Rico | |||
Defined Contribution Plans | |||
Maximum contributions of a participant's eligible compensation (as a percent) | 25.00% | ||
Dollar-for-dollar match of employee's annual eligible compensation (as a percent) | 4.00% | ||
Company match, first level (as a percent) | 50.00% | ||
Profit sharing contribution calculated on eligible earnings (as a percent) | 2.00% |
EMPLOYEE BENEFIT PLANS - Compon
EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - Defined benefit pension plans - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Service cost, net | $ 6.3 | $ 5.2 | $ 6 |
Interest cost | 0.5 | 0.9 | 0.8 |
Expected return on plan assets | (1) | (1.4) | (1.3) |
Settlements and curtailment gain | 0 | 0 | (7.4) |
Amortization of actuarial loss | 1.6 | 0.9 | 0.8 |
Amortization of prior service credit | (0.7) | (0.2) | (0.1) |
Net periodic pension benefit cost (credit) | $ 6.7 | $ 5.4 | $ (1.2) |
EMPLOYEE BENEFIT PLANS - Sche_2
EMPLOYEE BENEFIT PLANS - Schedule of Weighted-Average Assumptions Used to Determine Benefit Obligations (Details) - Defined benefit pension plans | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Weighted-average assumptions used to determine the benefit obligations | |||
Discount rate | 0.30% | 0.50% | |
Rate of compensation increase | 2.60% | 2.70% | |
Cash balance interest crediting rate | 2.50% | 2.60% | |
Social securities increase | 1.60% | 1.60% | |
Pension increase | 1.80% | 1.80% | |
Weighted-average assumptions used to determine the net periodic benefit cost | |||
Discount rate | 0.50% | 0.90% | 0.90% |
Expected return on plan assets | 1.50% | 2.30% | 2.30% |
Rate of compensation increase | 2.70% | 2.80% | 2.60% |
Cash balance interest crediting rate | 1.50% | 1.50% | 1.50% |
Social securities increase | 1.60% | 1.80% | 1.50% |
Pension increase | 1.80% | 1.80% | 1.80% |
EMPLOYEE BENEFIT PLANS - Sche_3
EMPLOYEE BENEFIT PLANS - Schedule of Target Weighted-Average Asset Allocations and Fair Value (Details) - Defined benefit pension plans - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Defined Benefit Plan Disclosure [Line Items] | |||
Target asset allocations (as a percent) | 100.00% | ||
Plan assets at fair value | $ 73.3 | $ 63.2 | $ 60.4 |
Total plan assets measured at fair value | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 65.5 | 56.1 | |
Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 55.8 | 48.5 | |
Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 8.7 | 6.7 | |
Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 1 | 0.9 | |
Alternative investments measured at net asset value | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 7.8 | 7.1 | |
Cash | Total plan assets measured at fair value | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 3 | 3.8 | |
Cash | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 3 | 3.8 | |
Cash | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
Cash | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | $ 0 | 0 | |
Equity securities | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Target asset allocations (as a percent) | 25.30% | ||
United States equities | Total plan assets measured at fair value | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | $ 3.3 | 3 | |
United States equities | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 3.3 | 3 | |
United States equities | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
United States equities | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
International equities | Total plan assets measured at fair value | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 16.1 | 11.2 | |
International equities | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 16.1 | 11.2 | |
International equities | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
International equities | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | $ 0 | 0 | |
Debt securities | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Target asset allocations (as a percent) | 47.50% | ||
United States government bonds | Total plan assets measured at fair value | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | $ 7.4 | 8.2 | |
United States government bonds | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 7.4 | 8.2 | |
United States government bonds | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
United States government bonds | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
Foreign government bonds | Total plan assets measured at fair value | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 26 | 22.3 | |
Foreign government bonds | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 26 | 22.3 | |
Foreign government bonds | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
Foreign government bonds | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | $ 0 | 0 | |
Real estate | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Target asset allocations (as a percent) | 7.70% | ||
Real estate | Total plan assets measured at fair value | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | $ 5.6 | 4.4 | |
Real estate | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
Real estate | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 5.6 | 4.4 | |
Real estate | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
Mortgages | Total plan assets measured at fair value | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 3.1 | 2.3 | |
Mortgages | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
Mortgages | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 3.1 | 2.3 | |
Mortgages | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
Insurance contracts | Total plan assets measured at fair value | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 1 | 0.9 | |
Insurance contracts | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
Insurance contracts | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | 0 | 0 | |
Insurance contracts | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Plan assets at fair value | $ 1 | $ 0.9 | $ 1 |
Other | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Target asset allocations (as a percent) | 19.50% |
EMPLOYEE BENEFIT PLANS - Summar
EMPLOYEE BENEFIT PLANS - Summary of Changes in Fair Value of Defined Benefit Plan Assets Classified as Level 3 (Details) - Defined benefit pension plans - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Defined Benefit Plan Disclosure [Line Items] | ||
Beginning of year | $ 63.2 | $ 60.4 |
Currency exchange rate impact | 6 | 1.1 |
End of year | 73.3 | 63.2 |
Level 3 | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Beginning of year | 0.9 | |
End of year | 1 | 0.9 |
Level 3 | Insurance Contracts | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Beginning of year | 0.9 | 1 |
Purchases, sales and settlements | (0.1) | |
Currency exchange rate impact | 0.1 | |
End of year | $ 1 | $ 0.9 |
EMPLOYEE BENEFIT PLANS - Sche_4
EMPLOYEE BENEFIT PLANS - Schedule of Benefit Payments Which Reflect Expected Future Service (Details) $ in Millions | Dec. 31, 2020USD ($) |
Retirement Benefits [Abstract] | |
2021 | $ 4.6 |
2022 | 4.9 |
2023 | 6.7 |
2024 | 5.6 |
2025 | 5.3 |
2024-2026 | $ 36.7 |
COMMON STOCK - Treasury Stock (
COMMON STOCK - Treasury Stock (Narrative) (Details) - USD ($) shares in Millions | 12 Months Ended | |||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | May 31, 2019 | |
Treasury Stock | ||||
Aggregate cost of stock repurchases | $ 625,400,000 | $ 263,300,000 | $ 795,500,000 | |
Treasury Stock | ||||
Treasury Stock | ||||
Shares repurchased (in shares) | 3.1 | 1.5 | 5.5 | |
Aggregate cost of stock repurchases | $ 625,400,000 | $ 263,300,000 | $ 795,500,000 | |
May 2019 | ||||
Treasury Stock | ||||
Authorized amount for share repurchase | $ 1,000,000,000 |
COMMON STOCK - Accelerated Shar
COMMON STOCK - Accelerated Share Repurchases (Details) - USD ($) $ / shares in Units, shares in Millions | May 29, 2020 | May 07, 2020 | Jun. 30, 2019 | May 31, 2019 | Nov. 30, 2018 | Oct. 31, 2018 | Jul. 31, 2018 | Apr. 30, 2018 |
Accelerated Share Repurchase | ||||||||
Stock split, conversion ratio | 300.00% | 300.00% | ||||||
April 2018 | ||||||||
Accelerated Share Repurchase | ||||||||
Amount Paid | $ 400,000,000 | |||||||
Shares repurchased (in shares) | 2.5 | |||||||
Initial delivery, price per share (in dollars per share) | $ 127.36 | |||||||
Value of Shares as % of Contract Value | 80.00% | |||||||
July 2018 | ||||||||
Accelerated Share Repurchase | ||||||||
Shares repurchased (in shares) | 2.8 | |||||||
Final settlement per share price (in dollars per share) | $ 142.37 | |||||||
October 2018 | ||||||||
Accelerated Share Repurchase | ||||||||
Amount Paid | $ 250,000,000 | |||||||
Shares repurchased (in shares) | 1.4 | |||||||
Initial delivery, price per share (in dollars per share) | $ 139.22 | |||||||
Value of Shares as % of Contract Value | 80.00% | |||||||
November 2018 | ||||||||
Accelerated Share Repurchase | ||||||||
Shares repurchased (in shares) | 1.7 | |||||||
Final settlement per share price (in dollars per share) | $ 150.54 | |||||||
Initial Delivery of Shares Settled May 2019 | ||||||||
Accelerated Share Repurchase | ||||||||
Amount Paid | $ 150,000,000 | |||||||
Shares repurchased (in shares) | 0.7 | |||||||
Initial delivery, price per share (in dollars per share) | $ 178.66 | |||||||
Value of Shares as % of Contract Value | 80.00% | |||||||
Purchased and sold in May 2019 | ||||||||
Accelerated Share Repurchase | ||||||||
Shares repurchased (in shares) | 0.8 | |||||||
Final settlement per share price (in dollars per share) | $ 178.42 | |||||||
Initial Delivery of Shares Settled June 2019 | ||||||||
Accelerated Share Repurchase | ||||||||
Amount Paid | $ 100,000,000 | |||||||
Shares repurchased (in shares) | 0.5 | |||||||
Initial delivery, price per share (in dollars per share) | $ 170.02 | |||||||
Value of Shares as % of Contract Value | 80.00% | |||||||
Purchased in May 2019 and sold in June 2019 | ||||||||
Accelerated Share Repurchase | ||||||||
Shares repurchased (in shares) | 0.6 | |||||||
Final settlement per share price (in dollars per share) | $ 178.46 |
COMMON STOCK - Employee and Dir
COMMON STOCK - Employee and Director Stock Plans (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Jan. 01, 2021 | |
Option Awards | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Estimated annual forfeiture rate | 6.40% | |||
Average risk-free interest rate | 0.30% | 2.30% | 2.90% | |
Expected volatility | 33.00% | 30.00% | 29.00% | |
MRSUs | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Average risk-free interest rate | 0.20% | 2.20% | 2.70% | |
Expected volatility | 32.70% | 29.40% | 29.70% | |
ESPP | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Average risk-free interest rate | 1.30% | 2.40% | 1.70% | |
Expected volatility | 33.00% | 27.00% | 31.00% | |
The Program | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Common stock available for issuance (in shares) | 327,600,000 | |||
The Program | Option Awards | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Expiration date | 7 years | |||
The Program | Option Awards | Low | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting period | 3 years | |||
The Program | Option Awards | High | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting period | 4 years | |||
The Program | Restricted stock units | Low | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting period | 3 years | |||
The Program | Restricted stock units | High | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting period | 4 years | |||
The Program | MRSUs | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting period | 3 years | |||
The Program | Restricted stock or restricted stock units | High | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Common stock available for issuance (in shares) | 33,600,000 | |||
Nonemployee Directors Program | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Common stock available for issuance (in shares) | 8,400,000 | |||
Nonemployee Directors Program | Annual award to nonemployee director | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Limit on total value of the award | $ 0.2 | |||
Nonemployee Directors Program | Option Awards | Awards granted in 2012 and later | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting period | 1 year | |||
Nonemployee Directors Program | Option Awards | High | Annual award to nonemployee director | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Common stock available for issuance (in shares) | 120,000 | |||
Nonemployee Directors Program | Restricted stock units | High | Annual award to nonemployee director | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Common stock available for issuance (in shares) | 48,000 | |||
ESPP | ESPP | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Common stock available for issuance (in shares) | 45,900,000 | |||
Percentage of lower of fair market value of common stock on effective date of subscription or date of purchase | 85.00% | |||
Maximum percentage of compensation employees can authorize to be withheld for common stock purchases | 12.00% | |||
ESPP | ESPP | Subsequent Event | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Maximum percentage of compensation employees can authorize to be withheld for common stock purchases | 15.00% |
COMMON STOCK - Schedule of Weig
COMMON STOCK - Schedule of Weighted-Average Assumptions (Details) - $ / shares | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Option Awards | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Average risk-free interest rate | 0.30% | 2.30% | 2.90% |
Expected dividend yield | 0.00% | 0.00% | 0.00% |
Expected volatility | 33.00% | 30.00% | 29.00% |
Expected life (years) | 5 years | 5 years 1 month 6 days | 5 years |
Fair value, per share (in dollars per share) | $ 21.70 | $ 18.17 | $ 14.17 |
ESPP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Average risk-free interest rate | 1.30% | 2.40% | 1.70% |
Expected dividend yield | 0.00% | 0.00% | 0.00% |
Expected volatility | 33.00% | 27.00% | 31.00% |
Expected life (years) | 7 months 6 days | 7 months 6 days | 7 months 6 days |
Fair value, per share (in dollars per share) | $ 16.61 | $ 16.43 | $ 12.18 |
COMMON STOCK - Schedule of Stoc
COMMON STOCK - Schedule of Stock Option (Details) - Stock option activity $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended |
Dec. 31, 2020USD ($)$ / sharesshares | |
Shares | |
Beginning balance (in shares) | shares | 17.1 |
Options granted (in shares) | shares | 1.8 |
Options exercised (in shares) | shares | (4.3) |
Options forfeited (in shares) | shares | (0.3) |
Ending balance (in shares) | shares | 14.3 |
Exercisable as of period end (in shares) | shares | 9.5 |
Vested and expected to vest as of period end (in shares) | shares | 13.6 |
Weighted- Average Exercise Price | |
Beginning balance (in dollars per share) | $ / shares | $ 32.19 |
Options granted (in dollars per share) | $ / shares | 73.02 |
Options exercised (in dollars per share) | $ / shares | 18.16 |
Options forfeited (in dollars per share) | $ / shares | 49.74 |
Ending balance (in dollars per share) | $ / shares | 41.27 |
Exercisable as of period end (in dollars per share) | $ / shares | 32.32 |
Vested and expected to vest as of period end (in dollars per share) | $ / shares | $ 40.37 |
Weighted- Average Remaining Contractual Term | |
Outstanding as of period end | 3 years 4 months 24 days |
Exercisable as of period end | 2 years 6 months |
Vested and expected to vest as of period end | 3 years 3 months 18 days |
Aggregate Intrinsic Value | |
Outstanding as of period end | $ | $ 712.5 |
Exercisable as of period end | $ | 558.1 |
Vested and expected to vest as of period end | $ | $ 690.4 |
COMMON STOCK - Schedule of Rest
COMMON STOCK - Schedule of Restricted Stock Unit Activity (Details) - Nonvested restricted stock unit activity shares in Millions | 12 Months Ended |
Dec. 31, 2020$ / sharesshares | |
Shares | |
Beginning balance (in shares) | shares | 2.7 |
Granted (in shares) | shares | 0.9 |
Vested (in shares) | shares | (0.9) |
Forfeited (in shares) | shares | (0.1) |
Ending balance (in shares) | shares | 2.6 |
Weighted- Average Grant-Date Fair Value | |
Beginning balance (in dollars per share) | $ / shares | $ 46.89 |
Granted (in dollars per share) | $ / shares | 71.31 |
Vested (in dollars per share) | $ / shares | 40.03 |
Forfeited (in dollars per share) | $ / shares | 49.90 |
Ending balance (in dollars per share) | $ / shares | $ 57.59 |
COMMON STOCK - Schedule of Re_2
COMMON STOCK - Schedule of Restricted Stock Unit Activity (Narrative) (Details) - MRSUs | 12 Months Ended |
Dec. 31, 2020shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Granted (in shares) | 100,000 |
Shares related to previous year's grant (in shares) | 100,000 |
COMMON STOCK - Additional Infor
COMMON STOCK - Additional Information (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Equity [Abstract] | |||
Intrinsic value of stock options exercised and restricted stock units vested | $ 323.5 | $ 382.1 | $ 281.1 |
Cash from exercises of stock options | 79.2 | 110.4 | 103.7 |
Realized tax benefits from exercises of stock options and vesting of restricted stock units | 72.1 | 85.1 | 62.5 |
Total grant date fair value of stock options vested | 34 | $ 31.2 | $ 29 |
Employee stock purchase subscriptions | $ 140.9 | ||
Weighted-average remaining requisite service period | 30 months |
ACCUMULATED OTHER COMPREHENSI_3
ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Activity for Each Component of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | $ 4,148.3 | $ 3,140.4 | $ 2,956.2 |
Ending balance | 4,574.3 | 4,148.3 | 3,140.4 |
Foreign Currency Translation Adjustments | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | (154.8) | (143.6) | (100.1) |
Other comprehensive (loss) income before reclassifications | 35.7 | (1.5) | (36.7) |
Amounts reclassified from accumulated other comprehensive loss | (6.4) | (6.6) | 0 |
Deferred income tax expense | 3.1 | (3.1) | (1.9) |
Ending balance | (122.4) | (154.8) | (143.6) |
Unrealized (Loss) Gain on Hedges | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | 12.5 | 23.6 | (13.9) |
Other comprehensive (loss) income before reclassifications | (34.8) | 27.9 | 35.1 |
Amounts reclassified from accumulated other comprehensive loss | (19.2) | (44.2) | 19.1 |
Deferred income tax expense | 13.8 | 5.2 | (13.8) |
Ending balance | (27.7) | 12.5 | 23.6 |
Unrealized (Loss) Gain on Available-for-sale Investments | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | 1.7 | (5) | (4.6) |
Other comprehensive (loss) income before reclassifications | 8 | 7.9 | (3.1) |
Amounts reclassified from accumulated other comprehensive loss | 0.3 | 0.4 | 2.9 |
Deferred income tax expense | (1.4) | (1.6) | (0.2) |
Ending balance | 8.6 | 1.7 | (5) |
Unrealized Pension Costs | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | (15.4) | (13.5) | (14.1) |
Other comprehensive (loss) income before reclassifications | (5.5) | (3.2) | 7.6 |
Amounts reclassified from accumulated other comprehensive loss | 0.9 | 0.7 | (6.7) |
Deferred income tax expense | 0.4 | 0.6 | (0.3) |
Ending balance | (19.6) | (15.4) | (13.5) |
Total Accumulated Other Comprehensive Loss | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | (156) | (138.5) | (132.7) |
Other comprehensive (loss) income before reclassifications | 3.4 | 31.1 | 2.9 |
Amounts reclassified from accumulated other comprehensive loss | (24.4) | (49.7) | 15.3 |
Deferred income tax expense | 15.9 | 1.1 | (16.2) |
Ending balance | $ (161.1) | $ (156) | (138.5) |
Impact to retained earnings from adoption of ASU 2016-16 and ASU 2018-02 | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | 2.6 | ||
Impact to retained earnings from adoption of ASU 2016-16 and ASU 2018-02 | Foreign Currency Translation Adjustments | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | (4.9) | ||
Impact to retained earnings from adoption of ASU 2016-16 and ASU 2018-02 | Unrealized (Loss) Gain on Hedges | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | (2.9) | ||
Impact to retained earnings from adoption of ASU 2016-16 and ASU 2018-02 | Unrealized (Loss) Gain on Available-for-sale Investments | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | 0 | ||
Impact to retained earnings from adoption of ASU 2016-16 and ASU 2018-02 | Unrealized Pension Costs | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | 0 | ||
Impact to retained earnings from adoption of ASU 2016-16 and ASU 2018-02 | Total Accumulated Other Comprehensive Loss | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | (7.8) | ||
Cumulative Effect, Period of Adoption, Adjusted Balance | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | 2,958.8 | ||
Cumulative Effect, Period of Adoption, Adjusted Balance | Foreign Currency Translation Adjustments | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | (105) | ||
Cumulative Effect, Period of Adoption, Adjusted Balance | Unrealized (Loss) Gain on Hedges | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | (16.8) | ||
Cumulative Effect, Period of Adoption, Adjusted Balance | Unrealized (Loss) Gain on Available-for-sale Investments | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | (4.6) | ||
Cumulative Effect, Period of Adoption, Adjusted Balance | Unrealized Pension Costs | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | (14.1) | ||
Cumulative Effect, Period of Adoption, Adjusted Balance | Total Accumulated Other Comprehensive Loss | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | |||
Beginning balance | $ (140.5) |
ACCUMULATED OTHER COMPREHENSI_4
ACCUMULATED OTHER COMPREHENSIVE LOSS - Change in Unrealized Pension Costs (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Prior service credit | |||
Pre-Tax Amount | |||
Prior service credit arising during period | $ 0.6 | $ 4.6 | $ 3.3 |
Amortization of prior service credit | (0.7) | (0.2) | (0.1) |
Other comprehensive income (loss) | (0.1) | 4.4 | 3.2 |
Tax (Expense) Benefit | |||
Prior service credit arising during period | (0.2) | (0.6) | (0.9) |
Amortization of prior service credit | 0.1 | 0.1 | 0 |
Other comprehensive income (loss) | (0.1) | (0.5) | (0.9) |
Net of Tax Amount | |||
Prior service credit arising during period | 0.4 | 4 | 2.4 |
Amortization of prior service credit | (0.6) | (0.1) | (0.1) |
Other comprehensive income (loss) | (0.2) | 3.9 | 2.3 |
Net actuarial gain (loss) arising during period | |||
Pre-Tax Amount | |||
Other comprehensive income (loss) | (4.5) | (6.9) | (2.3) |
Tax (Expense) Benefit | |||
Other comprehensive income (loss) | 0.5 | 1.1 | 0.6 |
Net of Tax Amount | |||
Other comprehensive income (loss) | (4) | (5.8) | (1.7) |
Unrealized pension credits (cost), net | |||
Pre-Tax Amount | |||
Prior service credit arising during period | (5.5) | (3.2) | 7.6 |
Other comprehensive income (loss) | (4.6) | (2.5) | 0.9 |
Tax (Expense) Benefit | |||
Other comprehensive income (loss) | 0.4 | 0.6 | (0.3) |
Net of Tax Amount | |||
Other comprehensive income (loss) | $ (4.2) | $ (1.9) | $ 0.6 |
ACCUMULATED OTHER COMPREHENSI_5
ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Information About Amounts Reclassified from Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Amounts reclassified from accumulated other comprehensive loss to affected line on Consolidated Statements of Operations | |||||||||||
Other income, net | $ 11.5 | $ 8.2 | $ 4 | ||||||||
Provision for income taxes | (93.3) | (119.6) | (39.2) | ||||||||
Net income | $ 309.5 | $ 325.2 | $ (121.9) | $ 310.6 | $ 280.2 | $ 274.7 | $ 242.3 | $ 249.7 | 823.4 | 1,046.9 | 722.2 |
Cost of sales | (1,080.6) | (1,114.4) | (939.4) | ||||||||
Selling, general, and administrative expenses | (1,228.4) | (1,242.2) | (1,088.5) | ||||||||
Income before provision for income taxes | 916.7 | 1,166.5 | 761.4 | ||||||||
Special charges (gain), net | 0 | 0 | $ (7.1) | ||||||||
Amount Reclassified from Accumulated Other Comprehensive Loss | Foreign currency translation adjustments | |||||||||||
Amounts reclassified from accumulated other comprehensive loss to affected line on Consolidated Statements of Operations | |||||||||||
Other income, net | 6.4 | 6.6 | |||||||||
Provision for income taxes | (1.6) | (1.6) | |||||||||
Net income | 4.8 | 5 | |||||||||
Amount Reclassified from Accumulated Other Comprehensive Loss | (Loss) gain on hedges | |||||||||||
Amounts reclassified from accumulated other comprehensive loss to affected line on Consolidated Statements of Operations | |||||||||||
Provision for income taxes | (5) | (11) | |||||||||
Net income | 14.2 | 33.2 | |||||||||
Cost of sales | 18.4 | 40.9 | |||||||||
Selling, general, and administrative expenses | 2.2 | 1.9 | |||||||||
Other income, net | 1.4 | (1.4) | |||||||||
Income before provision for income taxes | 19.2 | 44.2 | |||||||||
Amount Reclassified from Accumulated Other Comprehensive Loss | (Loss) gain on available-for-sale investments | |||||||||||
Amounts reclassified from accumulated other comprehensive loss to affected line on Consolidated Statements of Operations | |||||||||||
Other income, net | (0.3) | (0.4) | |||||||||
Provision for income taxes | (0.6) | (0.3) | |||||||||
Net income | (0.9) | (0.7) | |||||||||
Amount Reclassified from Accumulated Other Comprehensive Loss | Amortization of pension adjustments | |||||||||||
Amounts reclassified from accumulated other comprehensive loss to affected line on Consolidated Statements of Operations | |||||||||||
Other income, net | (0.9) | (0.7) | |||||||||
Provision for income taxes | 0.2 | 0.1 | |||||||||
Net income | $ (0.7) | $ (0.6) |
OTHER INCOME, NET (Details)
OTHER INCOME, NET (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Other Income and Expenses [Abstract] | |||
Foreign exchange gains, net | $ (12.3) | $ (5.9) | $ (6.7) |
Gain on investments | (0.6) | (0.5) | 1.7 |
Non-service cost components of net periodic pension benefit cost (credit) | 0.4 | 0.2 | (0.1) |
Other | 1 | (2) | 1.1 |
Total other income, net | $ (11.5) | $ (8.2) | $ (4) |
INCOME TAXES - Schedule of Inco
INCOME TAXES - Schedule of Income Before Provisions for Income Taxes (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |||
United States | $ 151.3 | $ 383.4 | $ 266.1 |
International, including Puerto Rico | 765.4 | 783.1 | 495.3 |
Income before provision for income taxes | $ 916.7 | $ 1,166.5 | $ 761.4 |
INCOME TAXES - Provision for In
INCOME TAXES - Provision for Income Taxes (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
United States: | |||
Federal | $ 23.4 | $ 31.3 | $ 10.9 |
State and local | 48.2 | 48.7 | 13.6 |
International, including Puerto Rico | 73.9 | 29.1 | 35.9 |
Current income tax expense | 145.5 | 109.1 | 60.4 |
United States: | |||
Federal | 11 | 28.3 | (16.1) |
State and local | (32.9) | (18.3) | (22.4) |
International, including Puerto Rico | (30.3) | 0.5 | 17.3 |
Deferred income tax (benefit) expense | (52.2) | 10.5 | (21.2) |
Total income tax provision | $ 93.3 | $ 119.6 | $ 39.2 |
INCOME TAXES - Components of De
INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Deferred tax assets | ||
Compensation and benefits | $ 88.6 | $ 90.1 |
Benefits from uncertain tax positions | 27 | 22.5 |
Net tax credit carryforwards | 125.5 | 108.4 |
Net operating loss carryforwards | 64.1 | 57.6 |
Accrued liabilities | 105 | 41.3 |
Inventories | 16.3 | 12.9 |
Cash flow and net investment hedges | 3.3 | 0 |
State income taxes | 0.5 | 0.5 |
Investments | 1.8 | 1.5 |
Lease liability obligations | 7.7 | 18.4 |
Other | 3.6 | 3.4 |
Total deferred tax assets | 443.4 | 356.6 |
Deferred tax liabilities | ||
Property, plant, and equipment | (53.4) | (22.6) |
Cash flow and net investment hedges | 0 | (6.8) |
Deferred tax on foreign earnings | (29.2) | (35.3) |
Right-of-use assets | (7) | (17.5) |
Other intangible assets | (76.3) | (71) |
Other | (3.1) | (2.2) |
Total deferred tax liabilities | (169) | (155.4) |
Valuation allowance | (71.6) | (65.8) |
Net deferred tax assets | $ 202.8 | $ 135.4 |
INCOME TAXES - Narrative (Detai
INCOME TAXES - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | |||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Operating Loss Carryforwards [Line Items] | ||||
Net deferred tax assets increase | $ 67.4 | |||
Valuation allowance that reduces certain deferred tax assets | 71.6 | $ 65.8 | ||
Carryforward Amount | 170 | |||
Tax benefit from remeasurement of deferred taxes | $ 3.3 | |||
Effects of mandatory deemed repatriation | 297.4 | |||
Tax benefit from harvesting foreign tax credits | 32.3 | |||
Adjustment to transition tax | $ 12.8 | |||
Deferred tax asset provisional income tax expense (benefit) | 3.7 | |||
Foreign earnings to be indefinitely reinvested | 1,100 | |||
Foreign earnings to be repatriated | 599.8 | |||
Estimated net tax liability on permanently reinvested earnings | 21.1 | |||
Unrecognized tax benefits | 281.8 | 203.1 | 150.7 | $ 225.6 |
Estimated decrease in unrecognized tax benefits | 95.1 | 50.1 | ||
Net amounts favorably affecting tax rate | 186.7 | 153 | ||
Accrued interest related to unrecognized tax benefits, net of tax benefit | 14.3 | 9.3 | ||
Tax benefit of accrued interest | 5.1 | 3.5 | ||
Interest expense (benefit), net of tax benefit | 5 | 4.7 | (2.8) | |
Non-U.S. | ||||
Operating Loss Carryforwards [Line Items] | ||||
Tax reductions compared to local statutory rates | $ 189.2 | $ 157.6 | $ 144.9 | |
Tax reductions compared to local statutory rates per diluted share (in dollars per share) | $ 0.30 | $ 0.25 | $ 0.23 | |
Research expenditure tax credits | Carryforward period indefinite | California | State and local jurisdiction | ||||
Operating Loss Carryforwards [Line Items] | ||||
Carryforward Amount | $ 145.1 | |||
Puerto Rico purchases credit | Carryforward period indefinite | Puerto Rico | Non-U.S. | ||||
Operating Loss Carryforwards [Line Items] | ||||
Carryforward Amount | $ 23.4 |
INCOME TAXES - Summary of Net O
INCOME TAXES - Summary of Net Operating Loss Carryforwards (Details) $ in Millions | Dec. 31, 2020USD ($) |
Operating Loss Carryforwards [Line Items] | |
Carryforward Amount | $ 419.8 |
Tax Benefit Amount | 64.3 |
Valuation Allowance | (45.9) |
Net Tax Benefit | 18.4 |
United States federal net operating losses | United States | Carryforward Period Ends 2030-2037 | |
Operating Loss Carryforwards [Line Items] | |
Carryforward Amount | 26.6 |
Tax Benefit Amount | 5.6 |
Valuation Allowance | 0 |
Net Tax Benefit | 5.6 |
United States federal net operating losses | United States | Carryforward Period Indefinite | |
Operating Loss Carryforwards [Line Items] | |
Carryforward Amount | 11.3 |
Tax Benefit Amount | 2.4 |
Valuation Allowance | 0 |
Net Tax Benefit | 2.4 |
United States federal net operating losses | United States | Carryforward Period Ends 2022 | |
Capital Loss Carryforward [Abstract] | |
Carryforward Amount | 34.1 |
Tax Benefit Amount | 0.2 |
Valuation Allowance | (0.2) |
Net Tax Benefit | 0 |
United States state net operating losses | United States | Carryforward Period Indefinite | |
Operating Loss Carryforwards [Line Items] | |
Carryforward Amount | 1 |
Tax Benefit Amount | 0.1 |
Valuation Allowance | (0.1) |
Net Tax Benefit | 0 |
United States state net operating losses | United States | Carryforward Period Ends 2026-2039 | |
Operating Loss Carryforwards [Line Items] | |
Carryforward Amount | 33.5 |
Tax Benefit Amount | 2.1 |
Valuation Allowance | (2.1) |
Net Tax Benefit | 0 |
Non-United States net operating losses | International | Carryforward Period Indefinite | |
Operating Loss Carryforwards [Line Items] | |
Carryforward Amount | 295.1 |
Tax Benefit Amount | 49.2 |
Valuation Allowance | (39.9) |
Net Tax Benefit | 9.3 |
Non-United States net operating losses | International | Carryforward Period Ends 2020-2027 | |
Operating Loss Carryforwards [Line Items] | |
Carryforward Amount | 18.2 |
Tax Benefit Amount | 4.7 |
Valuation Allowance | (3.6) |
Net Tax Benefit | $ 1.1 |
INCOME TAXES - Summary of Tax C
INCOME TAXES - Summary of Tax Credit Carryforwards (Details) $ in Millions | Dec. 31, 2020USD ($) |
Tax credit carryforwards and the related carryforward periods | |
Carryforward Amount | $ 170 |
Valuation Allowance | (23.4) |
Net Tax Benefit | 146.6 |
California research expenditure tax credits | California | Research expenditure tax credits | Carryforward Period Indefinite | |
Tax credit carryforwards and the related carryforward periods | |
Carryforward Amount | 145.1 |
Valuation Allowance | 0 |
Net Tax Benefit | 145.1 |
Federal research expenditure tax credits | United States | Research expenditure tax credits | Carryforward Period Indefinite | |
Tax credit carryforwards and the related carryforward periods | |
Carryforward Amount | 1.5 |
Valuation Allowance | 0 |
Net Tax Benefit | 1.5 |
Puerto Rico purchases credit | Puerto Rico | Purchases credit | Carryforward Period Indefinite | |
Tax credit carryforwards and the related carryforward periods | |
Carryforward Amount | 23.4 |
Valuation Allowance | (23.4) |
Net Tax Benefit | $ 0 |
INCOME TAXES - Reconciliation o
INCOME TAXES - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |||
Income tax expense at U.S. federal statutory rate | $ 192.5 | $ 245 | $ 159.9 |
Foreign income taxed at different rates | (80.5) | (75) | (16.2) |
State and local taxes, net of federal tax benefit | 5 | 11.9 | 6.8 |
Tax credits, federal and state | (43.1) | (42.9) | (36.7) |
Build (release) of reserve for prior years' uncertain tax positions | 4.2 | 5 | (35.5) |
U.S. tax on foreign earnings, net of credits | 1.5 | (2.9) | (12.2) |
Tax on global intangible low-taxed income | 49.2 | 32 | 0 |
Foreign-derived intangible income deduction | (2.6) | (7.2) | (6.6) |
U.S. federal deductible employee share-based compensation | (48.3) | (57.6) | (41.8) |
Nondeductible employee share-based compensation | 4.2 | 3.2 | 2.8 |
Impact related to 2017 U.S. Tax Reform | 0 | 2.8 | 15.8 |
Other | 11.2 | 5.3 | 2.9 |
Total income tax provision | $ 93.3 | $ 119.6 | $ 39.2 |
INCOME TAXES - Reconciliation_2
INCOME TAXES - Reconciliation of Beginning and Ending Amount of Uncertain Tax Positions (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns | |||
Uncertain gross tax positions, beginning balance | $ 203.1 | $ 150.7 | $ 225.6 |
Current year tax positions | 86.4 | 55.4 | 37.8 |
Increase in prior year tax positions | 6 | 0.8 | 13.9 |
Decrease in prior year tax positions | (10) | (3.8) | (78.8) |
Settlements | (3.7) | 0 | (46.5) |
Lapse of statutes of limitations | 0 | 0 | (1.3) |
Uncertain gross tax positions, ending balance | $ 281.8 | $ 203.1 | $ 150.7 |
LEGAL PROCEEDINGS (Details)
LEGAL PROCEEDINGS (Details) $ in Millions | 1 Months Ended | 12 Months Ended | ||
Jun. 30, 2020USD ($) | Dec. 31, 2020USD ($)lawsuit | Dec. 31, 2019USD ($) | Dec. 31, 2018USD ($) | |
Loss Contingencies [Line Items] | ||||
Intellectual property litigation expenses | $ 405.4 | $ 33.4 | $ 214 | |
Number of lawsuits that if settled could have a material adverse impact on net income or cash flows | lawsuit | 1 | |||
Accrual for environmental loss contingencies, component amount | $ 1 | |||
Abbott Laboratories | ||||
Loss Contingencies [Line Items] | ||||
Intellectual property litigation expenses | $ 367.9 |
SEGMENT INFORMATION - Schedule
SEGMENT INFORMATION - Schedule of Information About Reportable Segments (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Segment Reporting Information [Line Items] | |||||||||||
Segment Net Sales | $ 1,191.7 | $ 1,140.9 | $ 925 | $ 1,128.7 | $ 1,174.1 | $ 1,094 | $ 1,086.9 | $ 993 | $ 4,386.3 | $ 4,348 | $ 3,722.8 |
Segment Operating Income | 916.7 | 1,166.5 | 761.4 | ||||||||
Operating segments | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Segment Net Sales | 4,362.1 | 4,333.5 | 3,676 | ||||||||
Segment Operating Income | 2,643.1 | 2,614.5 | 2,115.5 | ||||||||
Operating segments | United States | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Segment Net Sales | 2,516.8 | 2,532.7 | 2,055.2 | ||||||||
Segment Operating Income | 1,727.3 | 1,742.3 | 1,368.1 | ||||||||
Operating segments | Europe | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Segment Net Sales | 945.2 | 926.1 | 826.4 | ||||||||
Segment Operating Income | 479.3 | 472 | 394.8 | ||||||||
Operating segments | Japan | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Segment Net Sales | 448.6 | 441.4 | 398.4 | ||||||||
Segment Operating Income | 286.4 | 272.3 | 237 | ||||||||
Operating segments | Rest of World | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Segment Net Sales | 451.5 | 433.3 | 396 | ||||||||
Segment Operating Income | $ 150.1 | $ 127.9 | $ 115.6 |
SEGMENT INFORMATION - Reconcili
SEGMENT INFORMATION - Reconciliation of Segment Net Sales and Pre-Tax Income to Consolidated Net Sales and Pre-Tax Income (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Net Sales Reconciliation | |||||||||||
Net sales | $ 1,191.7 | $ 1,140.9 | $ 925 | $ 1,128.7 | $ 1,174.1 | $ 1,094 | $ 1,086.9 | $ 993 | $ 4,386.3 | $ 4,348 | $ 3,722.8 |
Pre-tax Income Reconciliation | |||||||||||
Operating income | 897.6 | 1,146.8 | 748.2 | ||||||||
Unallocated amounts: | |||||||||||
Special charges | 0 | (64.6) | (116.2) | ||||||||
Change in fair value of contingent consideration liabilities, net | (13.6) | 6.1 | 5.7 | ||||||||
Foreign currency | 12.3 | 5.9 | 6.7 | ||||||||
Consolidated pre-tax income | 916.7 | 1,166.5 | 761.4 | ||||||||
Operating segments | |||||||||||
Net Sales Reconciliation | |||||||||||
Net sales | 4,362.1 | 4,333.5 | 3,676 | ||||||||
Pre-tax Income Reconciliation | |||||||||||
Operating income | 2,643.1 | 2,614.5 | 2,115.5 | ||||||||
Unallocated amounts: | |||||||||||
Consolidated pre-tax income | 2,643.1 | 2,614.5 | 2,115.5 | ||||||||
Segment reconciling items | |||||||||||
Net Sales Reconciliation | |||||||||||
Net sales | 24.2 | 14.5 | 46.8 | ||||||||
Unallocated amounts: | |||||||||||
Special charges | 0 | (64.6) | |||||||||
Intellectual property litigation expenses, net | (405.4) | (33.4) | (214) | ||||||||
Foreign currency | 31.5 | 63.9 | 15.3 | ||||||||
Non-operating income | 19.1 | 19.7 | 13.2 | ||||||||
Corporate items | |||||||||||
Unallocated amounts: | |||||||||||
Corporate items | $ (1,358) | $ (1,439.7) | $ (1,058.1) |
SEGMENT INFORMATION - Schedul_2
SEGMENT INFORMATION - Schedule of Enterprise-Wide Information (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Net Sales by Geographic Area and by Major Product Area | |||||||||||
Net sales | $ 1,191.7 | $ 1,140.9 | $ 925 | $ 1,128.7 | $ 1,174.1 | $ 1,094 | $ 1,086.9 | $ 993 | $ 4,386.3 | $ 4,348 | $ 3,722.8 |
Long-lived Tangible Assets by Geographic Area | |||||||||||
Long-lived tangible assets | 1,608.4 | 1,241.7 | 1,608.4 | 1,241.7 | 899.8 | ||||||
Transcatheter Aortic Valve Replacement | |||||||||||
Net Sales by Geographic Area and by Major Product Area | |||||||||||
Net sales | 2,857.3 | 2,737.9 | 2,283.8 | ||||||||
Transcatheter Mitral and Tricuspid Therapies | |||||||||||
Net Sales by Geographic Area and by Major Product Area | |||||||||||
Net sales | 41.8 | 28.2 | 2.9 | ||||||||
Surgical Structural Heart | |||||||||||
Net Sales by Geographic Area and by Major Product Area | |||||||||||
Net sales | 761.8 | 841.7 | 761.6 | ||||||||
Critical Care | |||||||||||
Net Sales by Geographic Area and by Major Product Area | |||||||||||
Net sales | 725.4 | 740.2 | 674.5 | ||||||||
United States | |||||||||||
Net Sales by Geographic Area and by Major Product Area | |||||||||||
Net sales | 2,516.8 | 2,532.7 | 2,055.3 | ||||||||
Long-lived Tangible Assets by Geographic Area | |||||||||||
Long-lived tangible assets | 1,084.3 | 849.1 | 1,084.3 | 849.1 | 642.1 | ||||||
Europe | |||||||||||
Net Sales by Geographic Area and by Major Product Area | |||||||||||
Net sales | 973.6 | 941.2 | 885.1 | ||||||||
Long-lived Tangible Assets by Geographic Area | |||||||||||
Long-lived tangible assets | 192.7 | 101.5 | 192.7 | 101.5 | 36.6 | ||||||
Japan | |||||||||||
Net Sales by Geographic Area and by Major Product Area | |||||||||||
Net sales | 460.1 | 444.7 | 396.8 | ||||||||
Long-lived Tangible Assets by Geographic Area | |||||||||||
Long-lived tangible assets | 20.4 | 21.7 | 20.4 | 21.7 | 6.7 | ||||||
Rest of World | |||||||||||
Net Sales by Geographic Area and by Major Product Area | |||||||||||
Net sales | 435.8 | 429.4 | 385.6 | ||||||||
Long-lived Tangible Assets by Geographic Area | |||||||||||
Long-lived tangible assets | $ 311 | $ 269.4 | $ 311 | $ 269.4 | $ 214.4 |
QUARTERLY FINANCIAL RESULTS A_3
QUARTERLY FINANCIAL RESULTS AND MARKET FOR THE COMPANY'S STOCK (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Class of Stock [Line Items] | |||||||||||
Net sales | $ 1,191.7 | $ 1,140.9 | $ 925 | $ 1,128.7 | $ 1,174.1 | $ 1,094 | $ 1,086.9 | $ 993 | $ 4,386.3 | $ 4,348 | $ 3,722.8 |
Gross profit | 895.4 | 859.9 | 686.8 | 863.6 | 887.9 | 801.6 | 782.9 | 761.2 | 3,305.7 | 3,233.6 | 2,783.4 |
Net income | $ 309.5 | $ 325.2 | $ (121.9) | $ 310.6 | $ 280.2 | $ 274.7 | $ 242.3 | $ 249.7 | $ 823.4 | $ 1,046.9 | $ 722.2 |
Earnings per common share: | |||||||||||
Basic (in dollars per share) | $ 0.50 | $ 0.52 | $ (0.20) | $ 0.50 | $ 0.45 | $ 0.44 | $ 0.39 | $ 0.40 | $ 1.32 | $ 1.68 | $ 1.15 |
Diluted (in dollars per share) | 0.49 | 0.52 | (0.20) | 0.49 | 0.44 | 0.43 | 0.38 | 0.39 | 1.30 | 1.64 | $ 1.13 |
High | |||||||||||
Earnings per common share: | |||||||||||
Market price (in dollars per share) | 92.08 | 87.79 | 78.43 | 81.90 | 82.55 | 76.06 | 65 | 65.95 | 92.08 | 82.55 | |
Low | |||||||||||
Earnings per common share: | |||||||||||
Market price (in dollars per share) | $ 70.92 | $ 66.87 | $ 56.44 | $ 51.51 | $ 71.08 | $ 61 | $ 55.23 | $ 46.95 | $ 51.51 | $ 46.95 |
QUARTERLY FINANCIAL RESTULTS AN
QUARTERLY FINANCIAL RESTULTS AND MARKET FOR THE COMPANY'S STOCK (UNAUDITED) - Narrative (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||
Dec. 31, 2019 | Dec. 31, 2020 | Jun. 30, 2020 | Sep. 30, 2019 | Jun. 30, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Mar. 31, 2019 | |
Class of Stock [Line Items] | |||||||||
Gain (loss) on litigation settlement | $ 367.9 | ||||||||
Inventory write off | $ 26.9 | $ 46.2 | $ 0 | $ 73.1 | $ 0 | ||||
Early-stage Transcatheter Intellectual Property | |||||||||
Class of Stock [Line Items] | |||||||||
Acquisition transaction costs | $ 24 | ||||||||
Developed technology | Valtech | |||||||||
Class of Stock [Line Items] | |||||||||
Impairment of intangible assets | $ 40.6 | ||||||||
Rest of World | Developed technology | Valtech | |||||||||
Class of Stock [Line Items] | |||||||||
Impairment of intangible assets | $ 40.6 |
VALUATION AND QUALIFYING ACCO_2
VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Allowance for doubtful accounts | |||
Movement in Valuation Allowances and Reserves | |||
Balance at Beginning of Period | $ 14.7 | $ 13.6 | $ 13.7 |
Charged to Costs and Expenses | 3.1 | 4.7 | 2.2 |
Charged to Other Accounts | 0 | 0.2 | 1 |
Deductions | (1.4) | (3.8) | (3.3) |
Balance at End of Period | 16.4 | 14.7 | 13.6 |
Tax valuation allowance | |||
Movement in Valuation Allowances and Reserves | |||
Balance at Beginning of Period | 64 | 44.9 | 41.6 |
Charged to Costs and Expenses | 6.3 | 18.9 | 7.1 |
Charged to Other Accounts | 0.6 | 0.2 | (1.8) |
Deductions | (1.1) | 0 | (2) |
Balance at End of Period | $ 69.8 | $ 64 | $ 44.9 |
SUBSEQUENT EVENT (Details)
SUBSEQUENT EVENT (Details) - Subsequent Event - February 2021 Stock Repurchase Program shares in Millions | Feb. 12, 2021USD ($)shares |
Subsequent Event [Line Items] | |
Authorized amount for share repurchase | $ | $ 250,000,000 |
Shares repurchased (in shares) | shares | 2.4 |
Percentage of shares repurchased | 80.00% |